
<html lang="en"     class="pb-page"  data-request-id="1dfb4249-8807-46c3-8576-9b6868cb22f2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;article:article:10.1021/acs.jmedchem.0c01521;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach" /></meta><meta name="dc.Creator" content="Mengyang  Xu" /></meta><meta name="dc.Creator" content="Chao  Zhao" /></meta><meta name="dc.Creator" content="Biying  Zhu" /></meta><meta name="dc.Creator" content="Liangyue  Wang" /></meta><meta name="dc.Creator" content="Huihao  Zhou" /></meta><meta name="dc.Creator" content="Daoguang  Yan" /></meta><meta name="dc.Creator" content="Qiong  Gu" /></meta><meta name="dc.Creator" content="Jun  Xu" /></meta><meta name="dc.Description" content="Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel ..." /></meta><meta name="Description" content="Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 5, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01521" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01521" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01521" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01521" /></link>
        
    
    

<title>Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01521" /></meta><meta property="og:title" content="Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0011.jpeg" /></meta><meta property="og:description" content="Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel and druggable Hsp90 inhibitors are still demanding. Here, we report a new way to discover high potent Hsp90 inhibitors as antinasopharyngeal carcinoma agents through assembling fragments. With chemotyping analysis, we extract seven chemotypes from 3482 known Hsp90 inhibitors, screen 500 fragments that are compatible with the chemotypes, and confirm 15 anti-Hsp90 fragments. Click chemistry is employed to construct 172 molecules and synthesize 21 compounds among them. The best inhibitor 3d was further optimized and resulted in more potent 4f (IC50 = 0.16 μM). In vitro and in vivo experiments confirmed that 4f is a promising agent against nasopharyngeal carcinoma. This study may provide a strategy in discovering new ligands against targets without well-understood structures." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01521"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01521">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01521&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01521&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01521&amp;href=/doi/10.1021/acs.jmedchem.0c01521" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 2010-2023</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01504" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01360" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mengyang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengyang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div><div class="loa-info-affiliations-info">Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengyang++Xu">Mengyang Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div><div class="loa-info-affiliations-info">Shenzhen Cell Inspire Therapeutics Co., Ltd., Shenzhen 518101, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zhao">Chao Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Biying Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Biying Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Biying++Zhu">Biying Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liangyue Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liangyue Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liangyue++Wang">Liangyue Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huihao Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huihao Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huihao++Zhou">Huihao Zhou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9675-5007" title="Orcid link">http://orcid.org/0000-0002-9675-5007</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daoguang Yan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daoguang Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e3979a8784a3898d96cd868796cd808d"><span class="__cf_email__" data-cfemail="15616c7172557f7b603b7071603b767b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daoguang++Yan">Daoguang Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiong Gu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiong Gu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c1a6b4b0a8aeafa681aca0a8adefb2b8b2b4efa4a5b4efa2af"><span class="__cf_email__" data-cfemail="d4b3a1a5bdbbbab394b9b5bdb8faa7ada7a1fab1b0a1fab7ba">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiong++Gu">Qiong Gu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6011-3697" title="Orcid link">http://orcid.org/0000-0001-6011-3697</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jun Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</div><div class="loa-info-affiliations-info">School of Biotechnology and Health Sciences, Wuyi University, 99 Yingbin Road, Jiangmen 529020, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#345e415a4c4174565d5b575c51595b5951471a575b59"><span class="__cf_email__" data-cfemail="69031c07111c290b00060a010c0406040c1a470a0604">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Xu">Jun Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1075-0337" title="Orcid link">http://orcid.org/0000-0002-1075-0337</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01521&amp;href=/doi/10.1021%2Facs.jmedchem.0c01521" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 2010–2023</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 5, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 September 2020</li><li><span class="item_label"><b>Published</b> online</span>5 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01521" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01521</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2010%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMengyang%2BXu%252C%2BChao%2BZhao%252C%2BBiying%2BZhu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01521%26title%3DDiscovering%2BHigh%2BPotent%2BHsp90%2BInhibitors%2Bas%2BAntinasopharyngeal%2BCarcinoma%2BAgents%2Bthrough%2BFragment%2BAssembling%2BApproach%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2023%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01521"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">937</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01521" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mengyang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Biying&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Liangyue&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Huihao&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Daoguang&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Qiong&quot;,&quot;last_name&quot;:&quot;Gu&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Xu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2010-2023&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01521&quot;},&quot;abstract&quot;:&quot;Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel and druggable Hsp90 inhibitors are still demanding. Here, we report a new way to discover high potent Hsp90 inhibitors as antinasopharyngeal carcinoma agents through assembling fragments. With chemotyping analysis, we extract seven chemotypes from 3482 known Hsp90 inhibitors, screen 500 fragments that are compatible with the chemotypes, and confirm 15 anti-Hsp90 fragments. Click chemistry is employed to construct 172 molecules and synthesize 21 compounds among them. The best inhibitor 3d was further optimized and resulted in more potent 4f (IC50 = 0.16 μM). In vitro and in vivo experiments confirmed that 4f is a promising agent against nasopharyngeal carcinoma. This study may provide a strategy in discovering new ligands against targets without well-understood structures.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01521&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01521" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01521&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01521" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01521&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01521" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01521&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01521&amp;href=/doi/10.1021/acs.jmedchem.0c01521" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01521" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01521" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01521%26sid%3Dliteratum%253Aachs%26pmid%3D33543615%26genre%3Darticle%26aulast%3DXu%26date%3D2021%26atitle%3DDiscovering%2BHigh%2BPotent%2BHsp90%2BInhibitors%2Bas%2BAntinasopharyngeal%2BCarcinoma%2BAgents%2Bthrough%2BFragment%2BAssembling%2BApproach%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D2010%26epage%3D2023%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292330" title="Chemical synthesis">Chemical synthesis</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel and druggable Hsp90 inhibitors are still demanding. Here, we report a new way to discover high potent Hsp90 inhibitors as antinasopharyngeal carcinoma agents through assembling fragments. With chemotyping analysis, we extract seven chemotypes from 3482 known Hsp90 inhibitors, screen 500 fragments that are compatible with the chemotypes, and confirm 15 anti-Hsp90 fragments. Click chemistry is employed to construct 172 molecules and synthesize 21 compounds among them. The best inhibitor 3d was further optimized and resulted in more potent 4f (IC<sub>50</sub> = 0.16 μM). <i>In vitro</i> and <i>in vivo</i> experiments confirmed that 4f is a promising agent against nasopharyngeal carcinoma. This study may provide a strategy in discovering new ligands against targets without well-understood structures.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Heat shock protein 90 (Hsp90, a molecular chaperone participating in the regulation of cell proliferation and apoptosis) is highly expressed in tumor cells. More than 200 oncogenic proteins are clients of Hsp90, such as HER2, EGFR, AKT, p53, BCR-ABL, and Raf.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Targeting Hsp90 is a new promising strategy for anticancer drug development.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Recently, Hsp90 was reported to play an important role in virus infection such as Dengue virus and Epstein–Barr virus,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8">(3−8)</a> and Hsp90 inhibitors were used to treat aging-related disease.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">Hsp90 consists of N-terminal domain for adenosine triphosphate (ATP) binding, middle domain for client protein binding, and C-terminal domain for dimerization. ATP binding causes Hsp90 conformational change, which activates Hsp90 chaperone function. Thus, many ATP-competitive inhibitors were developed to disrupt Hsp90 function for treating cancers. These inhibitors belong to three major classes: (1) geldanamycin analogues,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> such as 17-DMAG,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> 17-AAG,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and IPI-504;<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (2) radicicol derivatives like NVP-AUY922,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> STA-9090,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and AT13387;<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and (3) purine-based Hsp90 inhibitors such as BIIB021.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Over 20 Hsp90 N-terminal inhibitors entered clinical trials; however, they were all discontinued due to toxicity. Therefore, novel druggable Hsp90 inhibitors are still demanding.</div><div class="NLM_p">Fragment-based drug discovery (FBDD) has been employed for years with significant success.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25">(20−25)</a> FBDD starts with a smaller number of fragments<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> rather than screening a large number of druglike compounds. There can be 10<sup>60–200</sup> possible druglike compounds, but only 10<sup>7</sup> possible fragments.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> FBDD can significantly reduce chemical space for lead identification.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, optimizing fragments to leads (F2L) is still a challenge for FBDD. Fragment growing, merging, and linking are common techniques for F2L. These techniques require well-understood fragment–receptor binding models, which have to be supported by structure biology experiments.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Moreover, F2L has to chemically combine fragments with the binding model restructions.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">To develop new approaches for combining fragments, we reported a strategy that discovered liver X receptor-β (LXRβ) agonists by connecting LXRβ privileged fragments that extracted from known LXRβ agonists.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Later on, we reported a promoted strategy called chemotype-based drug discovery (CBDD) and identified antiosteoporosis leads with the chemotyping analysis approach and their assembly rules.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> These results indicate that compounds with same target or function constructed with chemotypes through certain rules. This may help us to accelerate the F2L process and discovery novel Hsp90 inhibitors.</div><div class="NLM_p last">In this study, we report a second-generation CBDD method that utilizes both fragment-linking approach and the chemotyping analysis approach. And we apply this method in the discovery of novel Hsp90 inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemotypes Derived from Known Anti-Hsp90 Agents</h3><div class="NLM_p">We started with 3482 known Hsp90 inhibitors derived from ChEMBL database. These inhibitors partitioned into potent library (library P, 1384 inhibitors with pChEMBL values greater than 6), moderate potent library (library M, 1233 inhibitors with pChEMBL values between 6 and 5), and nonactive library (library N, 865 inhibitors with pChEMBL values less than 5). The smallest set of smallest rings (SSSR) analyses indicated that inhibitors with three rings were most popular (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and potent Hsp90 inhibitors had at least two rings. Therefore, we hypothesize that Hsp90 inhibitors can be generated by linking chemotypes that have same ring in each fragment.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) SSSR of molecules in Library P. (B) The SSSR of molecules in Library M. (C) The SSSR of molecules in Library N. (D) The example of chemotypes assembly to known Hsp90 inhibitor ACO1. The pink color shows that the functional group does not include in chemotype-assembled motif. SSSR = smallest set of smallest rings.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using a de novo substructure generation algorithm (DSGA), we derived 29 privileged fragments (PF) and 164 other fragments. Many privileged fragments of Hsp90 inhibitors have five- or six-membered rings. The privileged fragments were summarized into four motifs (<b>PF1–4</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). <b>PF1</b> and <b>PF4</b> exhibited much higher popularity in library P than libraries M and N. <b>PF2</b> and <b>PF3</b> showed that even frequency in all libraries.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Privileged Anti-Hsp90 Chemotypes and Their Frequency in Different Libraries<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0008.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">A = nonhydrogen atom, usually is C, O, N, and S; Q = nonhydrogen heteroatom; Y = any function group, such as C, N, O, S, CONH<sub>2</sub>, CH<sub>2</sub>OH, etc. Dashed lines = any bonds (single or double bond). Double dashed lines = aromatic bond.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Library P = potent library.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Library M = moderate potent library.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Library N = nonactive library.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">PF = privileged fragments.</p></div></div><div></div></div><div class="NLM_p last">The chemotypes and their popularities are listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, which indicates that library P contains more chemotypes <b>C1</b> and <b>C2</b> than libraries M and N do. Thus, we hypothesize that compounds containing <b>C1</b> and <b>C2</b> can be more potent Hsp90 inhibitors. Chemotype <b>C3</b> is associated with mild Hsp90 inhibition, which is related to the compounds in libraries P and M. The popularities of chemotypes <b>C4–6</b> are evenly distributed in all three libraries. Chemotype <b>C7</b> is a rare chemotype. Thus, we hypothesize that linking chemotypes <b>C1</b> and <b>C4</b> can generate more potent Hsp90 inhibitors. A potent known Hsp90 inhibitor <b>ACO1</b> is assembled by <b>C1</b>, <b>C3</b>, and <b>C4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D). The chemotypes <b>C1</b> and <b>C3</b> link through merging six-membered aromatic rings, and then newly formed motif link with <b>C4</b> through overlapping the same five-membered aromatic ring. This indicated that Hsp90 inhibitor can be formed by linking anti-Hsp90 chemotypes.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Novel Hsp90 Inhibitors Design Based on Newly Discovered Active Anti-Hsp90 Fragments</h3><div class="NLM_p">A library containing 500 fragments were virtually screened based on the PFs and chemotypes via substructure retrieval, resulting in 328 fragments, which were then acquired and assayed with surface plasmon resonance (SPR)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> experiments. Thus, we identified 28 hits (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) that exhibited a response value higher than 30. The hits are all compatible with the privileged chemotypes of Hsp90 inhibitors. For instance, hits F01-04 belong to mono-ring PF1 and F14-16 belong to chemotype C1. These results imply that they all can be used to generate potential Hsp90 inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Designing Hsp90 inhibitors through assembling privileged chemotypes. (A) Thirty fragments for building potential Hsp90 inhibitors. 5Har = five-membered heteroaromatic ring; 6Ar = six-membered aromatic ring; 6r = six-membered aliphatic ring. (B) Chemotypes assembling to form potential anti-Hsp90 scaffolds. (C) Chemotype <b>C1</b> or <b>C4</b> assembles with a non-anti-Hsp90 chemotype to form potential non-anti-Hsp90 scaffolds. (D) Click chemistry synthetical scheme for assembling potential Hsp90 inhibitors from privileged fragments (chemotypes). (E) Commercially available starting materials from active fragments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Linking chemotypes <b>C1</b>, <b>C4</b>, and <b>C7</b> to form triazole derivatives can be efficiently executed with click chemistry syntheses. This requires converting out hits (fragments) to brominated or alkynyl products as starting materials for click chemistry reactions. Thus, the hits with multisubstituted fragments were simplified to mono-substituted fragments (precursors of brominated or alkynyl products) with the condition of commercial availability (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E). This resulted in seven bromides and two alkynes as the precursors, and two designed scaffolds for potential Hsp90 inhibitory molecules, as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B. For negative control, we purposely assembled molecules that contained chemotypes that were not considered as Hsp90 inhibitory fragments (such as 2-ethynylthiophene). Twenty-one compounds (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) were synthesized with the scheme shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures of 15 Newly Designed Compounds and Their Hsp90 Inhibitory Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The percent of Hsp90α ATPase activity inhibition at the 10 μM of testing compounds.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Anti-Hsp90 and Nasopharyngeal Carcinoma Hit Discovered</h3><div class="NLM_p">We validated the inhibitory activities of the synthesized compounds with Hsp90α ATPase assay. Our results indicated that most compounds containing the Hsp90 binding chemotypes (see <b>3a</b>–<b>3n</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) exhibited Hsp90 inhibitory activities indeed. However, compounds (see <b>3o</b>–<b>3u</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) with other chemotypes (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) significantly lost activities (lower than 10% inhibition at 10 μM). Compounds <b>3d</b> and <b>3n</b> also showed potent binding affinity with Hsp90α and Hsp90β as well as their inhibition effects (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Furthermore, the cytotoxicities of <b>3d</b> and <b>3n</b> were tested on liver cancer, cervical carcinoma, and nasopharyngeal carcinoma (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>3d</b> selectively inhibits nasopharyngeal carcinoma with an IC<sub>50</sub> value of 3.98 μM. Compound <b>3d</b> provides a hit scaffold for further study.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Chemotype-Constructed Substructures and Their Frequency</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">bioassays</th><th class="colsep0 rowsep0" align="center"><b>3d</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>3n</b></th><th class="colsep0 rowsep0" align="center" char="±">17-AAG</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hsp90α <i>K</i><sub>d</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hsp90β <i>K</i><sub>d</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.8 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hsp90α IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hsp90β IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5.6 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char="±">18.1 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hela<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char="±">22.4 ± 3.3</td><td class="colsep0 rowsep0" align="char" char="±">19.4 ± 3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CNE2<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">4.0 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 0.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>d</sub> is tested by SPR.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> indicates ATPase inhibition effects.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">HepG2 indicates liver cancer.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Hela indicates cervical carcinoma.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">CNE2 denotes nasopharyngeal carcinoma.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Binding Model of Hit Compound <b>3d</b> with Hsp90</h3><div class="NLM_p">Molecular dynamic<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> simulations indicate that <b>3d</b> binds to the ATP binding pocket of Hsp90α (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>) through two hydrogen bonds with Thr184 (one of the hydrogen bonds is through a water bridge). Also, a water-mediated interaction net connects <b>3d</b>’s triazole ring to Phe138 and Asn51, which makes the <i>t</i>-butyl benzene ring be docked into a hydrophobic pocket formed with Ala111, Tyr139, Leu107, Phe22, Trp162, and Phe138. This compound does not interact with the key residue Asp93. To further enhance the activity of <b>3d</b>, the benzene ring needs to be modified to establish the binding between <b>3d</b> and Asp93 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compared to NVP-HSP990 and NVP-AUY992, compound <b>3d</b> occupied a different hydrophobic pocket by the <i>t</i>-butyl benzyl group (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,C), and this is similar to TAS-116 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Binding model of compound <b>3d</b> with Hsp90α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>). Compound <b>3d</b> binds to Thr184 through a water bridge (red ball). (B) Overlay of compound <b>3d</b> with NVP-HSP990 (blue color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>). (C) Overlay of compound <b>3d</b> with NVP-AUY922 (red color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>). (D) Overlay of compound <b>3d</b> with TSA-116 (yellow color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Compounds <b>4a</b>–<b>f</b> and <b>5a</b>,<b>b</b> with Their Binding Affinities on Hsp90 Homologues and Inhibition Effects on CNE2 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0010.gif" alt="" id="fx3" /></img><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Anti-Hsp90 Lead Compound <b>4f</b> Discovered</h3><div class="NLM_p">Hence, we synthesized seven <b>3d</b> derivatives (<b>4a</b>–<b>4f</b>) by introducing −OH or −NH<sub>2</sub> groups onto the scaffold of <b>3d</b>. These derivatives exhibited enhanced Hsp90α or Hsp90β inhibitory activities. Specifically, the compounds with <i>para</i>-hydroxyl benzene have significantly increased Hsp90 inhibitory activities. However, the −NH<sub>2</sub> group in ortho position suppresses the activity. The intermediate compound <b>5a</b> further revealed that <i>ortho</i>-NH<sub>2</sub> decreases the Hsp90 inhibition effect. As we hypothesize before, the hydroxy groups do increase the activity like <b>4f</b> 16-fold more potent than <b>5a</b>. Among them, compound <b>4f</b> showed 5-fold more potent Hsp90 inhibition effects than 17-AAG.</div><div class="NLM_p">A molecular dynamics simulation indicates that more binding interactions were formed between 4f and Hsp90α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>) compared to compound <b>4a</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). As expected, two hydroxy groups of <b>4f</b> provide two more hydrogen bonds with Asp93 and one more hydrogen bond with Thr184 compared to <b>3d</b>. Another hydroxy group forms a water-mediated hydrogen bond with Met98. The α-carbon of benzyl provides a hydrogen-bond network with Asn51, Gly135, and Phe138 through water. A p−π conjugation is formed between Leu107 and <i>tert</i>-butyl benzene ring. When Asp93 was mutated to Gly93, the binding affinity between <b>4f</b> and Hsp90α was decreased in 1600-fold (the table in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The mutations at Leu71 and Thr184 also result in a significant decrease of Hsp90 binding affinity. These data proved that the binding model is reasonable.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding model of compound <b>4f</b> with Hsp90α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>) and binding affinity of <b>4f</b> with WT-Hsp90α or mutated Hsp90α. The H-bonds are represented as yellow dashed lines. Waters are represented as the red ball.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Compound <b>4f</b> Prevents Nasopharyngeal Carcinoma <i>in vivo</i> and <i>in vitro</i> through Inhibiting Hsp90</h3><div class="NLM_p">The activity of these newly synthesized compounds was tested on nasopharyngeal carcinoma (see the last column in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">S3</a>). Compound <b>4f</b> exhibited the most potent activity in a dose-dependent manner without cytotoxicity on normal cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">S2, Table S3</a>). Protein kinase B (PKB, <i>aka</i> AKT, an Hsp90 client protein) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">S3</a>) was degraded through the induction of compound <b>4f</b> without changing Hsp90 expression. Thus, PI3K/AKT signaling pathway, which activates many cell survival-related proteins, is regulated. Consequently, <b>4f</b> causes the CNE2 cell apoptosis through PI3K/AKT signaling pathway. The degradation of protein B-cell lymphoma-extra large (Bcl-xL) indicates that compound <b>4f</b> may induce mitochondrial-mediated apoptosis in CNE2 cells. Another key protein HER2 related to cell death was also decreased at 500 nM. All of these data revealed that <b>4f</b> causes cell apoptosis through a multipathway, proteostasis disruption.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vitro</i> and <i>in vivo</i> experiments prove <b>4f</b> is a promising lead against nasopharyngeal carcinoma. (A) Quantification of the apoptotic rate in control and different-dose <b>4f</b>-treated Annexin V-FITC/PI stained CNE2 cells at 48 h. (B) Western blots analysis of the effects of <b>4f</b> on Hsp90, AKT, <i>p</i>-mTOR, and Bcl-xL. (C) Changes in cell viability upon Hsp90α knockdown with and without compound <b>4f</b> at 70 nM. (D) Western blots analysis of the effects of <b>4f</b> on Hsp90, AKT, and Bcl-xL when Hsp90 is knockdown. (E) Cell apoptosis of CNE2 in the mock group and the Hsp90 overexpression group without and with <b>4f</b> treatment. (F) AKT and BCL-2 expression in the mock group and the Hsp90 overexpression group without and with <b>4f</b> treatment. ***: <i>P</i> ≤ 0.001 compared to related groups; ns: nonsignificant difference compared to related groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D also demonstrates that <b>4f</b> cannot induce the CNE2 cell apoptosis after two different Hsp90 siRNAs were treated and <b>4f</b> cannot alter the amount of AKT and Bcl-xL after knockdown of the Hsp90 gene. These data proved that <b>4f</b> does induce the CNE2 cell apoptosis through Hsp90 inhibition. Another rescue assay further confirmed that <b>4f</b> cause CNE2 apoptosis through Hsp90 inhibition. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E, the overexpression of Hsp90 can rescue the cell compared to the mock group (not Hsp90 overexpression) after <b>4f</b> treatment. However, without treating <b>4f</b>, the cell apoptosis is quite similar between the mock group and the Hsp90 overexpression group. The amounts of related proteins like AKT and BCL2 were also increased by Hsp90 overexpression.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B, <i>in vivo</i> studies demonstrated that the tumor sizes were shrunken after 32-day treatment with <b>4f</b>. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C indicates that <b>4f</b> can inhibit the nasopharyngeal tumor growth in a time-dependent manner. Finally, a pharmacokinetic (PK) study was applied to test the druggable property. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D, <i>t</i><sub>1/2</sub> of <b>4f</b> is 1.10 h and the bioavailability (<i>F</i> value) is 12%.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Images of tumors (<i>n</i> = 10) treated with <b>4f</b> or vehicle after 32 days. (B) Tumor weight treated with <b>4f</b> or vehicle after 32 days. (C) Tumor volume in mice (<i>n</i> = 10) treated for the indicated time with <b>4f</b> or vehicle. (D) Pharmacokinetic study of <b>4f</b> in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Here, we reported a novel strategy of hit fragments discovering and assembling. The most potent compound <b>4f</b> was confirmed as an Hsp90 inhibitor to treat nasopharyngeal carcinoma by <i>in vitro</i> and <i>in vivo</i> studies. First, we discovered PFs and chemotypes from known Hsp90. These PFs and chemotypes were then applied for hit fragments discovery. Here, seven main fragments were found, four of which were considered as privileged fragments, two were considered as normal fragments (NFs, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">Table S1</a>), and the last one is considered as a bad fragment (BF, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">Table S1</a>). Like PFs, the NFs also exhibit higher frequency in library P than the other two libraries (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">Table S1</a>). However, their frequency in library P is much lower than PFs (NF1 is 4.19% and NF2 is 2.82%). Different from PFs and NFs, the frequency of BF1 in nonactive library is higher than the other two libraries (4.28% in library N vs 3.68% in library P and 2.11% in library M). Therefore, we consider it as BF because it may decrease activities. The fragments that contain BF1 were also filtered before SPR screening. According to the PFs and BF, 328 hit fragments were extracted from 500 and then confirmed by SPR. The chemotypes are defined as two fragments from PFs and BFs assembled through the linker between them. The linkers are discovered according to our previous study.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this study, PFs and chemotypes are applied for screening fragments to discover potential anti-Hsp90 hit fragments. Since the PFs and chemotypes are extracted from known compounds, they can be employed to build specific fragment databases for given targets in future. These databases may provide a higher success rate of hit fragment identification.</div><div class="NLM_p">The process of optimizing the hit fragments to leads is usually considered as the bottleneck of FBDD. In most cases, it is difficult to understand fragment–protein interactions (reasonable binding model of fragment–protein), which plays a key role in the F2L process. Theoretically, chemotypes can assemble with each other to grow up through same ring overlapping (including homo- and hetero-assembling, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D). This strategy provides a possibility for optimizing fragments when the fragment–protein binding model is difficult to obtain. Our study proved that chemotype assembly can be used for the F2L process without understanding fragment–protein interactions. The novelty of leads discovered by this method is warranted. The combination of different chemotypes provides various novel scaffolds. For example, only two chemotypes assembling can provide more than 80 motifs of scaffold (Markush structures).</div><div class="NLM_p last">The triazole ring formed by click chemistry is a good bioisostere in drug discovery. Norrild et al. also applied the click chemistry for Hsp90 inhibitors and obtained a more potent lead compared to NVP-AUY992.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> At the same time, the triazole ring also matches the chemotypes C1, C2, C4, and C7. All of these encourage us to perform click chemistry for chemotypes assembling. According to the chemotypes and click chemistry, several virtual leads were formed and synthesized. A series <i>in vitro</i> studies were then applied, <b>3d</b> and <b>3n</b> were selected due to their potent Hsp90 binding affinity and inhibition effects. Compound <b>3d</b> exhibited selectivity on nasopharyngeal carcinoma against liver cancer and cervical carcinoma compared to <b>3n</b> and 17-AAG. A possible reason is the isoform selectivity of <b>3d</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">Table S2</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Compound <b>3d</b> exhibited around 10-fold activity on Hsp90α, Hsp90β, and TRAP1 over GRP94, while 17-AAG showed potent activity on GRP94. Compound <b>3d</b> was further optimized due to its selectivity on nasopharyngeal carcinoma. Compound <b>4f</b> with the most potent activity (IC<sub>50</sub> of 160 nM on Hsp90 and 40 nM on nasopharyngeal carcinoma) was obtained. Unusually, the cell apoptosis effect is stronger than the ATPase inhibition effect. Hsp90 is a central chaperone that directs the folding and conformational maturation of its clients. The inhibition of Hsp90 will cause several proteins disfunction or degradation like AKT and HER2. This will lead a multipathway disturbed and therefore cause more potent inhibition effects on cell death.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, with chemotyping analysis approach and click chemistry, we have designed, synthesized, and validated new Hsp90 inhibitors with a novel scaffold. <i>In vitro</i> and <i>in vivo</i> experiments demonstrate that the new inhibitor can be a promising lead for nasopharyngeal carcinoma treatment. Our method might be applied in discovering new ligands against the targets that structures of the binding models are not well understood. Of cause, it will be even better if the binding mechanisms are understood.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Materials</h3><div class="NLM_p last">Chemicals were purchased from Energy Chemical Co., Sigma-Aldrich Co., or Tokyo Chemical Industry Co. and utilized without further purification. Solvents were distilled prior to use. For <i>in vitro</i> and <i>in vivo</i> assay, RPMI 1640 medium and Lipofectamine 2000 were purchased from Thermo Fisher (Thermo Fisher Scientific); Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco (Gibco); penicillin and streptomycin were purchased from Hyclone (Hyclone); and phosphate-buffered saline (PBS) was purchased from Gibco (Gibco, NY). Cell apoptosis was detected using Annexin V-FITC Apoptosis Detection Kit (Yeasen, China). ATPase activity was detected using the ATP, nicotinamide adenine dinucleotide (NADH), phosphoenolpyruvate (PEP), and pyruvate kinase/lactic dehydrogenasea. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide (MTT) and cell dissociation solution were obtained from Sigma-Aldrich (Sigma-Aldrich, St Louis, MO).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> NMR Spectroscopy and Mass Spectrometry</h3><div class="NLM_p last"><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were collected on a BRUKER 400 MHz spectrometer and were calibrated with tetramethylsilane. The NMR data are displayed as follows: chemical shifts (δ) are recorded as ppm, coupling constants (<i>J</i>) in hertz (Hz), integrity as the number of protons, and multiplicity as s (singlet), d (doublet), t (triplet), q (quartet), quintet, sextet, and m (multiplet). Mass spectra were obtained on a Shimadzu LCMS-2010EV utilizing the electron-spray ionization method (ESI-MS). Thin-layer chromatography (TLC) was carried out using plates coated with silica gel GF254, purchased from Merck. Column chromatography was performed using Merck silica gel 60 (70–230 mesh).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Purity</h3><div class="NLM_p last">Purity of all final compounds was ≥95%, as determined by high-performance liquid chromatography (HPLC, SHIMADZU LC-20AT, Japan). Compounds were dissolved at a concentration of 0.5 mg/mL in methanol. Then, 150 μL of the sample was injected into an Agilent XDB-C18 HPLC column (4.6 m × 250 mm; particle size, 5 μm) and chromatographed using a gradient of water/MeCN from 90:10 to 50:50 for 15 min at a flow rate of 250 μL/min. UV absorption was detected from 100 to 950 nm using a diode array detector.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Animals</h3><div class="NLM_p last">We performed all procedures on mice and rats with approval by the Sun Yat-sen University Institutional Animal Care and Use Committee. The C57BL/6 mice and female Sprague-Dawley (SD) rats were obtained from Guangdong Medical Lab Animal Center. The mice and rats were maintained in pressurized ventilated cages under conditions of repeated controlled illumination (12 h dark; 12 h light) with ad libitum access to sterilized water and food.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Synthesis Procedure</h3><div class="NLM_p">Bromide-substituted compound <b>1</b>, NaN<sub>3</sub>, and CuI were added into dimethyl sulfoxide (DMSO) and H<sub>2</sub>O (5:1). The mixture was stirred at room temperature for 0.5 h. Then, the alkene-substituted materials <b>2</b> and DBU were added into the mixture and stirred at 70 °C for 8 h. The mixture was followed by extraction with EtOAc. The extract was then washed with water brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated <i>in vacuo</i>. The residue was purified by column chromatography to give products as a solid.</div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6-(4-(4-Methoxyphenyl)-1<i>H</i>-1,2,3-triazol-1-yl)isoquinoline (<b>3a</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromoisoquinoline (208 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3a</b> as a white solid (259 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.91 (s, 1H), 8.20 (d, <i>J</i> = 8.0 Hz, 1H), 8.07 (s, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.71 (d, <i>J</i> = 8.0 Hz, 2H), 7.62 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 2H), 1.35 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 152.5, 151.3, 148.0, 143.4, 136.6, 131.4, 130.2, 128.9, 128.0, 127.4, 127.3, 125.5, 125.4, 123.9, 120.9, 34.2, 31.3. ESI-MS <i>m</i>/<i>z</i>: 329.16 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-(4-(4-(<i>tert</i>-Butyl)phenyl)-1<i>H</i>-1,2,3-triazol-1-yl)isoquinoline (<b>3b</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromoisoquinoline (208 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3b</b> as a white solid (163 mg, 54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.98 (s, 1H), 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (s, 1H), 7.55 (s, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 2H), 7.42–7.40 (m, 2H), 7.05 (d, <i>J</i> = 8.0 Hz, 2H), 3.83 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.6, 152.5, 148.0, 143.4, 136.6, 131.4, 130.2, 128.9, 127.4, 123.9, 122.7, 120.9, 114.8, 55.8. ESI-MS <i>m</i>/<i>z</i>: 302.11 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-(4-(<i>tert</i>-Butyl)benzyl)-4-(4-(<i>tert</i>-butyl)phenyl)-1<i>H</i>-1,2,3-triazole (<b>3c</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-<i>(t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3c</b> as a white solid (246 mg, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.64 (s, 1H), 7.36–7.33 (m, 3H), 7.16 (d, <i>J</i> = 8.0 Hz, 2H), 5.45 (s, 2H), 1.25 (s, 9H), 1.24 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.8, 150.2, 147.1, 130.7, 126.8, 126.7, 125.0, 124.7, 124.4, 118.2, 52.9, 33.6, 30.2, 30.2. ESI-MS <i>m</i>/<i>z</i>: 348.24 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-(4-(<i>tert</i>-Butyl)benzyl)-4-(4-methoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3d</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-<i>(t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3d</b> as a white solid (189 mg, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.50 (s, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 2H), 7.17 (d, <i>J</i> = 8.0 Hz, 2H), 6.84 (d, <i>J</i> = 8.0 Hz, 2H), 5.44 (s, 2H), 3.74 (s, 3H), 1.21 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.5, 150.8, 147.0, 130.7, 126.8, 126.0, 125.0, 122.3, 117.7, 113.1, 113.1, 54.3, 52.9, 33.6, 30.2, 28.7. ESI-MS <i>m</i>/<i>z</i>: 322.18 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(4-(<i>tert</i>-Butyl)phenyl)-1-(4-phenoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3e</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromo-4-phenoxybenzene (248 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3e</b> as a white solid (239 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (s, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 2H), 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.43–7.41 (m, 2H), 7.34–7.30 (m, 2H), 7.13–7.06(m, 3H), 7.02–6.99 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 156.79, 155.35, 150.55, 147.36, 131.31, 128.99, 126.38, 124.82, 124.56, 123.09, 121.22, 118.37, 118.31, 116.39, 33.70, 30.27. ESI-MS <i>m</i>/<i>z</i>: 370.18 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-(4-Methoxyphenyl)-1-(4-phenoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3f</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromo-4-phenoxybenzene (248 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3f</b> as a white solid (209 mg, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 2H), 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.35–7.31 (m, 2H), 7.13–7.08 (m, 4H), 6.99–6.91 (m, 3H), 3.79 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3)</sub> δ 158.78, 156.79, 131.31, 128.99, 126.13, 123.10, 121.91, 121.21, 118.39, 118.30, 115.91, 113.31, 54.33. ESI-MS <i>m</i>/<i>z</i>: 344.13 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-(4-(<i>tert</i>-Butyl)phenyl)-1-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-1<i>H</i>-1,2,3-triazole (<b>3g</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine (213 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3g</b> as a white solid (211 mg, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07 (s, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (s, 1H), 7.26 (d, <i>J</i> = 8.0 Hz, 1H), 4.34 (s, 3H), 1.39 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 151.5, 148.2, 144.1, 144.0, 131.0, 127.5, 125.8, 125.6, 118.0, 117.4, 113.7, 110.2, 64.4, 64.4, 34.7, 31.3. ESI-MS <i>m</i>/<i>z</i>: 336.16 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-4-(4-methoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3h</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine (213 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3h</b> as a white solid (127 mg, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.78 (s, 1H), 7.27 (s, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 2H), 6.95 (s, 1H), 6.89–6.77 (m, 3H), 4.30–4.29 (m, 4H), 3.82 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.7, 147.5, 144.3, 144.0, 130.9, 127.1, 123.4, 119.1, 118.4, 114.9, 113.4, 109.6, 64.8, 64.6, 55.7. ESI-MS <i>m</i>/<i>z</i>: 310.11 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-4-(4-(<i>tert</i>-butyl)phenyl)-1<i>H</i>-1,2,3-triazole (<b>3i</b>)</h4><div class="NLM_p last">The general procedure was applied with 5-bromobenzo[<i>d</i>][1,3]dioxole (200 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3i</b> as a white solid (179 mg, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.75 (d, <i>J</i> = 8.0 Hz, 2H), 7.41 (d, <i>J</i> = 8.0 Hz, 2H), 7.24 (d, <i>J</i> = 4.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.85 (d, <i>J</i> = 8.0 Hz, 1H), 6.01 (s, 2H), 1.29 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.5, 147.6, 147.2, 146.9, 130.6, 126.4, 124.8, 124.5, 116.6, 113.1, 107.5, 101.7, 101.1, 33.7, 30.3, 28.7. ESI-MS <i>m</i>/<i>z</i>: 322.14 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-4-(4-methoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3j</b>)</h4><div class="NLM_p last">The general procedure was applied with 5-bromobenzo[<i>d</i>][1,3]dioxole (200 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3j</b> as a white solid (126 mg, 43%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.01 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.10 (d, <i>J</i> = 8.0 Hz, 2H), 7.08 (d, <i>J</i> = 8.0 Hz, 1H), 6.89 (d, <i>J</i> = 8.0 Hz, 1H), 6.83 (s, 1H), 6.07(s, 2H), 3.84 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.6, 148.8, 148.0, 131.4, 128.5, 122.7, 121.8, 118.9, 114.8, 114.6, 109.3, 101.2, 55.8. ESI-MS <i>m</i>/<i>z</i>: 296.09 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(4-(<i>tert</i>-Butyl)phenyl)-1-(4-(trifluoromethyl)benzyl)-1<i>H</i>-1,2,3-triazole (<b>3k</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-(trifluoromethyl)benzene (225 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3k</b> as a white solid (183 mg, 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 8.0 Hz, 2H), 7.60 (s, 1H), 7.56 (d, <i>J</i> = 8.0 Hz, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (d, <i>J</i> = 8.0 Hz, 2H), 5.56 (s, 2H), 1.26 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.50, 147.53, 137.75, 127.07, 126.39, 125.10, 125.07, 125.03, 124.76, 124.44, 118.28, 52.46, 33.65, 30.24. ESI-MS <i>m</i>/<i>z</i>: 360.05 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(4-Methoxyphenyl)-1-(4-(trifluoromethyl)benzyl)-1<i>H</i>-1,2,3-triazole (<b>3l</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-(trifluoromethyl)benzene (225 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3k</b> as a white solid (179 mg, 54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.58–7.55 (m, 3H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H), 6.87 (d, <i>J</i> = 8.0 Hz, 2H), 5.55 (s, 2H), 3.76 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.7, 147.4, 137.7, 133.0, 127.1, 126.0, 125.1, 125.1, 125.0, 121.9, 117.7, 113.2, 113.1, 54.3, 52.5. ESI-MS <i>m</i>/<i>z</i>: 334.10 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(3,5-Bis(trifluoromethyl)benzyl)-4-(4-(<i>tert</i>-butyl)phenyl)-1<i>H</i>-1,2,3-triazole (<b>3m</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene (305 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3m</b> as a white solid (277 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (s, 1H), 7.69–7.66 (m, 5H), 7.37 (d, <i>J</i> = 8.0 Hz, 2H), 5.62 (s, 2H), 1.26 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.7, 147.8, 136.4, 131.8, 131.4, 126.9, 126.9, 126.2, 124.8, 124.5, 121.8, 121.8, 121.7, 118.3, 51.9, 33.7, 30.22. ESI-MS <i>m</i>/<i>z</i>: 428.14 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(3,5-Bis(trifluoromethyl)benzyl)-4-(4-methoxyphenyl)-1<i>H</i>-1,2,3-triazole (<b>3n</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene (305 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxybenzene (132 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3n</b> as a white solid (236 mg, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.66 (s, 1H), 7.48 (s, 2H), 7.31 (d, <i>J</i> = 8.0 Hz, 2H), 5.50 (s, 2H), 3.84 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.7, 147.4, 137.7, 133.0, 127.1, 126.0, 125.1, 125.1, 125.0, 121.9, 117.7, 113.2, 113.1, 54.3, 52.5. ESI-MS <i>m</i>/<i>z</i>: 402.09 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-(4-(Thiophen-2-yl)-1<i>H</i>-1,2,3-triazol-1-yl)isoquinoline (<b>3o</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromoisoquinoline (206 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3o</b> as a yellow solid (239 mg, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.15 (s, 1H), 8.56 (d, <i>J</i> = 4.0 Hz, 1H), 7.91–8.86 (m, 3H), 7.39 (t, <i>J</i> = 4.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 151.7, 143.4, 133.9, 132.9, 128.6, 126.7, 126.4, 120.5, 118.3. ESI-MS <i>m</i>/<i>z</i>: 279.16 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(4-(<i>tert</i>-Butyl)benzyl)-4-(thiophen-2-yl)-1<i>H</i>-1,2,3-triazole (<b>3p</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-(<i>t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3p</b> as a white solid (216 mg, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50–7.47 (m, 4H), 7.24–7.22 (m, 3H), 5.48 (s, 2H), 2.21 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.6, 175.3, 169.4, 165.6, 158.2, 138.3, 138.1, 114.4, 113.9, 95.70, 91.2, 51.3, 30.7, 21.7. ESI-MS <i>m</i>/<i>z</i>: 298.41 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(4-Phenoxyphenyl)-4-(thiophen-2-yl)-1<i>H</i>-1,2,3-triazole (<b>3q</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromo-4-phenoxybenzene (248 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3q</b> as a yellow solid (178 mg, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.66–7.62 (m, 2H), 7.41–7.40 (m, 1H), 7.35–7.31 (m, 2H), 7.30–7.27 (m, 1H), 7.11–6.99 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 156.9, 129.0, 126.7, 124.4, 123.5, 123.2, 121.3, 118.4, 118.3, 116.2, 28.7. ESI-MS <i>m</i>/<i>z</i>: 320.07 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-4-(thiophen-2-yl)-1<i>H</i>-1,2,3-triazole (<b>3r</b>)</h4><div class="NLM_p last">The general procedure was applied with 6-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine (213 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3r</b> as a white solid (131 mg, 46%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92(s, 0.5H), 8.82 (s, 0.5H), 7.27–7.12 (m, 2H), 7.04–6.90 (m, 3H), 4.24 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 143.1, 131.4, 129.6, 126.7, 124.8, 124.3, 124.1, 123.5, 117.0, 116.3, 112.8, 109.3, 63.4. ESI-MS <i>m</i>/<i>z</i>: 286.05 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-4-(thiophen-2-yl)-1<i>H</i>-1,2,3-triazole (<b>3s</b>)</h4><div class="NLM_p last">The general procedure was applied with 5-bromobenzo[<i>d</i>][1,3]dioxole (200 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3s</b> as a white solid (143 mg, 53%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (s, 1H), 7.59 (d, <i>J</i> = 4.0 Hz, 1H), 7.53 (d, <i>J</i> = 4.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.19 (t, <i>J</i> = 4.0 Hz, 1H), 7.16 (d, <i>J</i> = 8.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 148.7, 148.0, 142.9, 132.9, 131.4, 128.5, 126.3, 124.9, 119.6, 114.4, 109.1, 102.7, 102.5. ESI-MS <i>m</i>/<i>z</i>: 272.057 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(Thiophen-2-yl)-1-(4-(trifluoromethyl)benzyl)-1<i>H</i>-1,2,3-triazole (<b>3t</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-(trifluoromethyl)benzene (225 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3t</b> as a white solid (207 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.55 (s, 2H), 7.32 (d, <i>J</i> = 8.0 Hz, 2H), 7.27 (d, <i>J</i> = 4.0 Hz, 1H), 7.21 (d, <i>J</i> = 4.0 Hz, 1H), 7.19 (s, 1H), 6.98 (t, <i>J</i> = 4.0 Hz, 1H), 5.54 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 142.58, 137.45, 131.52, 127.16, 126.62, 125.14, 125.07, 124.24, 123.33, 118.05, 52.53. ESI-MS <i>m</i>/<i>z</i>: 310.05 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(3,5-Bis(trifluoromethyl)benzyl)-4-(thiophen-2-yl)-1<i>H</i>-1,2,3-triazole (<b>3u</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene (305 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 2-ethynylthiophene (108 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide product <b>3u</b> as a white solid (297 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82 (s, 1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.31 (d, <i>J</i> = 4.0 Hz, 1H), 7.24 (d, <i>J</i> = 4.0 Hz, 1H), 7.00 (t, <i>J</i> = 4.0 Hz, 1H), 5.61 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 142.9, 136.1, 131.9, 131.6, 131.3, 127.1, 126. 7, 124.5, 123.6, 121.9, 120.5, 118.0, 52.0. ESI-MS <i>m</i>/<i>z</i>: 378.04 [M + H] <sup>+</sup>.</div></div><div id="sec5_5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-(1-(4-(<i>tert</i>-Butyl)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)phenol (<b>4a</b>)</h4><div class="NLM_p last">Compound <b>3d</b> (160 mg, 0.5 mmol) was added into hydrobromic acid (48% in water, 10 mL) and stirred at 120 °C for 12 h. Then, the solvent was removed <i>in vacuo</i> to give targeted compound <b>4a</b> as a white solid (291 mg, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.56 (d, <i>J</i> = 8.0 Hz, 2H), 7.51 (s, 1H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H), 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 6.81 (d, <i>J</i> = 8.0 Hz, 1H), 5.45 (s, 2H), 1.24 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.7, 151.1, 147.4, 133.7, 128.1, 127.0, 125.9, 122.2, 120.5, 116.1, 53.1, 34.8, 31.5. ESI-MS <i>m</i>/<i>z</i>: 308.39 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-(<i>tert</i>-Butyl)-5-((4-(4-hydroxyphenyl)-1<i>H</i>-1,2,3-triazol-1-yl)methyl)phenol (<b>4b</b>)</h4><div class="NLM_p last">The general procedure was applied with 4-(bromomethyl)-1-(<i>tert-</i>butyl)-2-methoxybenzene (256 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 4-<i>t</i>-butylphenylacetylene (158 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide intermediate as a white solid. The intermediate (176 mg, 0.5 mmol) was added into hydrobromic acid (48% in water, 10 mL) and stirred at 120 °C for 12 h. Then, the solvent was removed in vacuum to give targeted compound <b>4b</b> as a white solid (141 mg, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.57 (s, 1H), 9.44 (s, 1H), 8.39 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 2H), 6.72–6.55 (m, 2H), 5.48 (s, 2H), 1.31 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.7, 156.5, 147.4, 135.6, 135.2, 127.1, 127.0, 120.6, 118.4, 116.1, 115.5, 53.0, 34.6, 29.7. ESI-MS <i>m</i>/<i>z</i>: 324.38 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(1-(4-(<i>tert</i>-Butyl)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)-5-methoxyaniline (<b>4c</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-<i>(t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxy-2-nitrobenzene (177 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide intermediate as a white solid. The intermediate (188 mg, 0.5 mmol) was then added into MeOH with Pd/C (50 mg). The air was replaced by H<sub>2</sub>. The mixture was stirred at r.t. for 8 h and filtered. The filtrate was collected and purified by falsh column to afford the desired compound <b>4c</b> as a white solid (145 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47 (s, 1H), 7.42–7.29 (m, 4H), 6.34–6.18 (m, 3H), 5.59 (s, 2H), 3.35 (s, 3H), 1.26 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.2, 151.1, 148.2, 147.6, 133.6, 129.2, 128.2, 126.0, 120.8, 106.6, 103.2, 100.5, 55.2, 53.2, 34.7, 31.5. ESI-MS <i>m</i>/<i>z</i>: 337.43 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(1-(4-(<i>tert</i>-Butyl)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)-3-nitrophenol (<b>4d</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-(<i>t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 1-ethynyl-4-methoxy-2-nitrobenzene (177 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide intermediate as a white solid. The intermediate (188 mg, 0.5 mmol) was added into hydrobromic acid (48% in water, 10 mL) and stirred at 120 °C for 12 h. Then, the solvent was removed in vacuum to give targeted compound <b>4d</b> as a white solid (169 mg, 96%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (brs, 1H), 8.40 (s, 1H), 7.61 (d, <i>J</i> = 8.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 2H), 7.28 (d, <i>J</i> = 8.0 Hz, 2H), 7.23 (d, <i>J</i> = 8.0 Hz, 1H), 7.44–7.11 (m, 1H), 5.60 (s, 2H), 1.27 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.4, 149.4, 142.6, 133.5, 132.2, 128.2, 126.0, 123.2, 120.0, 114.8, 110.9, 53.1, 34.8, 31.5. ESI-MS <i>m</i>/<i>z</i>: 353.38 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-Amino-4-(1-(4-(<i>tert</i>-butyl)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)phenol (<b>4e</b>)</h4><div class="NLM_p last">Compound <b>4d</b> (176 mg, 0.5 mmol) was then added into MeOH with Pd/C (50 mg). The air was replaced by H<sub>2</sub>. The mixture was stirred at r.t. for 8 h and filtered. The filtrate was collected and purified by flash column to afford desired compound <b>4e</b> as a white solid (148 mg, 92%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.52 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 2H), 7.26 (d, <i>J</i> = 8.0 Hz, 2H), 6.33 (s, 1H), 6.19 (d, <i>J</i> = 8.0 Hz, 1H), 5.58 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.4, 148.3, 145.9, 133.1, 130.3, 128.6, 126.1, 123.2, 120.1, 104.7, 101,2, 56.5, 34.7, 31.4. ESI-MS <i>m</i>/<i>z</i>: 323.41 [M + H]<sup>+</sup>.</div></div><div id="sec5_5_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-(1-(4-(<i>tert</i>-Butyl)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)benzene-1,2,3-triol (<b>4f</b>)</h4><div class="NLM_p last">The general procedure was applied with 1-bromomethyl-4-<i>(t</i>-butyl)benzene (212 mg, 1 mmol), NaN<sub>3</sub> (65 mg, 1 mmol), CuI (19 mg, 0.1 mmol), 5-ethynyl-1,2,3-trimethoxybenzene (192 mg, 1 mmol), and DBU (304 mg, 2 mmol) to provide intermediate as a white solid. The intermediate <b>5a</b> (190 mg, 0.5 mmol) was added into hydrobromic acid (48% in water, 10 mL) and stirred at 120 °C for 12 h. Then, the solvent was removed in vacuum to give targeted compound <b>4f</b> as a white solid (160 mg, 94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 8.32 (s, 1H), 8.20 (s, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 2H), 7.28 (d, <i>J</i> = 8.0 Hz, 2H), 6.72 (d, <i>J</i> = 8.0 Hz, 1H), 5.53 (s, 2H), 1.26 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.0, 147.7, 146.8, 133.7, 133.6, 128.2, 125.9, 121.7, 120.6, 104.9, 53.1, 34.7, 31.5. ESI-MS <i>m</i>/<i>z</i>: 340.38 [M + H]<sup>+</sup>. Purity: 97.3%.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Expression and Purification of Proteins</h3><div class="NLM_p last">The <i>Escherichia coli</i> strain BL21 was transformed with pET28a-Hsp90α, pET28a- Hsp90β, and pET28a-Hsp90α-mutants; cultured in LB medium containing 50 mg/mL kanamycin at 37 °C to an absorbance of 0.6 at 600 nm; and induced with 1 mM IPTG for 16 h at 16 °C before being harvested by centrifugation. The cell pellets were suspended in lysis buffer (10 mM Tris, pH 7.5, 200 mM NaCl, 1 mM DTT) and disrupted by sonication. After centrifugation, the supernatant was applied to a Ni-NTA column and proteins were eluted with elution buffer (10 mM Tris, pH 7.5, 200 mM NaCl, 1 mM DTT, and 400 mM imidazole). The 6-His-tag was removed by digestion with thrombin. The samples were exchanged and further purified with the buffer using size exclusion chromatography (S200 Sephacryl column, GE) in 50 mM HEPES, 200 mM NaCl, and 1 mM DTT. Fractions containing the protein were analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and fractions showing a single band corresponding to the expected molecular weight were pooled, resulting in >95% pure protein samples.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Surface Plasmon Resonance (SPR) Assay</h3><div class="NLM_p last">SPR technology-based binding assays were performed on a Biacore T200 instrument (GE Healthcare) at 25 °C with running buffer PBST (phosphate-buffered saline, pH 7.4, containing 0.005% Tween-20). Protein was dissolved in the coupling buffer (20 μg/mL in 10 mM sodium acetate [pH 5.0]) and immobilized onto the CM5 chip. The chip was first equilibrated with PBST overnight. Inhibitors with 10 μM were serially diluted and injected at a flow rate of 30 μL/min for 120 s (contact phase) followed by 120 s (dissociation phase). The binding data were determined using Biacore T200 evaluation software (GE Healthcare).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> ATPase Activity Assay</h3><div class="NLM_p last">The ATPase activity assay is based on the conversion of phosphoenolpyruvate (PEP) to pyruvate by pyruvate kinase (PK) coupled to the conversion of pyruvate to lactate by lactate dehydrogenase (LDH) at the expense of NADH.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> NADH has an excitation wavelength of 340 nm, and the oxidation of NADH to NAD<sup>+</sup> produces a decrease of absorbance at 340 nm. The reaction buffer contained 150 mM Tris-HCl, pH 7.6, 40 mM KCl, 10 mM MgCl<sub>2</sub>, 1.2 mM ATP, 0.1 mM NADH, 8 mM PEP, and 10 μL of pyruvate kinase/lactic dehydrogenase enzymes (Sigma). The reaction was started by addition of 2 μM Hsp90 protein at 37 °C. The ATPase activity was determined by tracking the decrease in the absorbance at 340 nm. The compounds were added to the reaction mixture to test the inhibition of Hsp90 ATPase activity. 17-AAG as a positive control.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Cells Culture and Cytotoxicity Assay</h3><div class="NLM_p last">The poorly differentiated human nasopharyngeal carcinoma (CNE2), HeLa, and HepG2 cell lines were obtained from the Cancer Center of Sun Yat-sen University. CNE2 was cultured in RPMI 1640 medium with 10% fetal bovine serum (v/v) and supplementary 1% (v/v) penicillin/streptomycin. HeLa and HepG2 cell lines were cultured in DMEM with 10% fetal bovine serum (v/v) and supplementary 1% (v/v) penicillin/streptomycin. All cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. Exponentially growing cells were seeded at 3 × 10<sup>3</sup> cells per well in 96-well culture plates for 24 h. The cells were exposed to increasing concentrations (0–20 μM) of inhibitors for 48 h. The equal volume of DMSO was used as the solvent control. MTT solution (10 μL) was added to each well (0.5 mg/mL) and incubated for another 3 h. Then, the formazan crystals were dissolved in 150 μL of DMSO and light absorbance of the solution was measured at 570 nm, with a reference wavelength of 630 nm, on a multiscanner autoreader (M450; Bio-Rad). The IC<sub>50</sub> values were calculated using the PrismPad program.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Apoptosis Assay</h3><div class="NLM_p last">CNE2 cells were seeded in a 24-well plate (5 × 10<sup>4</sup> cells/well). After 24 h, the cells were treated with compound (DMSO 0.05%). After 12 h, the cells were washed twice with PBS and collected from the 24-well plate into FACS tubes. The tubes were centrifuged at 1500 rpm for 5 min and washed with 1 mL of PBS. The cells were centrifuged again at 1500 rpm for 5 min and prepared in mastermix (100 μL of 1 × binding buffer, 5 μL of Annexin V/FITC, and 3 μL of PI in each sample). The resuspended cells in 100 μL of mastermix were incubated for 15 min at room temperature in the dark and tested by FACS to evaluate apoptotic cells. Results are represented as mean and s.e.m. of at least three independent experiments.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Immunoblotting</h3><div class="NLM_p last">CNE2 (15 × 10<sup>6</sup> cells/mL) cells were incubated with inhibitors for 24 h. The cells were collected and washed with ice-cold PBS three times. Then, the cells were lysed with RIPA buffer for 30 min on ice. Total cellular protein from each sample was loaded onto 8–12% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) gels. The proteins were transferred to poly(vinylidene fluoride) (PVDF) membranes (Millipore), and the membranes were blocked with 5% nonfat milk for 1 h. The membranes were probed with primary antibodies overnight, washed with TBST for 30 min, exposed to horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h, and washed again in TBST for 30 min. Immunoreactive material was detected using the chemiluminescence method. Actin was used as the loading control.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Hsp90α Knockdown Assay</h3><div class="NLM_p last">For transient transfection, the cells were transfected with siHsp90-1 (5′-AAAGCGUUCAUGGAAGCUUUG-3′) or siHsp90-2 (5′-GCUUGACAGAUCCCAGUAATT-3′) at a final concentration of 150 nM using Lipofectamine 2000. The cells were then collected for cytotoxicity assay and immunoblotting assay.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Xenograft Studies</h3><div class="NLM_p last">Nude mice (nu/nu, male 6–8 weeks old) were subcutaneously injected with 10 × 10<sup>6</sup> CNE2 cell on their right flanks. For evaluation of inhibitor using xenograft mice, the molecule was administered daily by i.p. oral with a dose of 1 mg/kg for 6 days after subcutaneous injection of CNE2 cells on the right flank of each mouse. Tumor growth was recorded by measurement of two perpendicular diameters of the tumors over a 3-week period using the formula 4π/3 × (width/2)<sup>2</sup> × (length/2). The tumors were harvested and weighed at the experimental endpoint, and the masses of tumors (g) treated with vehicle control (DMSO) and <b>4f</b> were compared by a two-tailed unpaired Student’s <i>t</i> test.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> PK Study</h3><div class="NLM_p last">Nine male Kunming mice were treated on pharmacokinetic study. All of the animals were 9–11 weeks old with body weight of about 23 g. For two PK studies, four mice per group received a single dose of <b>4f</b>. For both intravenous injection and oral administration PK studies, 2 mg/kg of <b>4f</b> were given. Blood samples were collected at 0 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, and 6 h post dose. Preparation of samples from the pharmacokinetic studies on the mice was performed using 40 μL of plasma sample, then centrifugation supernatant was obtained. Acetonitrile was added (200 μL) to precipitate plasma proteins, and then the sample was centrifuged for 10 min at 12 000 rpm. The supernatant was transferred to a new tube and frozen at −80 °C until analysis by HPLC (WOOKING, K2025, China). Pharmacokinetic data were analyzed by Pkweb.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Statistics</h3><div class="NLM_p last">Mean ± s.d. was calculated to express numerical data and histograms. A two-tailed Student’s <i>t</i>-test was performed between two groups and a difference was considered statistically significant with <i>P</i> < 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01521" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01521?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01521</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra and HPLC traces of compound <b>4f</b>; SPR response of hit fragments with HSP90 (Figure S1); nontoxicity of compound <b>4f</b> on normal human hepatic cells (Figure S2); gray values of AKT expression in CNE2 cells after <b>4f</b> treatment (Figure S3); anti-Hsp90 fragments and their frequencies (Table S1); selectivity of 17-AAG, <b>3d</b>, and <b>4f</b> among Hsp90 isoforms (Table S2); and cytotoxicity of <b>4a–f</b> on normal cell 293T (Table S3) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf">jm0c01521_si_001.pdf (2.25 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_002.csv">jm0c01521_si_002.csv (2.0 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01521" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daoguang Yan</span> - <span class="hlFld-Affiliation affiliation">Department
of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#592d203d3e1933372c773c3d2c773a37"><span class="__cf_email__" data-cfemail="becac7dad9fed4d0cb90dbdacb90ddd0">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiong Gu</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6011-3697" title="Orcid link">http://orcid.org/0000-0001-6011-3697</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#187f6d697177767f5875797174366b616b6d367d7c6d367b76"><span class="__cf_email__" data-cfemail="c4a3b1b5adabaaa384a9a5ada8eab7bdb7b1eaa1a0b1eaa7aa">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Xu</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Biotechnology and Health Sciences, Wuyi
University, 99 Yingbin
Road, Jiangmen 529020, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1075-0337" title="Orcid link">http://orcid.org/0000-0002-1075-0337</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4228372c3a3702202b2d212a272f2d2f27316c212d2f"><span class="__cf_email__" data-cfemail="97fde2f9efe2d7f5fef8f4fff2faf8faf2e4b9f4f8fa">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengyang Xu</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zhao</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span>; 
    <span class="hlFld-Affiliation affiliation">Shenzhen
Cell Inspire Therapeutics Co., Ltd., Shenzhen 518101, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biying Zhu</span> - <span class="hlFld-Affiliation affiliation">Department
of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liangyue Wang</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huihao Zhou</span> - <span class="hlFld-Affiliation affiliation">Research
Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9675-5007" title="Orcid link">http://orcid.org/0000-0002-9675-5007</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.X. and C.Z. contributed equally to this work. M.X., C.Z., Q.G., and J.X. designed the overall study. C.Z. performed the in silico experiments and chemical experiments. M.X. and L.W. performed in vitro biological experiments and SPR study. B.Z. performed in vivo study. H.Z., D.Y., Q.G., and J.X. supervised the overall study. C.Z., H.Z., D.Y., Q.G., and J.X. wrote and edited the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2948-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded in part by the National Natural Science Foundation of China (8180131061, 81473138, 81573310, 81803361), National Key R&D Program of China (2017YFB0203403), the Science and Technology Program of Guangzhou (201604020109), the Guangdong Provincial Key Lab. of New Drug Design and Evaluation (Grant 2011A060901014), and the China Postdoctoral Science Foundation(2020M673089).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">FBDD</td><td class="NLM_def"><p class="first last">fragment-based drug design</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">receptor tyrosine-protein kinase erbB-2</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">BCR-ABL</td><td class="NLM_def"><p class="first last">breakpoint cluster region-c-abl oncogene 1</p></td></tr><tr><td class="NLM_term">F2L</td><td class="NLM_def"><p class="first last">fragment to lead</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">TSA</td><td class="NLM_def"><p class="first last">thermal shift assays</p></td></tr><tr><td class="NLM_term">SSSR</td><td class="NLM_def"><p class="first last">smallest set of smallest rings</p></td></tr><tr><td class="NLM_term">LXRβ</td><td class="NLM_def"><p class="first last">liver X receptor-β</p></td></tr><tr><td class="NLM_term">DSGA</td><td class="NLM_def"><p class="first last">de novo substructure generation algorithm</p></td></tr><tr><td class="NLM_term">SCA</td><td class="NLM_def"><p class="first last">scaffold-based classification approach</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat-shock protein 90</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">Bcl-xL</td><td class="NLM_def"><p class="first last">B-cell lymphoma-extra large</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2Fj.chembiol.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=30639261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=352-365&author=Z.+Liuauthor=H.+Liauthor=L.+Heauthor=Y.+Xiangauthor=C.+Tianauthor=C.+Liauthor=P.+Tanauthor=J.+Jingauthor=Y.+Tianauthor=L.+Duauthor=Y.+Huangauthor=L.+Hanauthor=M.+Liauthor=Y.+Zhou&title=Discovery+of+Small-Molecule+Inhibitors+of+the+HSP90-Calcineurin-NFAT+Pathway+against+Glioblastoma&doi=10.1016%2Fj.chembiol.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma</span></div><div class="casAuthors">Liu, Zhenzhen; Li, Hongli; He, Lian; Xiang, Yu; Tian, Chengsen; Li, Can; Tan, Peng; Jing, Ji; Tian, Yanpin; Du, Lupei; Huang, Yun; Han, Leng; Li, Minyong; Zhou, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-365.e7</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is among the most common and malignant types of primary brain tumors in adults, with a dismal prognosis.  Although alkylating agents such as temozolomide are widely applied as the first-line treatment for GBM, they often cause chemoresistance and remain ineffective with recurrent GBM.  Alternative therapeutics against GBM are urgently needed in the clinic.  We report herein the discovery of a class of inhibitors (YZ129 and its derivs.) of the calcineurin-NFAT pathway that exhibited potent anti-tumor activity against GBM.  YZ129-induced GBM cell-cycle arrest at the G2/M phase promoted apoptosis and inhibited tumor cell proliferation and migration.  At the mol. level, YZ129 directly engaged HSP90 to antagonize its chaperoning effect on calcineurin to abrogate NFAT nuclear translocation, and also suppressed other proto-oncogenic pathways including hypoxia, glycolysis, and the PI3K/AKT/mTOR signaling axis.  Our data highlight the potential for targeting the cancer-promoting HSP90 chaperone network to treat GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofnM49ki0s27Vg90H21EOLACvtfcHk0lhoO6guzhzbUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFOjug%253D%253D&md5=ebc761eb787ddda1532ea6f9a33192d4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Small-Molecule%2520Inhibitors%2520of%2520the%2520HSP90-Calcineurin-NFAT%2520Pathway%2520against%2520Glioblastoma%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D352%26epage%3D365%26doi%3D10.1016%2Fj.chembiol.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Unleashing the Full Potential of Hsp90 Inhibitors as Cancer Therapeutics through Simultaneous Inactivation of Hsp90, Grp94, and TRAP1</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/s12276-019-0360-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs12276-019-0360-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=31956271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=79-91&author=H.+K.+Parkauthor=N.+G.+Yoonauthor=J.+E.+Leeauthor=S.+Huauthor=S.+Yoonauthor=S.+Y.+Kimauthor=J.+H.+Hongauthor=D.+Namauthor=Y.+C.+Chaeauthor=J.+B.+Parkauthor=B.+H.+Kang&title=Unleashing+the+Full+Potential+of+Hsp90+Inhibitors+as+Cancer+Therapeutics+through+Simultaneous+Inactivation+of+Hsp90%2C+Grp94%2C+and+TRAP1&doi=10.1038%2Fs12276-019-0360-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1</span></div><div class="casAuthors">Park, Hye-Kyung; Yoon, Nam Gu; Lee, Ji-Eun; Hu, Sung; Yoon, Sora; Kim, So Yeon; Hong, Jun-Hee; Nam, Dougu; Chae, Young Chan; Park, Jong Bae; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-91</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The Hsp90 family proteins Hsp90, Grp94, and TRAP1 are present in the cell cytoplasm, endoplasmic reticulum, and mitochondria, resp.; all play important roles in tumorigenesis by regulating protein homeostasis in response to stress.  Thus, simultaneous inhibition of all Hsp90 paralogs is a reasonable strategy for cancer therapy.  However, since the existing pan-Hsp90 inhibitor does not accumulate in mitochondria, the potential anticancer activity of pan-Hsp90 inhibition has not yet been fully examd. in vivo.  Anal. of The Cancer Genome Atlas database revealed that all Hsp90 paralogs were upregulated in prostate cancer.  Inactivation of all Hsp90 paralogs induced mitochondrial dysfunction, increased cytosolic calcium, and activated calcineurin.  Active calcineurin blocked prosurvival heat shock responses upon Hsp90 inhibition by preventing nuclear translocation of HSF1.  The purine scaffold deriv. DN401 inhibited all Hsp90 paralogs simultaneously and showed stronger anticancer activity than other Hsp90 inhibitors.  Pan-Hsp90 inhibition increased cytotoxicity and suppressed mechanisms that protect cancer cells, suggesting that it is a feasible strategy for the development of potent anticancer drugs.  The mitochondria-permeable drug DN401 is a newly identified in vivo pan-Hsp90 inhibitor with potent anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvPfio5ICfWrVg90H21EOLACvtfcHk0lh5Dzj0HCn1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislensr4%253D&md5=6bf153aba53f9ac1acf4cbf376f2a8f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs12276-019-0360-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-019-0360-x%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DYoon%26aufirst%3DN.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DHong%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DChae%26aufirst%3DY.%2BC.%26aulast%3DPark%26aufirst%3DJ.%2BB.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DUnleashing%2520the%2520Full%2520Potential%2520of%2520Hsp90%2520Inhibitors%2520as%2520Cancer%2520Therapeutics%2520through%2520Simultaneous%2520Inactivation%2520of%2520Hsp90%252C%2520Grp94%252C%2520and%2520TRAP1%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2020%26volume%3D52%26spage%3D79%26epage%3D91%26doi%3D10.1038%2Fs12276-019-0360-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenigsberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begassat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do-Vale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestadier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemecek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulaouic, H.</span></span> <span> </span><span class="NLM_article-title">The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25504634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=384-394&author=C.+Egileauthor=M.+Kenigsbergauthor=C.+Delaisiauthor=F.+Begassatauthor=V.+Do-Valeauthor=J.+Mestadierauthor=F.+Boncheauthor=T.+Benardauthor=J.+P.+Nicolasauthor=S.+Valenceauthor=C.+Lefrancauthor=E.+Francesconiauthor=C.+Castellauthor=A.+M.+Lefebvreauthor=C.+Nemecekauthor=L.+Calvetauthor=H.+Goulaouic&title=The+Selective+Intravenous+Inhibitor+of+the+MET+Tyrosine+Kinase+SAR125844+Inhibits+Tumor+Growth+in+MET-Amplified+Cancer&doi=10.1158%2F1535-7163.MCT-14-0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer</span></div><div class="casAuthors">Egile, Coumaran; Kenigsberg, Mireille; Delaisi, Christine; Begassat, Francoise; Do-Vale, Veronique; Mestadier, Jessica; Bonche, Fabrice; Benard, Tsiala; Nicolas, Jean-Paul; Valence, Sandrine; Lefranc, Celine; Francesconi, Elisa; Castell, Christelle; Lefebvre, Anne-Marie; Nemecek, Conception; Calvet, Loreley; Goulaouic, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">384-394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the MET/HGF pathway is common in human cancer and is thought to promote tumor initiation, metastasis, angiogenesis, and resistance to diverse therapies.  We report here the pharmacol. characterization of the triazolopyridazine deriv. SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for i.v. administration.  SAR125844 displayed nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and the M1250T and Y1235D mutants.  Broad biochem. profiling revealed that SAR125844 was highly selective for MET kinase.  SAR125844 inhibits MET autophosphorylation in cell-based assays in the nanomolar range, and promotes low nanomolar proapoptotic and antiproliferative activities selectively in cell lines with MET gene amplification or pathway addiction.  In two MET-amplified human gastric tumor xenograft models, SNU-5 and Hs 746T, i.v. treatment with SAR125844 leads to potent, dose- and time-dependent inhibition of the MET kinase and to significant impact on downstream PI3K/AKT and RAS/MAPK pathways.  Long duration of MET kinase inhibition up to 7 days was achieved with a nanosuspension formulation of SAR125844.  Daily or every-2-days i.v. treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body wt. loss.  Our data demonstrated that SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclin. toxicity profile, supporting its clin. development in patients with MET-amplified and MET pathway-addicted tumors.  Mol Cancer Ther; 14(2); 384-94. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphB-Rou5kYcLVg90H21EOLACvtfcHk0lh5Dzj0HCn1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsb0%253D&md5=12a76fc417063f4b5d7cdc970f2ec605</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0428%26sid%3Dliteratum%253Aachs%26aulast%3DEgile%26aufirst%3DC.%26aulast%3DKenigsberg%26aufirst%3DM.%26aulast%3DDelaisi%26aufirst%3DC.%26aulast%3DBegassat%26aufirst%3DF.%26aulast%3DDo-Vale%26aufirst%3DV.%26aulast%3DMestadier%26aufirst%3DJ.%26aulast%3DBonche%26aufirst%3DF.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DNicolas%26aufirst%3DJ.%2BP.%26aulast%3DValence%26aufirst%3DS.%26aulast%3DLefranc%26aufirst%3DC.%26aulast%3DFrancesconi%26aufirst%3DE.%26aulast%3DCastell%26aufirst%3DC.%26aulast%3DLefebvre%26aufirst%3DA.%2BM.%26aulast%3DNemecek%26aufirst%3DC.%26aulast%3DCalvet%26aufirst%3DL.%26aulast%3DGoulaouic%26aufirst%3DH.%26atitle%3DThe%2520Selective%2520Intravenous%2520Inhibitor%2520of%2520the%2520MET%2520Tyrosine%2520Kinase%2520SAR125844%2520Inhibits%2520Tumor%2520Growth%2520in%2520MET-Amplified%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D384%26epage%3D394%26doi%3D10.1158%2F1535-7163.MCT-14-0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanamaru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, S.</span></span> <span> </span><span class="NLM_article-title">Retinal Toxicity Induced by Small-Molecule Hsp90 Inhibitors in Beagle Dogs</span>. <i>J. Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.2131/jts.39.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.2131%2Fjts.39.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=24418710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=59-69&author=C.+Kanamaruauthor=Y.+Yamadaauthor=S.+Hayashiauthor=T.+Matsushitaauthor=A.+Sudaauthor=M.+Nagayasuauthor=K.+Kimuraauthor=S.+Chiba&title=Retinal+Toxicity+Induced+by+Small-Molecule+Hsp90+Inhibitors+in+Beagle+Dogs&doi=10.2131%2Fjts.39.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs</span></div><div class="casAuthors">Kanamaru, Chisako; Yamada, Yuichiro; Hayashi, Shuji; Matsushita, Tomochika; Suda, Atsushi; Nagayasu, Miho; Kimura, Kazuya; Chiba, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-69</span>CODEN:
                <span class="NLM_cas:coden">JTSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0388-1350</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicology</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a constitutively expressed mol. chaperone and plays an important role in the folding of client proteins with key regulatory roles in growth, survival, differentiation and metastasis.  Because inhibition of Hsp90 degrades multiple oncogenic client proteins, it is considered to be an attractive anticancer therapy, and clin. trials of several Hsp90 inhibitors have been carried out.  In the present study, two structurally distinct Hsp90 inhibitors, CH5164840 and CH5449302, were orally administered to beagle dogs to evaluate systemic toxicity.  CH5164840 induced symptoms that suggest visual disorder, and ophthalmol. observation and electroretinog. (ERG) revealed loss of pupillary light reflex and abnormal waveforms, resp.  Histopathol. examn. showed changes in the photoreceptor cell layer and the outer nuclear layer of retina.  On the other hand, while there were no clin. symptoms related to visual disorder, animals treated with CH5449302 showed similar abnormalities of ERG responses and histopathol. changes in the photoreceptor cell layer and the outer nuclear layer of retina.  The visual symptoms and abnormalities of ERG responses were noted at an earlier stage or lower dose than other toxicities in both compds.  Considering that two structurally distinct Hsp90 inhibitors induced a retinal toxicity in dogs after repeated administration, and that visual disorders were also reported in some clin. trials of Hsp90 inhibitors, it would seem highly likely that Hsp90 inhibition induces retinal toxicity.  Also, our study indicated that a detailed ocular examn. to evaluate the safety of Hsp90 inhibitors would be useful in both preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmECT70CVt7Vg90H21EOLACvtfcHk0ljC9upcPSNzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslynsbs%253D&md5=1b49f09d2e4de9184cb5dfd46104d84e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2131%2Fjts.39.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2131%252Fjts.39.59%26sid%3Dliteratum%253Aachs%26aulast%3DKanamaru%26aufirst%3DC.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DNagayasu%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DS.%26atitle%3DRetinal%2520Toxicity%2520Induced%2520by%2520Small-Molecule%2520Hsp90%2520Inhibitors%2520in%2520Beagle%2520Dogs%26jtitle%3DJ.%2520Toxicol.%2520Sci.%26date%3D2014%26volume%3D39%26spage%3D59%26epage%3D69%26doi%3D10.2131%2Fjts.39.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciarelli, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollapour, M.</span></span> <span> </span><span class="NLM_article-title">Targeting Hsp90 in Non-Cancerous Maladies</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2792</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.2174%2F1568026616666160413141753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27072697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2792-2804&author=M.+R.+Woodfordauthor=D.+M.+Dunnauthor=J.+G.+Ciciarelliauthor=K.+Beebeauthor=L.+Neckersauthor=M.+Mollapour&title=Targeting+Hsp90+in+Non-Cancerous+Maladies&doi=10.2174%2F1568026616666160413141753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Hsp90 in Non-Cancerous Maladies</span></div><div class="casAuthors">Woodford, Mark R.; Dunn, Diana M.; Ciciarelli, Joseph G.; Beebe, Kristin; Neckers, Len; Mollapour, Mehdi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2792-2804</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Heat shock protein-90 (Hsp90) is a mol. chaperone crit. to the folding, stability and activity of over 200 client proteins including many responsible for tumor initiation, progression and metastasis.  Hsp90 chaperone function is linked to its ATPase activity and Hsp90 inhibitors interfere with this activity, thereby making Hsp90 an attractive target for cancer therapy.  Also post-translational modification (PTM) and co-chaperone proteins modulate Hsp90 function, providing addnl. targets for secondary inhibition.  Recent reports have shown that pathogens utilize both their own Hsp90 and that of their host for the propagation of infectious elements.  In this review we will summarize our current knowledge of Hsp90 structure and function in both the pathogen and the host.  We will focus on the role of Hsp90 in viral and parasitic diseases and the potential beneficial application of Hsp90 inhibitors alone and in combination with disease-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIP4opz26nxLVg90H21EOLACvtfcHk0ljC9upcPSNzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsr7N&md5=e64b5c25cc96e0734fc319624a436033</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141753%26sid%3Dliteratum%253Aachs%26aulast%3DWoodford%26aufirst%3DM.%2BR.%26aulast%3DDunn%26aufirst%3DD.%2BM.%26aulast%3DCiciarelli%26aufirst%3DJ.%2BG.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DMollapour%26aufirst%3DM.%26atitle%3DTargeting%2520Hsp90%2520in%2520Non-Cancerous%2520Maladies%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2792%26epage%3D2804%26doi%3D10.2174%2F1568026616666160413141753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeier, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duellman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, S. C.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Inhibitors Block outgrowth of EBV-Infected Malignant Cells in vitro and in vivo Through an EBNA1-Dependent Mechanism</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3146</span>– <span class="NLM_lpage">3151</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910717107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.0910717107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=20133771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Clu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=3146-3151&author=X.+Sunauthor=E.+A.+Barlowauthor=S.+Maauthor=S.+R.+Hagemeierauthor=S.+J.+Duellmanauthor=R.+R.+Burgessauthor=J.+Tellamauthor=R.+Khannaauthor=S.+C.+Kenney&title=Hsp90+Inhibitors+Block+outgrowth+of+EBV-Infected+Malignant+Cells+in+vitro+and+in+vivo+Through+an+EBNA1-Dependent+Mechanism&doi=10.1073%2Fpnas.0910717107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1 dependent mechanism</span></div><div class="casAuthors">Sun, Xiaoping; Barlow, Elizabeth A.; Ma, Shidong; Hagemeier, Stacy R.; Duellman, Sarah J.; Burgess, Richard R.; Tellam, Judy; Khanna, Rajiv; Kenney, Shannon C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3146-3151, S3146/1-S3146/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">EBV causes infectious mononucleosis and is assocd. with certain malignancies.  EBV nuclear antigen 1 (EBNAI) mediates EBV genome replication, partition, and transcription, and is essential for persistence of the viral genome in host cells.  Here we demonstrate that Hsp90 inhibitors decrease EBNA1 expression and translation, and that this effect requires the Gly-Ala repeat domain of EBNA1.  Hsp90 inhibitors induce the death of established, EBV-transformed lymphoblastoid cell lines at doses nontoxic to normal cells, and this effect is substantially reversed when lymphoblastoid cell lines are stably infected with a retrovirus expressing a functional EBNA1 mutant lacking the Gly-Ala repeats.  Hsp90 inhibitors prevent EBV transformation of primary B cells, and strongly inhibit the growth of EBV-induced lymphoproliferative disease in SCID mice.  These results suggest that Hsp90 inhibitors may be particularly effective for treating EBV-induced diseases requiring the continued presence of the viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEeZuKjmP_1bVg90H21EOLACvtfcHk0ljC9upcPSNzQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Clu7k%253D&md5=dafaee796e75d1e865daae2fb567d2ed</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910717107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910717107%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DBarlow%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DHagemeier%26aufirst%3DS.%2BR.%26aulast%3DDuellman%26aufirst%3DS.%2BJ.%26aulast%3DBurgess%26aufirst%3DR.%2BR.%26aulast%3DTellam%26aufirst%3DJ.%26aulast%3DKhanna%26aufirst%3DR.%26aulast%3DKenney%26aufirst%3DS.%2BC.%26atitle%3DHsp90%2520Inhibitors%2520Block%2520outgrowth%2520of%2520EBV-Infected%2520Malignant%2520Cells%2520in%2520vitro%2520and%2520in%2520vivo%2520Through%2520an%2520EBNA1-Dependent%2520Mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D3146%26epage%3D3151%26doi%3D10.1073%2Fpnas.0910717107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shatzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. I.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, an HSP90 Inhibitor, Kills Epstein-Barr Virus (EBV)-Infected B and T Cells and Reduces the Percentage of EBV-Infected Cells in the Blood</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1213823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1080%2F10428194.2016.1213823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27686857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOms7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=923-931&author=A.+Shatzerauthor=M.+A.+Aliauthor=M.+Chavezauthor=K.+Dowdellauthor=M.+J.+Leeauthor=Y.+Tomitaauthor=I.+El-Hariryauthor=J.+B.+Trepelauthor=D.+A.+Proiaauthor=J.+I.+Cohen&title=Ganetespib%2C+an+HSP90+Inhibitor%2C+Kills+Epstein-Barr+Virus+%28EBV%29-Infected+B+and+T+Cells+and+Reduces+the+Percentage+of+EBV-Infected+Cells+in+the+Blood&doi=10.1080%2F10428194.2016.1213823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood</span></div><div class="casAuthors">Shatzer, Amber; Ali, Mir A.; Chavez, Mayra; Dowdell, Kennichi; Lee, Min-Jung; Tomita, Yusuke; El-Hariry, Iman; Trepel, Jane B.; Proia, David A.; Cohen, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">923-931</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HSP90 inhibitors have been shown to kill Epstein-Barr virus (EBV)-infected cells by reducing the level of EBV EBNA-1 and/or LMP1.  We treated virus-infected cells with ganetespib, an HSP90 inhibitor currently being evaluated in multiple clin. trials for cancer and found that the drug killed EBV-pos. B and T cells and reduced the level of both EBV EBNA-1 and LMP1.  Treatment of cells with ganetespib also reduced the level of pAkt.  Ganetespib delayed the onset of EBV-pos. lymphomas and prolonged survival in SCID mice inoculated with one EBV-transformed B-cell line, but not another B-cell line.  The former cell line showed lower levels of EBNA-1 after treatment with ganetespib in vitro.  Treatment of a patient with T-cell chronic active EBV with ganetespib reduced the percentage of EBV-pos. cells in the peripheral blood.  These data indicate that HSP90 inhibitors may have a role in the therapy of certain EBV-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaYnthf9rXRbVg90H21EOLACvtfcHk0li5VeRK_TD3jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOms7vL&md5=1a3d79c47523d0819a54eb7adbb8bedb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1213823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1213823%26sid%3Dliteratum%253Aachs%26aulast%3DShatzer%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DM.%2BA.%26aulast%3DChavez%26aufirst%3DM.%26aulast%3DDowdell%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26atitle%3DGanetespib%252C%2520an%2520HSP90%2520Inhibitor%252C%2520Kills%2520Epstein-Barr%2520Virus%2520%2528EBV%2529-Infected%2520B%2520and%2520T%2520Cells%2520and%2520Reduces%2520the%2520Percentage%2520of%2520EBV-Infected%2520Cells%2520in%2520the%2520Blood%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D923%26epage%3D931%26doi%3D10.1080%2F10428194.2016.1213823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srisutthisamphan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirakanwisal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramphan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tongluan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuadkitkan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. R.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Interacts with Multiple Dengue Virus 2 Proteins</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">4308</span> <span class="refDoi"> DOI: 10.1038/s41598-018-22639-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41598-018-22639-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29523827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsF2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=K.+Srisutthisamphanauthor=K.+Jirakanwisalauthor=S.+Ramphanauthor=N.+Tongluanauthor=A.+Kuadkitkanauthor=D.+R.+Smith&title=Hsp90+Interacts+with+Multiple+Dengue+Virus+2+Proteins&doi=10.1038%2Fs41598-018-22639-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 interacts with multiple dengue virus 2 proteins</span></div><div class="casAuthors">Srisutthisamphan Kanjana; Jirakanwisal Krit; Ramphan Suwipa; Tongluan Natthida; Kuadkitkan Atichat; Smith Duncan R</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Infections with the mosquito-borne dengue virus (DENV) remain a significant public health challenge.  In the absence of a commercial therapeutic to treat DENV infection, a greater understanding of the processes of cellular replication is required.  The abundant cellular chaperone protein heat shock protein 90 (Hsp90) has been shown to play a proviral role in the replication cycle of several viruses, predominantly through the stabilization of specific viral proteins.  To investigate any potential role of Hsp90 in DENV infection the interaction between Hsp90 and DENV proteins was determined through co-immunoprecipitation experiments.  Six DENV proteins namely envelope (E) and nonstructural (NS) proteins NS1, NS2B, NS3, NS4B and NS5 were shown to interact with Hsp90, and four of these proteins (E, NS1, NS3 and NS5) were shown to colocalize to a variable extent with Hsp90.  Despite the extensive interactions between Hsp90 and DENV proteins, inhibition of the activity of Hsp90 had a relatively minor effect on DENV replication, with inhibition of Hsp90 resulting in a decrease of cellular E protein (but not nonstructural proteins) coupled with an increase of E protein in the medium and an increased virus titer.  Collectively these results indicate that Hsp90 has a slight anti-viral effect in DENV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAACZdsi8QicScOqQTSkOffW6udTcc2eb2URNYVIwEvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsF2ltw%253D%253D&md5=d45e911734de981401f44ce9edcaa8ab</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-22639-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-22639-5%26sid%3Dliteratum%253Aachs%26aulast%3DSrisutthisamphan%26aufirst%3DK.%26aulast%3DJirakanwisal%26aufirst%3DK.%26aulast%3DRamphan%26aufirst%3DS.%26aulast%3DTongluan%26aufirst%3DN.%26aulast%3DKuadkitkan%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BR.%26atitle%3DHsp90%2520Interacts%2520with%2520Multiple%2520Dengue%2520Virus%25202%2520Proteins%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-22639-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann-Stroissnigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stripay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorronsoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchkonia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedernhofer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, P. D.</span></span> <span> </span><span class="NLM_article-title">Identification of HSP90 Inhibitors as a Novel Class of Senolytics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">422</span> <span class="refDoi"> DOI: 10.1038/s41467-017-00314-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41467-017-00314-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=28871086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1cbks1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=H.+Fuhrmann-Stroissniggauthor=Y.+Y.+Lingauthor=J.+Zhaoauthor=S.+J.+McGowanauthor=Y.+Zhuauthor=R.+W.+Brooksauthor=D.+Grassiauthor=S.+Q.+Greggauthor=J.+L.+Stripayauthor=A.+Dorronsoroauthor=L.+Corboauthor=P.+Tangauthor=C.+Bukataauthor=N.+Ringauthor=M.+Giaccaauthor=X.+Liauthor=T.+Tchkoniaauthor=J.+L.+Kirklandauthor=L.+J.+Niedernhoferauthor=P.+D.+Robbins&title=Identification+of+HSP90+Inhibitors+as+a+Novel+Class+of+Senolytics&doi=10.1038%2Fs41467-017-00314-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HSP90 inhibitors as a novel class of senolytics</span></div><div class="casAuthors">Fuhrmann-Stroissnigg Heike; Ling Yuan Yuan; Zhao Jing; McGowan Sara J; Brooks Robert W; Grassi Diego; Dorronsoro Akaitz; Corbo Lana; Tang Priscilla; Bukata Christina; Li Xuesen; Niedernhofer Laura J; Robbins Paul D; Zhu Yi; Tchkonia Tamara; Kirkland James L; Gregg Siobhan Q; Stripay Jennifer L; Ring Nadja; Giacca Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">422</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging is the main risk factor for many chronic degenerative diseases and cancer.  Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases.  Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging.  To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells.  We used primary Ercc1 (-/-) murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen.  This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells.  Treatment of Ercc1 (-/α) mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16(INK4a) expression.  These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.The accumulation of senescent cells is thought to contribute to the age-associated decline in tissue function.  Here, the authors identify HSP90 inhibitors as a new class of senolytic compounds in an in vitro screening and show that administration of a HSP90 inhibitor reduces age-related symptoms in progeroid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvWBwJCmQEN1UIs6wFK5xJfW6udTcc2eb2URNYVIwEvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbks1Cisg%253D%253D&md5=214359d8400f36e2ceccee3b0fed7dbf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00314-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00314-z%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann-Stroissnigg%26aufirst%3DH.%26aulast%3DLing%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMcGowan%26aufirst%3DS.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrooks%26aufirst%3DR.%2BW.%26aulast%3DGrassi%26aufirst%3DD.%26aulast%3DGregg%26aufirst%3DS.%2BQ.%26aulast%3DStripay%26aufirst%3DJ.%2BL.%26aulast%3DDorronsoro%26aufirst%3DA.%26aulast%3DCorbo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DBukata%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DN.%26aulast%3DGiacca%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTchkonia%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DJ.%2BL.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26atitle%3DIdentification%2520of%2520HSP90%2520Inhibitors%2520as%2520a%2520Novel%2520Class%2520of%2520Senolytics%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-00314-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishinevsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpaugh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolaender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattahi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishima, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, L.</span></span> <span> </span><span class="NLM_article-title">HSP90-Incorporating Chaperome Networks as Biosensor for Disease-Related Pathways in Patient-Specific Midbrain Dopamine Neurons</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">4345</span> <span class="refDoi"> DOI: 10.1038/s41467-018-06486-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41467-018-06486-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=30341316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlCnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=S.+Kishinevskyauthor=T.+Wangauthor=A.+Rodinaauthor=S.+Y.+Chungauthor=C.+Xuauthor=J.+Philipauthor=T.+Taldoneauthor=S.+Joshiauthor=M.+L.+Alpaughauthor=A.+Bolaenderauthor=S.+Gutbierauthor=D.+Sandhuauthor=F.+Fattahiauthor=B.+Zimmerauthor=S.+K.+Shahauthor=E.+Changauthor=C.+Indaauthor=J.+Korenauthor=N.+G.+Sauratauthor=M.+Leistauthor=S.+S.+Grossauthor=V.+E.+Seshanauthor=C.+Kleinauthor=M.+J.+Tomishimaauthor=H.+Erdjument-Bromageauthor=T.+A.+Neubertauthor=R.+C.+Henricksonauthor=G.+Chiosisauthor=L.+Studer&title=HSP90-Incorporating+Chaperome+Networks+as+Biosensor+for+Disease-Related+Pathways+in+Patient-Specific+Midbrain+Dopamine+Neurons&doi=10.1038%2Fs41467-018-06486-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons</span></div><div class="casAuthors">Kishinevsky Sarah; Chung Sun Young; Fattahi Faranak; Zimmer Bastian; Saurat Nathalie G; Tomishima Mark J; Studer Lorenz; Kishinevsky Sarah; Chung Sun Young; Fattahi Faranak; Zimmer Bastian; Saurat Nathalie G; Tomishima Mark J; Studer Lorenz; Kishinevsky Sarah; Wang Tai; Rodina Anna; Xu Chao; Taldone Tony; Joshi Suhasini; Alpaugh Mary L; Bolaender Alexander; Shah Smit K; Inda Carmen; Koren John 3rd; Chiosis Gabriela; Kishinevsky Sarah; Philip John; Chang Elizabeth; Henrickson Ronald C; Alpaugh Mary L; Gutbier Simon; Leist Marcel; Sandhu Davinder; Gross Steven S; Inda Carmen; Koren John 3rd; Seshan Venkatraman E; Klein Christine; Tomishima Mark J; Erdjument-Bromage Hediye; Neubert Thomas A; Erdjument-Bromage Hediye; Neubert Thomas A; Chiosis Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4345</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Environmental and genetic risk factors contribute to Parkinson's Disease (PD) pathogenesis and the associated midbrain dopamine (mDA) neuron loss.  Here, we identify early PD pathogenic events by developing methodology that utilizes recent innovations in human pluripotent stem cells (hPSC) and chemical sensors of HSP90-incorporating chaperome networks.  We show that events triggered by PD-related genetic or toxic stimuli alter the neuronal proteome, thereby altering the stress-specific chaperome networks, which produce changes detected by chemical sensors.  Through this method we identify STAT3 and NF-κB signaling activation as examples of genetic stress, and phospho-tyrosine hydroxylase (TH) activation as an example of toxic stress-induced pathways in PD neurons.  Importantly, pharmacological inhibition of the stress chaperome network reversed abnormal phospho-STAT3 signaling and phospho-TH-related dopamine levels and rescued PD neuron viability.  The use of chemical sensors of chaperome networks on hPSC-derived lineages may present a general strategy to identify molecular events associated with neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFdxVcVE1DUYIRAdBLKY41fW6udTcc2eY2sst-GQ743Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlCnsw%253D%253D&md5=aec154a5d7acfa354296a29de4d166b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06486-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06486-6%26sid%3Dliteratum%253Aachs%26aulast%3DKishinevsky%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DS.%2BY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DAlpaugh%26aufirst%3DM.%2BL.%26aulast%3DBolaender%26aufirst%3DA.%26aulast%3DGutbier%26aufirst%3DS.%26aulast%3DSandhu%26aufirst%3DD.%26aulast%3DFattahi%26aufirst%3DF.%26aulast%3DZimmer%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DS.%2BK.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DInda%26aufirst%3DC.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DSaurat%26aufirst%3DN.%2BG.%26aulast%3DLeist%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DSeshan%26aufirst%3DV.%2BE.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DTomishima%26aufirst%3DM.%2BJ.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DHenrickson%26aufirst%3DR.%2BC.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DStuder%26aufirst%3DL.%26atitle%3DHSP90-Incorporating%2520Chaperome%2520Networks%2520as%2520Biosensor%2520for%2520Disease-Related%2520Pathways%2520in%2520Patient-Specific%2520Midbrain%2520Dopamine%2520Neurons%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-018-06486-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Heat Shock Protein HSP90-pp60v-src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+Heat+Shock+Protein+HSP90-pp60v-src+Heteroprotein+Complex+Formation+by+Benzoquinone+Ansamycins%3A+Essential+Role+for+Stress+Proteins+in+Oncogenic+Transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0lj08Mnj4vIkGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520Heat%2520Shock%2520Protein%2520HSP90-pp60v-src%2520Heteroprotein%2520Complex%2520Formation%2520by%2520Benzoquinone%2520Ansamycins%253A%2520Essential%2520Role%2520for%2520Stress%2520Proteins%2520in%2520Oncogenic%2520Transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">The Benzoquinone Ansamycin 17-Allylamino-17-demethoxygeldanamycin Binds to HSP90 and Shares Important Biologic Activities with Geldanamycin</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1007/s002800050817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1007%2Fs002800050817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=9744771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=273-279&author=T.+W.+Schulteauthor=L.+M.+Neckers&title=The+Benzoquinone+Ansamycin+17-Allylamino-17-demethoxygeldanamycin+Binds+to+HSP90+and+Shares+Important+Biologic+Activities+with+Geldanamycin&doi=10.1007%2Fs002800050817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span></div><div class="casAuthors">Schulte, Theodor W.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Binding of 17-allylamino-17-demethoxygeldanamycin (17-AG) to the heat-shock protein HSP90 was studied in vitro using a geldanamycin (GA)-affinity beads competition assay.  The drug-induced destabilization was studied of p185erbB2, Raf-1, and mutant p53 in SKBR3 breast cancer cells by Western blotting.  The antiproliferative activities of 17-AG and GA were compared using the MTT assay.  The 17-AG bound specifically to HSP90 in a similar manner as GA itself.  It also led to degrdn. of the receptor Tyr kinase p185erbB2, the Ser/Thr kinase Raf-1, and mutant p53.  GA and 17-AG displayed comparable antiproliferative effects in SKBR3 and MCF7 cells.  Even though HSP90 binding with 17-AG was weaker than by GA, 17-AG and GA caused biol. effects in tumor cells at similar doses.  Since 17-AG had a better toxicity profile than GA, it was suggested as benzoquinone ansamycin candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj3pMDUB7kLVg90H21EOLACvtfcHk0lj08Mnj4vIkGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D&md5=3d6ac0592b10d66b391f824272523de2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs002800050817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050817%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DThe%2520Benzoquinone%2520Ansamycin%252017-Allylamino-17-demethoxygeldanamycin%2520Binds%2520to%2520HSP90%2520and%2520Shares%2520Important%2520Biologic%2520Activities%2520with%2520Geldanamycin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26spage%3D273%26epage%3D279%26doi%3D10.1007%2Fs002800050817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher-Nielson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainathan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin: an Orally Bioavailable Heat Shock Protein 90 Modulator</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4813</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-03-0795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1078-0432.CCR-03-0795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=15269157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4813-4821&author=G.+Kaurauthor=D.+Belottiauthor=A.+M.+Burgerauthor=K.+Fisher-Nielsonauthor=P.+Borsottiauthor=E.+Riccardiauthor=J.+Thillainathanauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=R.+Giavazzi&title=Antiangiogenic+Properties+of+17-%28Dimethylaminoethylamino%29-17-demethoxygeldanamycin%3A+an+Orally+Bioavailable+Heat+Shock+Protein+90+Modulator&doi=10.1158%2F1078-0432.CCR-03-0795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span></div><div class="casAuthors">Kaur, Gurmeet; Belotti, Dorina; Burger, Angelika M.; Fisher-Nielson, Kirsten; Borsotti, Patrizia; Riccardi, Elena; Thillainathan, Jagada; Hollingshead, Melinda; Sausville, Edward A.; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4813-4821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; NSC707545), a water-sol. benzoquinone ansamycin.  The activity of 17-DMAG, in vivo, was evaluated for inhibition of fibroblast growth factor (FGF)-2-induced angiogenesis in s.c. implanted Matrigel in mice.  In vitro, the activity of 17-DMAG on endothelial cells (human umbilical vein endothelial cells; HUVEC) was tested in FGF-2; and vascular endothelial growth factor (VEGF)-induced proliferation and apoptosis, motility, and extracellular matrix invasion; and on the alignment of capillary like structures in Matrigel.  The protein level of heat shock protein (Hsp)90 and client proteins was examd. by Western blot in FGF-2 and VEGF-stimulated HUVEC.  Daily oral administration of 17-DMAG affected the angiogenic response in Matrigel in a dose-dependent manner.  The Hb content in the Matrigel implants was significantly inhibited, and the histol. anal. confirmed a decrease of CD31+ endothelial cells and of structures organized in cord and erythrocyte-contg. vessels.  In vitro, the compd. inhibited dose-dependently the migration and the extracellular matrix-invasiveness of HUVEC and their capacity to form capillary like structures in Matrigel. 17-DMAG treatment also inhibited FGF-2 and VEGF-induced HUVEC proliferation and resulted in apoptosis.  Accordingly, the expression of Hsp90 direct client proteins (pAkt and c-Raf-1) or their downstream substrates including pERK was also affected. 17-DMAG consistently increased the expression of Hsp70.  Throughout the study similar results were obtained with 17-allylamino-17-demethoxygeldanamycin (17-AAG; NSC330507), the analog compd. currently undergoing clin. trials.  We show that the Hsp90 targeting agents 17-DMAG and 17-AAG inhibit angiogenesis.  The strong effects on endothelial cell functions, in vitro, indicate that the antiangiogenic activity of 17-DMAG/17-AAG could also be due to a direct effect on endothelial cells.  The oral bioavailability of 17-DMAG might be of advantage in investigating the potential of this compd. in clin. trials with antiangiogenic as well as antiproliferative endpoints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbGsLTxbCrQ7Vg90H21EOLACvtfcHk0lgNSIi0M7H5FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D&md5=e78331697485d2c1948adec2d4f124e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-03-0795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-03-0795%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DFisher-Nielson%26aufirst%3DK.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DThillainathan%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DAntiangiogenic%2520Properties%2520of%252017-%2528Dimethylaminoethylamino%2529-17-demethoxygeldanamycin%253A%2520an%2520Orally%2520Bioavailable%2520Heat%2520Shock%2520Protein%252090%2520Modulator%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4813%26epage%3D4821%26doi%3D10.1158%2F1078-0432.CCR-03-0795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4615</span>, <span class="refDoi"> DOI: 10.1021/jm0603116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbittsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Hydroquinone+Derivatives+of+17-Amino-17-demethoxygeldanamycin+as+Potent%2C+Water-Soluble+Inhibitors+of+Hsp90&doi=10.1021%2Fjm0603116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span></div><div class="casAuthors">Ge, Jie; Normant, Emmanuel; Porter, James R.; Ali, Janid A.; Dembski, Marlene S.; Gao, Yun; Georges, Asimina T.; Grenier, Louis; Pak, Roger H.; Patterson, Jon; Sydor, Jens R.; Tibbitts, Thomas T.; Tong, Jeffrey K.; Adams, Julian; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4606-4615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clin. trials for the treatment of cancer.  However, 17-AAG faces challenging formulation issues due to its poor soly.  Here we report the synthesis and evaluation of a highly sol. hydroquinone hydrochloride deriv. of 17-AAG, I (IPI-504), and several of the physiol. metabolites.  These compds. show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homolog, the 94 kDa glucose regulated protein (Grp94).  Furthermore, the compds. inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition.  There is a clear correlation between the measured binding affinity of the compds. and their cellular activities.  Upon the basis of its potent activity against Hsp90 and a significant improvement in soly., I is currently under evaluation in Phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9IjX75MjbULVg90H21EOLACvtfcHk0lgNSIi0M7H5FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D&md5=892e372e121f75465edc6f1251e55dc6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbitts%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Hydroquinone%2520Derivatives%2520of%252017-Amino-17-demethoxygeldanamycin%2520as%2520Potent%252C%2520Water-Soluble%2520Inhibitors%2520of%2520Hsp90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615%26doi%3D10.1021%2Fjm0603116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.+M.+Cheungauthor=I.+Collinsauthor=N.+G.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+Chaperone+Inhibitors%3A+Potential+Therapeutic+Agents+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lhG0MF9cRf6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520Chaperone%2520Inhibitors%253A%2520Potential%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The Novel HSP90 Inhibitor STA-9090 Exhibits Activity against Kit-Dependent and -Independent Malignant Mast Cell Tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&author=T.+Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+Novel+HSP90+Inhibitor+STA-9090+Exhibits+Activity+against+Kit-Dependent+and+-Independent+Malignant+Mast+Cell+Tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0lhG0MF9cRf6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520Novel%2520HSP90%2520Inhibitor%2520STA-9090%2520Exhibits%2520Activity%2520against%2520Kit-Dependent%2520and%2520-Independent%2520Malignant%2520Mast%2520Cell%2520Tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois Oindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-Dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-dihydrois+Oindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+Novel+Inhibitor+of+the+Molecular+Chaperone+Hsp90+by+Fragment+Based+Drug+Design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0lhG0MF9cRf6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-Dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-dihydrois%2520Oindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520the%2520Molecular%2520Chaperone%2520Hsp90%2520by%2520Fragment%2520Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed High-affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors that Exhibit Potent Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+Designed+High-affinity+2-Amino-6-halopurine+Heat+Shock+Protein+90+Inhibitors+that+Exhibit+Potent+Antitumor+Activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lh4HFyzVEtZtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520Designed%2520High-affinity%25202-Amino-6-halopurine%2520Heat%2520Shock%2520Protein%252090%2520Inhibitors%2520that%2520Exhibit%2520Potent%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span> <span> </span><span class="NLM_article-title">A phase 1, Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1078-0432.CCR-13-1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=24097863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=445-455&author=M.+W.+Saifauthor=C.+Takimotoauthor=M.+Mitaauthor=U.+Banerjiauthor=N.+Lamannaauthor=J.+Castroauthor=S.+O%E2%80%99Brienauthor=C.+Stogardauthor=D.+Von+Hoff&title=A+phase+1%2C+Dose-escalation%2C+Pharmacokinetic+and+Pharmacodynamic+Study+of+BIIB021+Administered+Orally+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Saif, Muhammad Wasif; Takimoto, Chris; Mita, Monica; Banerji, Udai; Lamanna, Nicole; Castro, Januario; O'Brien, Susan; Stogard, Christopher; Von Hoff, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-455</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin-based HSP90 inhibitor that showed activity in preclin. models at low nanomolar concns.  We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors.  Exptl. Design: Sixty patients received BIIB021 capsules orally on days 1, 4, 8, 11, 15, and 18 of each course in schedule 1, and on days 1, 4, 8, 11, 15, 18, 22, and 25 of each course in schedule 2.  The treatment schedules were repeated every 28 days.  In addn. to detg. the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)].  Results: The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 wk out of each 4-wk course.  The MTD for continuous dosing regimen was established at 600 mg twice weekly.  Gastrointestinal (nausea, vomiting), hot flashes, and neurol. (dizziness) events characterize the safety profile of BIIB021 dosed twice weekly, with events mostly mild or moderate.  Plasma exposure to BIIB021 was dose-dependent.  Cmax occurred at approx. 90 min and t1/2 was approx. 1 h across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.  The biol. activity of BIIB021 was demonstrated in serum, PBMCs, and tumor tissue.  Hsp70 levels were increased (>150% from baseline) and serum HER2-ECD was significantly decreased (>15% inhibition from baseline).  Conclusions: BIIB021 twice weekly, given with or without the 1 of 4-wk rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active.  Clin Cancer Res; 20(2); 445-55. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkorAuPfyrLVg90H21EOLACvtfcHk0lh4HFyzVEtZtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D&md5=48266b9da5e440eda185af9d42e9739b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1257%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DTakimoto%26aufirst%3DC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DStogard%26aufirst%3DC.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DA%2520phase%25201%252C%2520Dose-escalation%252C%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520BIIB021%2520Administered%2520Orally%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D445%26epage%3D455%26doi%3D10.1158%2F1078-0432.CCR-13-1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. S.</span></span> <span> </span><span class="NLM_article-title">Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">59</span> <span class="refDoi"> DOI: 10.1208/s12248-018-0216-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1208%2Fs12248-018-0216-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29633051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1MjgsVOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&author=Y.+Bianauthor=X.+S.+Xie&title=Computational+Fragment-Based+Drug+Design%3A+Current+Trends%2C+Strategies%2C+and+Applications&doi=10.1208%2Fs12248-018-0216-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications</span></div><div class="casAuthors">Bian Yuemin; Xie Xiang-Qun Sean; Bian Yuemin; Xie Xiang-Qun Sean; Bian Yuemin; Xie Xiang-Qun Sean; Xie Xiang-Qun Sean; Xie Xiang-Qun Sean</div><div class="citationInfo"><span class="NLM_cas:title">The AAPS journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fragment-based drug design (FBDD) has become an effective methodology for drug development for decades.  Successful applications of this strategy brought both opportunities and challenges to the field of Pharmaceutical Science.  Recent progress in the computational fragment-based drug design provide an additional approach for future research in a time- and labor-efficient manner.  Combining multiple in silico methodologies, computational FBDD possesses flexibilities on fragment library selection, protein model generation, and fragments/compounds docking mode prediction.  These characteristics provide computational FBDD superiority in designing novel and potential compounds for a certain target.  The purpose of this review is to discuss the latest advances, ranging from commonly used strategies to novel concepts and technologies in computational fragment-based drug design.  Particularly, in this review, specifications and advantages are compared between experimental and computational FBDD, and additionally, limitations and future prospective are discussed and emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVNCyUwVvezS86Js-BCLiifW6udTcc2eZkIR7KnWsSqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjgsVOrtg%253D%253D&md5=baf72e9387aacf16ee225570a0d5fdfd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1208%2Fs12248-018-0216-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-018-0216-7%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%2BS.%26atitle%3DComputational%2520Fragment-Based%2520Drug%2520Design%253A%2520Current%2520Trends%252C%2520Strategies%252C%2520and%2520Applications%26jtitle%3DAAPS%2520J.%26date%3D2018%26volume%3D20%26doi%3D10.1208%2Fs12248-018-0216-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descoteaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1386</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1002%2Fcmdc.201800161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29722149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1377-1386&author=Y.+Ayotteauthor=F.+Bilodeauauthor=A.+Descoteauxauthor=S.+R.+LaPlante&title=Fragment-Based+Phenotypic+Lead+Discovery%3A+Cell-Based+Assay+to+Target+Leishmaniasis&doi=10.1002%2Fcmdc.201800161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis</span></div><div class="casAuthors">Ayotte, Yann; Bilodeau, Francois; Descoteaux, Albert; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1377-1386</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A rapid and practical approach for the discovery of new chem. matter for targeting pathogens and diseases is described.  Fragment-based phenotypic lead discovery (FPLD) combines aspects of traditional fragment-based lead discovery (FBLD), which involves the screening of small-mol. fragment libraries to target specific proteins, with phenotypic lead discovery (PLD), which typically involves the screening of drug-like compds. in cell-based assays.  To enable FPLD, a diverse library of fragments was first designed, assembled, and curated.  This library of sol., low-mol.-wt. compds. was then pooled to expedite screening.  Axenic cultures of Leishmania promastigotes were screened, and single hits were then tested for leishmanicidal activity against intracellular amastigote forms in infected murine bone-marrow-derived macrophages without evidence of toxicity toward mammalian cells.  These studies demonstrate that FPLD can be a rapid and effective means to discover hits that can serve as leads for further medicinal chem. purposes or as tool compds. for identifying known or novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC85ixZC9T9bVg90H21EOLACvtfcHk0lhMcQgzHc8Adw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsrjF&md5=6b732097feb3a6f81f0c4d6309fbae63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800161%26sid%3Dliteratum%253Aachs%26aulast%3DAyotte%26aufirst%3DY.%26aulast%3DBilodeau%26aufirst%3DF.%26aulast%3DDescoteaux%26aufirst%3DA.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DFragment-Based%2520Phenotypic%2520Lead%2520Discovery%253A%2520Cell-Based%2520Assay%2520to%2520Target%2520Leishmaniasis%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1377%26epage%3D1386%26doi%3D10.1002%2Fcmdc.201800161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jencks, W. P.</span></span> <span> </span><span class="NLM_article-title">On the Attribution and Additivity of Binding Energies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">4046</span>– <span class="NLM_lpage">4050</span>, <span class="refDoi"> DOI: 10.1073/pnas.78.7.4046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.78.7.4046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=16593049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaL3MXlvVamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1981&pages=4046-4050&author=W.+P.+Jencks&title=On+the+Attribution+and+Additivity+of+Binding+Energies&doi=10.1073%2Fpnas.78.7.4046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">On the attribution and additivity of binding energies</span></div><div class="casAuthors">Jencks, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4046-50</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">It can be useful to describe the Gibbs free energy changes for the binding to a protein of a mol., A-B, and of its component parts, A and B, in terms of the intrinsic binding energies of A and B, ΔGiA and ΔGiB, and a connection Gibbs energy, ΔGs, that is derived largely from changes in translational and rotational entropy.  The relation between ΔGsand ΔGiA and ΔGiB is discussed.  This empirical approach avoids the difficult of interpreting obsd. ΔH and TΔS values for aq. solns.  The ΔGi and ΔGsterms can be large for binding to enzymes and other proteins.  The use and interpretation of these binding energies are discussed, esp. with respect to ATP interaction with myosin ATPase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2X3Thp5VESLVg90H21EOLACvtfcHk0lhMcQgzHc8Adw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlvVamtbo%253D&md5=1cdbbb8b6e3f9d3ff0ba2c662c772375</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.78.7.4046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.78.7.4046%26sid%3Dliteratum%253Aachs%26aulast%3DJencks%26aufirst%3DW.%2BP.%26atitle%3DOn%2520the%2520Attribution%2520and%2520Additivity%2520of%2520Binding%2520Energies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1981%26volume%3D78%26spage%3D4046%26epage%3D4050%26doi%3D10.1073%2Fpnas.78.7.4046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giacomo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koralek, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Cobimetinib Combined with Vemurafenib in Advanced BRAF(V600)-mutant Melanoma (coBRIM): Updated Efficacy Results from a Randomised, Double-blind, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2FS1470-2045%2816%2930122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27480103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1248-1260&author=P.+A.+Asciertoauthor=G.+A.+McArthurauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=A.+M.+Di+Giacomoauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=Y.+Yanauthor=M.+Wongchenkoauthor=I.+Changauthor=J.+J.+Hsuauthor=D.+O.+Koralekauthor=I.+Rooneyauthor=A.+Ribasauthor=J.+Larkin&title=Cobimetinib+Combined+with+Vemurafenib+in+Advanced+BRAF%28V600%29-mutant+Melanoma+%28coBRIM%29%3A+Updated+Efficacy+Results+from+a+Randomised%2C+Double-blind%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2816%2930122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Ascierto, Paolo A.; McArthur, Grant A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabrielle; Di Giacomo, Anna Maria; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Yan, Yibing; Wongchenko, Matthew; Chang, Ilsung; Hsu, Jessie J.; Koralek, Daniel O.; Rooney, Isabelle; Ribas, Antoni; Larkin, James</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1248-1260</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAFV600-mutant advanced melanoma, as previously reported in the coBRIM study.  In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.  In this double-blind, randomized, placebo-controlled, multicenter study, adult patients (aged ≥18 years) with histol. confirmed BRAFV600 mutation-pos. unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) using an interactive response system to receive cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) or placebo, in combination with oral vemurafenib (960 mg twice daily).  Progression-free and overall survival were primary and secondary endpoints, resp.; all analyses were done on the intention-to-treat population.  This study is registered with ClinicalTrials.gov, no. NCT01689519, and is ongoing but no longer recruiting participants.  Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248).  At a median follow-up of 14·2 mo (IQR 8·5-17·3), the updated investigator-assessed median progression-free survival was 12·3 mo (95% CI 9·5-13·4) for cobimetinib and vemurafenib vs. 7·2 mo (5·6-7·5) for placebo and vemurafenib (HR 0·58 [95% CI 0·46-0·72], p<0·0001).  The final anal. for overall survival occurred when 255 (52%) patients had died (Aug 28, 2015).  Median overall survival was 22·3 mo (95% CI 20·3-not estimable) for cobimetinib and vemurafenib vs. 17·4 mo (95% CI 15·0-19·8) for placebo and vemurafenib (HR 0·70, 95% CI 0·55-0·90; p=0·005).  The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were obsd. with longer follow-up.  The most common grade 3-4 adverse events occurring at a higher frequency in patients in the cobimetinib and vemurafenib group compared with the vemurafenib group were γ-glutamyl transferase increase (36 [15%] in the cobimetinib and vemurafenib group vs 25 [10%] in the placebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase (28 [11%] vs 15 [6%]).  Serious adverse events occurred in 92 patients (37%) in the cobimetinib and vemurafenib group and 69 patients (28%) in the vemurafenib group.  Pyrexia (six patients [2%]) and dehydration (five patients [2%]) were the most common serious adverse events reported in the cobimetinib and vemurafenib group.  A total of 259 patients have died: 117 (47%) in the cobimetinib and vemurafenib group and 142 (58%) in the vemurafenib group.  The primary cause of death was disease progression in most patients: 109 (93%) of 117 in the cobimetinib and vemurafenib group and 133 (94%) of 142 in the vemurafenib group.  These data confirm the clin. benefit of cobimetinib combined with vemurafenib and support the use of the combination as a std. first-line approach to improve survival in patients with advanced BRAFV600-mutant melanoma.F Hoffmann-La Roche-Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4OAKivAOwrVg90H21EOLACvtfcHk0lhu10ainIW-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsL%252FL&md5=e2823328573964158a9884043cf99acf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930122-X%26sid%3Dliteratum%253Aachs%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DDi%2BGiacomo%26aufirst%3DA.%2BM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWongchenko%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DHsu%26aufirst%3DJ.%2BJ.%26aulast%3DKoralek%26aufirst%3DD.%2BO.%26aulast%3DRooney%26aufirst%3DI.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DCobimetinib%2520Combined%2520with%2520Vemurafenib%2520in%2520Advanced%2520BRAF%2528V600%2529-mutant%2520Melanoma%2520%2528coBRIM%2529%253A%2520Updated%2520Efficacy%2520Results%2520from%2520a%2520Randomised%252C%2520Double-blind%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D1248%26epage%3D1260%26doi%3D10.1016%2FS1470-2045%2816%2930122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oltersdorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augeri, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckwerth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinges, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitten, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettesheim, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleksijew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petros, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1038/nature03579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fnature03579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=15902208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ogtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=677-681&author=T.+Oltersdorfauthor=S.+W.+Elmoreauthor=A.+R.+Shoemakerauthor=R.+C.+Armstrongauthor=D.+J.+Augeriauthor=B.+A.+Belliauthor=M.+Brunckoauthor=T.+L.+Deckwerthauthor=J.+Dingesauthor=P.+J.+Hajdukauthor=M.+K.+Josephauthor=S.+Kitadaauthor=S.+J.+Korsmeyerauthor=A.+R.+Kunzerauthor=A.+Letaiauthor=C.+Liauthor=M.+J.+Mittenauthor=D.+G.+Nettesheimauthor=S.+Ngauthor=P.+M.+Nimmerauthor=J.+M.+O%E2%80%99Connorauthor=A.+Oleksijewauthor=A.+M.+Petrosauthor=J.+C.+Reedauthor=W.+Shenauthor=S.+K.+Tahirauthor=C.+B.+Thompsonauthor=K.+J.+Tomaselliauthor=B.+Wangauthor=M.+D.+Wendtauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenberg&title=An+Inhibitor+of+Bcl-2+Family+Proteins+Induces+Regression+of+Solid+Tumours&doi=10.1038%2Fnature03579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of Bcl-2 family proteins induces regression of solid tumours</span></div><div class="casAuthors">Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R.; Armstrong, Robert C.; Augeri, David J.; Belli, Barbara A.; Bruncko, Milan; Deckwerth, Thomas L.; Dinges, Jurgen; Hajduk, Philip J.; Joseph, Mary K.; Kitada, Shinichi; Korsmeyer, Stanley J.; Kunzer, Aaron R.; Letai, Anthony; Li, Chi; Mitten, Michael J.; Nettesheim, David G.; Ng, Shi Chung; Nimmer, Paul M.; O'Connor, Jacqueline M.; Oleksijew, Anatol; Petros, Andrew M.; Reed, John C.; Shen, Wang; Tahir, Stephen K.; Thompson, Craig B.; Tomaselli, Kevin J.; Wang, Baole; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">7042</span>),
    <span class="NLM_cas:pages">677-681</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and contribute to tumor initiation, progression and resistance to therapy.  Bcl-XL expression correlates with chemo-resistance of tumor cell lines, and redns. in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival.  The development of inhibitors of these proteins as potential anticancer therapeutics has been previously explored, but obtaining potent small-mol. inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction.  Here, using NMR-based screening, parallel synthesis and structure-based design, the authors have discovered ABT-737, a small-mol. inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compds.  Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.  ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBt7_zVt8HrbVg90H21EOLACvtfcHk0lhu10ainIW-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ogtb0%253D&md5=4940d06838506f181b6310d3458a595f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature03579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03579%26sid%3Dliteratum%253Aachs%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DDeckwerth%26aufirst%3DT.%2BL.%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26aulast%3DKunzer%26aufirst%3DA.%2BR.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DNettesheim%26aufirst%3DD.%2BG.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BM.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26aulast%3DTomaselli%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26atitle%3DAn%2520Inhibitor%2520of%2520Bcl-2%2520Family%2520Proteins%2520Induces%2520Regression%2520of%2520Solid%2520Tumours%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D677%26epage%3D681%26doi%3D10.1038%2Fnature03579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Twenty Years on: the Impact of Fragments on Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fnrd.2016.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27417849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=605-619&author=D.+A.+Erlansonauthor=S.+W.+Fesikauthor=R.+E.+Hubbardauthor=W.+Jahnkeauthor=H.+Jhoti&title=Twenty+Years+on%3A+the+Impact+of+Fragments+on+Drug+Discovery&doi=10.1038%2Fnrd.2016.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years on: the impact of fragments on drug discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Fesik, Stephen W.; Hubbard, Roderick E.; Jahnke, Wolfgang; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">605-619</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream.  More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials.  FBDD has been widely applied in both academia and industry, as evidenced by the large no. of papers from universities, non-profit research institutions, biotechnol. companies and pharmaceutical companies.  Moreover, FBDD draws on a diverse range of disciplines, from biochem. and biophysics to computational and medicinal chem.  As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future.  This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them.  It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrXQhFttydkrVg90H21EOLACvtfcHk0lj9iBTO6rIsgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE&md5=fc2bcf0da6b7b1083a5ff263057cfa80</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.109%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DTwenty%2520Years%2520on%253A%2520the%2520Impact%2520of%2520Fragments%2520on%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D605%26epage%3D619%26doi%3D10.1038%2Fnrd.2016.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A ‘Rule of Three’ for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2eYNUBzsFbM7RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span> <span> </span><span class="NLM_article-title">Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-Like Bioisosteric Groups</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1021/ci0255782</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0255782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Cmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=374-380&author=P.+Ertl&title=Cheminformatics+Analysis+of+Organic+Substituents%3A+Identification+of+the+Most+Common+Substituents%2C+Calculation+of+Substituent+Properties%2C+and+Automatic+Identification+of+Drug-Like+Bioisosteric+Groups&doi=10.1021%2Fci0255782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups</span></div><div class="casAuthors">Ertl, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-380</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A large set of more than 3 million mols. was processed to find all the org. substituents contained in the set and to identify the most common ones.  During the anal., 849 574 unique substituents were found.  Extrapolated to the no. of known org. mols., this result suggests that about 3.1 million substituents are known.  Based on these findings the size of virtual org. chem. space accessible using currently known synthetic methods is estd. to be between 1020 and 1024 mols.  The extd. substituents were characterized by calcd. electronic, hydrophobic, steric, and hydrogen bonding properties as well as by the drug-likeness index.  Various possible applications of such a large database of drug-like substituents characterized by calcd. properties are discussed and illustrated by ref. to a Web-based tool for automatic identification of bioisosteric groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqODLrwzH2t4LVg90H21EOLACvtfcHk0lj9iBTO6rIsgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Cmtbs%253D&md5=9debc7ddfbb1c57ff85b7ff55c44a7d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci0255782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0255782%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DCheminformatics%2520Analysis%2520of%2520Organic%2520Substituents%253A%2520Identification%2520of%2520the%2520Most%2520Common%2520Substituents%252C%2520Calculation%2520of%2520Substituent%2520Properties%252C%2520and%2520Automatic%2520Identification%2520of%2520Drug-Like%2520Bioisosteric%2520Groups%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D374%26epage%3D380%26doi%3D10.1021%2Fci0255782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4990</span>– <span class="NLM_lpage">5003</span>, <span class="refDoi"> DOI: 10.1021/bi3005126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3005126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4990-5003&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=S.+A.+Hudsonauthor=C.+Abell&title=Fragment-Based+Approaches+in+Drug+Discovery+and+Chemical+Biology&doi=10.1021%2Fbi3005126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Hudson, Sean A.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4990-5003</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fragment-based approaches to finding novel small mols. that bind to proteins are now firmly established in drug discovery and chem. biol.  Initially developed primarily in a few centers in the biotech and pharma industry, this methodol. has now been adopted widely in both the pharmaceutical industry and academia.  After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes.  Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, β-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase.  The role of fragment-based approaches in an academic research environment is also examd. with an emphasis on neglected diseases such as tuberculosis.  The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2ry6mWC83bVg90H21EOLACvtfcHk0lj9iBTO6rIsgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D&md5=39a6f0f741e711fd572e24c95142f55d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi3005126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3005126%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DHudson%26aufirst%3DS.%2BA.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-Based%2520Approaches%2520in%2520Drug%2520Discovery%2520and%2520Chemical%2520Biology%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D4990%26epage%3D5003%26doi%3D10.1021%2Fbi3005126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregori-Puigjane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krojer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velupillai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz Torres, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span> <span> </span><span class="NLM_article-title">Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1580</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1580-1598&author=M.+Korczynskaauthor=D.+D.+Leauthor=N.+Youngerauthor=E.+Gregori-Puigjaneauthor=A.+Tumberauthor=T.+Krojerauthor=S.+Velupillaiauthor=C.+Gileadiauthor=R.+P.+Nowakauthor=E.+Iwasaauthor=S.+B.+Pollockauthor=I.+Ortiz+Torresauthor=U.+Oppermannauthor=B.+K.+Shoichetauthor=D.+G.+Fujimori&title=Docking+and+Linking+of+Fragments+To+Discover+Jumonji+Histone+Demethylase+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors</span></div><div class="casAuthors">Korczynska, Magdalena; Le, Daniel D.; Younger, Noah; Gregori-Puigjane, Elisabet; Tumber, Anthony; Krojer, Tobias; Velupillai, Srikannathasan; Gileadi, Carina; Nowak, Radoslaw P.; Iwasa, Eriko; Pollock, Samuel B.; Ortiz Torres, Idelisse; Oppermann, Udo; Shoichet, Brian K.; Fujimori, Danica Galonic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1580-1598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of tool mols. that inhibit Jumonji demethylases allows for the investigation of cancer-assocd. transcription.  While scaffolds such as 2,4-pyridinedicarboxylic acid (2,4-PDCA) are potent inhibitors, they exhibit limited selectivity.  To discover new inhibitors for the KDM4 demethylases, enzymes overexpressed in several cancers, we docked a library of 600 000 fragments into the high-resoln. structure of KDM4A.  Among the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overlapping orientations.  Docking poses informed the design of covalently linked fragment compds., which were further derivatized.  This combined approach improved affinity by ∼3 log-orders to yield compd. 35 (Ki = 43 nM).  Several hybrid inhibitors were selective for KDM4C over the related enzymes FIH, KDM2A, and KDM6B while lacking selectivity against the KDM3 and KDM5 subfamilies.  Cocrystal structures corroborated the docking predictions.  This study extends the use of structure-based docking from fragment discovery to fragment linking optimization, yielding novel KDM4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0n7_U9JkllrVg90H21EOLACvtfcHk0ljYfe91phWqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGjs7k%253D&md5=ee6bc4c9e355ab4ed5fe2a2e0b2dc3f2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01527%26sid%3Dliteratum%253Aachs%26aulast%3DKorczynska%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DYounger%26aufirst%3DN.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DKrojer%26aufirst%3DT.%26aulast%3DVelupillai%26aufirst%3DS.%26aulast%3DGileadi%26aufirst%3DC.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DIwasa%26aufirst%3DE.%26aulast%3DPollock%26aufirst%3DS.%2BB.%26aulast%3DOrtiz%2BTorres%26aufirst%3DI.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26atitle%3DDocking%2520and%2520Linking%2520of%2520Fragments%2520To%2520Discover%2520Jumonji%2520Histone%2520Demethylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1580%26epage%3D1598%26doi%3D10.1021%2Facs.jmedchem.5b01527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jehle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiana, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">Ligand Deconstruction: Why Some Fragment Binding Positions are Conserved and Others are Not</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E2585</span>– <span class="NLM_lpage">2594</span>, <span class="refDoi"> DOI: 10.1073/pnas.1501567112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.1501567112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25918377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E2585-2594&author=D.+Kozakovauthor=D.+R.+Hallauthor=S.+Jehleauthor=L.+Luoauthor=S.+O.+Ochianaauthor=E.+V.+Jonesauthor=M.+Pollastriauthor=K.+N.+Allenauthor=A.+Whittyauthor=S.+Vajda&title=Ligand+Deconstruction%3A+Why+Some+Fragment+Binding+Positions+are+Conserved+and+Others+are+Not&doi=10.1073%2Fpnas.1501567112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand deconstruction: Why some fragment binding positions are conserved and others are not</span></div><div class="casAuthors">Kozakov, Dima; Hall, David R.; Jehle, Sefan; Luo, Lingqi; Ochiana, Stefan O.; Jones, Elizabeth V.; Pollastri, Michael; Allen, Karen N.; Whitty, Adrian; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">E2585-E2594</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) relies on the premise that the fragment binding mode will be conserved on subsequent expansion to a larger ligand.  However, no general condition has been established to explain when fragment binding modes will be conserved.  We show that a remarkably simple condition can be developed in terms of how fragments coincide with binding energy hot spots-regions of the protein where interactions with a ligand contribute substantial binding free energy-the locations of which can easily be detd. computationally.  Because a substantial fraction of the free energy of ligand binding comes from interacting with the residues in the energetically most important hot spot, a ligand moiety that sufficiently overlaps with this region will retain its location even when other parts of the ligand are removed.  This hypothesis is supported by eight case studies.  The condition helps identify whether a protein is suitable for FBDD, predicts the size of fragments required for screening, and dets. whether a fragment hit can be extended into a higher affinity ligand.  Our results show that ligand binding sites can usefully be thought of in terms of an anchor site, which is the top-ranked hot spot and dominates the free energy of binding, surrounded by a no. of weaker satellite sites that confer improved affinity and selectivity for a particular ligand and that it is the intrinsic binding potential of the protein surface that dets. whether it can serve as a robust binding site for a suitably optimized ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH6jbOut_iv7Vg90H21EOLACvtfcHk0ljYfe91phWqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitrY%253D&md5=d56b18fb4e4befde24037b07e52d8b62</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501567112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501567112%26sid%3Dliteratum%253Aachs%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DJehle%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DJones%26aufirst%3DE.%2BV.%26aulast%3DPollastri%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DK.%2BN.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DLigand%2520Deconstruction%253A%2520Why%2520Some%2520Fragment%2520Binding%2520Positions%2520are%2520Conserved%2520and%2520Others%2520are%2520Not%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3DE2585%26epage%3D2594%26doi%3D10.1073%2Fpnas.1501567112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">A De Novo Substructure Generation Algorithm for Identifying the Privileged Chemical Fragments of Liver X Receptorbeta Agonists</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">11121</span> <span class="refDoi"> DOI: 10.1038/s41598-017-08848-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41598-017-08848-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=28894088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmvFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=H.+Pengauthor=Z.+Liuauthor=X.+Yanauthor=J.+Renauthor=J.+Xu&title=A+De+Novo+Substructure+Generation+Algorithm+for+Identifying+the+Privileged+Chemical+Fragments+of+Liver+X+Receptorbeta+Agonists&doi=10.1038%2Fs41598-017-08848-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists</span></div><div class="casAuthors">Peng He; Liu Zhihong; Yan Xin; Ren Jian; Xu Jun</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Liver X receptorβ (LXRβ) is a promising therapeutic target for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases.  Druggable LXRβ agonists have been explored over the past decades.  However, the pocket of LXRβ ligand-binding domain (LBD) is too large to predict LXRβ agonists with novel scaffolds based on either receptor or agonist structures.  In this paper, we report a de novo algorithm which drives privileged LXRβ agonist fragments by starting with individual chemical bonds (de novo) from every molecule in a LXRβ agonist library, growing the bonds into substructures based on the agonist structures with isomorphic and homomorphic restrictions, and electing the privileged fragments from the substructures with a popularity threshold and background chemical and biological knowledge.  Using these privileged fragments as queries, we were able to figure out the rules to reconstruct LXRβ agonist molecules from the fragments.  The privileged fragments were validated by building regularized logistic regression (RLR) and supporting vector machine (SVM) models as descriptors to predict a LXRβ agonist activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2fjqYJFxP4EcLvDNbOD4DfW6udTcc2eYh9iV5pWNQdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmvFajug%253D%253D&md5=9454fcf78d2658673f0daf8a0befdf24</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-08848-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-08848-4%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DA%2520De%2520Novo%2520Substructure%2520Generation%2520Algorithm%2520for%2520Identifying%2520the%2520Privileged%2520Chemical%2520Fragments%2520of%2520Liver%2520X%2520Receptorbeta%2520Agonists%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-08848-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5885</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVekt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5885-5900&author=C.+Zhaoauthor=D.+Huangauthor=R.+Liauthor=Y.+Xuauthor=S.+Suauthor=Q.+Guauthor=J.+Xu&title=Identifying+Novel+Anti-Osteoporosis+Leads+with+a+Chemotype-Assembly+Approach&doi=10.1021%2Facs.jmedchem.9b00517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach</span></div><div class="casAuthors">Zhao, Chao; Huang, Dane; Li, Ruyue; Xu, Yida; Su, Shimin; Gu, Qiong; Xu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5885-5900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we applied a chemotype-assembly approach for ligand-based drug discovery (LBDD) to discover novel anti-osteoporosis leads.  With this new approach, we identified 12 chemotypes and derived 18 major chemotype assembly rules from 245 known anti-osteoporosis compds.  Then, we selected 19 compds. from an inhouse compd. library using chemotype-assembly approach for anti-osteoporosis assays, which resulted in 13 hits.  Based on structural features in these 13 compds., we synthesized 50 possible anti-osteoporosis compds. from the anti-osteoporosis chemotypes by means of click chem. techniques and discovered a compd. (10a, IC50 = 2 nM) with nanomolar activity.  Compd. 10a was then proved to be an anti-osteoporosis lead since it can prevent bone loss in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodLGTK4nNTrVg90H21EOLACvtfcHk0lhiPG9uOEsjxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVekt77M&md5=b935f96d9194383d8e981f5a5731b368</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00517%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DIdentifying%2520Novel%2520Anti-Osteoporosis%2520Leads%2520with%2520a%2520Chemotype-Assembly%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5885%26epage%3D5900%26doi%3D10.1021%2Facs.jmedchem.9b00517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonsing-Carter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saadatzadeh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spragins, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprouse, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunter, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minto, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchal, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batuello, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanenberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Territo, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eischen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K. E.</span></span> <span> </span><span class="NLM_article-title">Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2850</span>– <span class="NLM_lpage">2863</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-15-0237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=26494859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2850-2863&author=E.+Tonsing-Carterauthor=B.+J.+Baileyauthor=M.+R.+Saadatzadehauthor=J.+Dingauthor=H.+Wangauthor=A.+L.+Sinnauthor=K.+M.+Petermanauthor=T.+K.+Spraginsauthor=J.+M.+Silverauthor=A.+A.+Sprouseauthor=T.+M.+Georgiadisauthor=T.+Z.+Gunterauthor=E.+C.+Longauthor=R.+E.+Mintoauthor=C.+C.+Marchalauthor=C.+N.+Batuelloauthor=A.+R.+Safaauthor=H.+Hanenbergauthor=P.+R.+Territoauthor=G.+E.+Sanduskyauthor=L.+D.+Mayoauthor=C.+M.+Eischenauthor=H.+E.+Shannonauthor=K.+E.+Pollok&title=Potentiation+of+Carboplatin-Mediated+DNA+Damage+by+the+Mdm2+Modulator+Nutlin-3a+in+a+Humanized+Orthotopic+Breast-to-Lung+Metastatic+Model&doi=10.1158%2F1535-7163.MCT-15-0237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model</span></div><div class="casAuthors">Tonsing-Carter, Eva; Bailey, Barbara J.; Saadatzadeh, M. Reza; Ding, Jixin; Wang, Haiyan; Sinn, Anthony L.; Peterman, Kacie M.; Spragins, Tiaishia K.; Silver, Jayne M.; Sprouse, Alyssa A.; Georgiadis, Taxiarchis M.; Gunter, T. Zachary; Long, Eric C.; Minto, Robert E.; Marchal, Christophe C.; Batuello, Christopher N.; Safa, Ahmad R.; Hanenberg, Helmut; Territo, Paul R.; Sandusky, George E.; Mayo, Lindsey D.; Eischen, Christine M.; Shannon, Harlan E.; Pollok, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2850-2863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) are typically resistant to treatment, and strategies that build upon frontline therapy are needed.  Targeting the murine double minute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers.  The Mdm2 protein-protein interaction inhibitor Nutlin-3a blocks the binding of Mdm2 to key signaling mols. such as p53 and p73α and can result in activation of cell death signaling pathways.  In the present study, the therapeutic potential of carboplatin and Nutlin-3a to treat TNBC was investigated, as carboplatin is under evaluation in clin. trials for TNBC.  In mutant p53 TMD231 TNBC cells, carboplatin and Nutlin-3a led to increased Mdm2 and was strongly synergistic in promoting cell death in vitro.  Furthermore, sensitivity of TNBC cells to combination treatment was dependent on p73α.  Following combination treatment, γH2AX increased and Mdm2 localized to a larger degree to chromatin compared with single-agent treatment, consistent with previous observations that Mdm2 binds to the Mre11/Rad50/Nbs1 complex assocd. with DNA and inhibits the DNA damage response.  In vivo efficacy studies were conducted in the TMD231 orthotopic mammary fat pad model in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice.  Using an intermittent dosing schedule of combined carboplatin and Nutlin-3a, there was a significant redn. in primary tumor growth and lung metastases compared with vehicle and single-agent treatments.  In addn., there was minimal toxicity to the bone marrow and normal tissues.  These studies demonstrate that Mdm2 holds promise as a therapeutic target in combination with conventional therapy and may lead to new clin. therapies for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_pRwn_Ma__7Vg90H21EOLACvtfcHk0lhiPG9uOEsjxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7vI&md5=aec5201362aff4b1b1f0c51999bde645</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0237%26sid%3Dliteratum%253Aachs%26aulast%3DTonsing-Carter%26aufirst%3DE.%26aulast%3DBailey%26aufirst%3DB.%2BJ.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSinn%26aufirst%3DA.%2BL.%26aulast%3DPeterman%26aufirst%3DK.%2BM.%26aulast%3DSpragins%26aufirst%3DT.%2BK.%26aulast%3DSilver%26aufirst%3DJ.%2BM.%26aulast%3DSprouse%26aufirst%3DA.%2BA.%26aulast%3DGeorgiadis%26aufirst%3DT.%2BM.%26aulast%3DGunter%26aufirst%3DT.%2BZ.%26aulast%3DLong%26aufirst%3DE.%2BC.%26aulast%3DMinto%26aufirst%3DR.%2BE.%26aulast%3DMarchal%26aufirst%3DC.%2BC.%26aulast%3DBatuello%26aufirst%3DC.%2BN.%26aulast%3DSafa%26aufirst%3DA.%2BR.%26aulast%3DHanenberg%26aufirst%3DH.%26aulast%3DTerrito%26aufirst%3DP.%2BR.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26aulast%3DMayo%26aufirst%3DL.%2BD.%26aulast%3DEischen%26aufirst%3DC.%2BM.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DPollok%26aufirst%3DK.%2BE.%26atitle%3DPotentiation%2520of%2520Carboplatin-Mediated%2520DNA%2520Damage%2520by%2520the%2520Mdm2%2520Modulator%2520Nutlin-3a%2520in%2520a%2520Humanized%2520Orthotopic%2520Breast-to-Lung%2520Metastatic%2520Model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2850%26epage%3D2863%26doi%3D10.1158%2F1535-7163.MCT-15-0237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voloshin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alishekevitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machluf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaked, Y.</span></span> <span> </span><span class="NLM_article-title">Blocking IL1beta Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25887886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1385-1394&author=T.+Voloshinauthor=D.+Alishekevitzauthor=L.+Kanetiauthor=V.+Millerauthor=E.+Isakovauthor=I.+Kaplanovauthor=E.+Voronovauthor=E.+Fremderauthor=M.+Benharauthor=M.+Machlufauthor=R.+N.+Apteauthor=Y.+Shaked&title=Blocking+IL1beta+Pathway+Following+Paclitaxel+Chemotherapy+Slightly+Inhibits+Primary+Tumor+Growth+but+Promotes+Spontaneous+Metastasis&doi=10.1158%2F1535-7163.MCT-14-0969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis</span></div><div class="casAuthors">Voloshin, Tali; Alishekevitz, Dror; Kaneti, Limor; Miller, Valeria; Isakov, Elina; Kaplanov, Irena; Voronov, Elena; Fremder, Ella; Benhar, Moran; Machluf, Marcelle; Apte, Ron N.; Shaked, Yuval</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1385-1394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired resistance to therapy is a major obstacle in clin. oncol., and little is known about the contributing mechanisms of the host response to therapy.  Here, we show that the proinflammatory cytokine IL1β is overexpressed in response to paclitaxel chemotherapy in macrophages, subsequently promoting the invasive properties of malignant cells.  In accordance, blocking IL1β, or its receptor, using either genetic or pharmacol. approach, results in slight retardation of primary tumor growth; however, it accelerates metastasis spread.  Tumors from mice treated with combined therapy of paclitaxel and the IL1 receptor antagonist anakinra exhibit increased no. of M2 macrophages and vessel leakiness when compared with paclitaxel monotherapy-treated mice, indicating a prometastatic role of M2 macrophages in the IL1β-deprived microenvironment.  Taken together, these findings demonstrate the dual effects of blocking the IL1 pathway on tumor growth.  Accordingly, treatments using "add-on" drugs to conventional therapy should be investigated in appropriate tumor models consisting of primary tumors and their metastases.  Mol Cancer Ther; 14(6); 1385-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn-_I15IspmbVg90H21EOLACvtfcHk0lhiPG9uOEsjxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOnsLw%253D&md5=cbc7c4620b4cecd70ad73911b27ba76a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0969%26sid%3Dliteratum%253Aachs%26aulast%3DVoloshin%26aufirst%3DT.%26aulast%3DAlishekevitz%26aufirst%3DD.%26aulast%3DKaneti%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DIsakov%26aufirst%3DE.%26aulast%3DKaplanov%26aufirst%3DI.%26aulast%3DVoronov%26aufirst%3DE.%26aulast%3DFremder%26aufirst%3DE.%26aulast%3DBenhar%26aufirst%3DM.%26aulast%3DMachluf%26aufirst%3DM.%26aulast%3DApte%26aufirst%3DR.%2BN.%26aulast%3DShaked%26aufirst%3DY.%26atitle%3DBlocking%2520IL1beta%2520Pathway%2520Following%2520Paclitaxel%2520Chemotherapy%2520Slightly%2520Inhibits%2520Primary%2520Tumor%2520Growth%2520but%2520Promotes%2520Spontaneous%2520Metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1385%26epage%3D1394%26doi%3D10.1158%2F1535-7163.MCT-14-0969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrild, J. C.</span>; <span class="NLM_string-name">Lauritsen, A.</span>; <span class="NLM_string-name">Björkling, F.</span>; <span class="NLM_string-name">Vadlamudi, S. M.</span></span> <span> </span><span class="NLM_article-title">4-Substituted-6-isopropyl-benzene-1,3-diol Compounds and Their use</span>. <span class="NLM_patent">WO2009/066060A2</span>, May 28, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+C.+Norrild&author=A.+Lauritsen&author=F.+Bj%C3%B6rkling&author=S.+M.+Vadlamudi&title=4-Substituted-6-isopropyl-benzene-1%2C3-diol+Compounds+and+Their+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNorrild%26aufirst%3DJ.%2BC.%26atitle%3D4-Substituted-6-isopropyl-benzene-1%252C3-diol%2520Compounds%2520and%2520Their%2520use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 Alpha and Beta, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+Highly+Selective+Inhibitor+of+Heat+Shock+Protein+90+Alpha+and+Beta%2C+Demonstrates+Potent+Antitumor+Activity+and+Minimal+Ocular+Toxicity+in+Preclinical+Models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0ljusc8zcTuALw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520Highly%2520Selective%2520Inhibitor%2520of%2520Heat%2520Shock%2520Protein%252090%2520Alpha%2520and%2520Beta%252C%2520Demonstrates%2520Potent%2520Antitumor%2520Activity%2520and%2520Minimal%2520Ocular%2520Toxicity%2520in%2520Preclinical%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of Celastrol to Inhibit Hsp90 and dc37 Interaction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35381</span>– <span class="NLM_lpage">35389</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.051532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1074%2Fjbc.M109.051532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=19858214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35381-35389&author=T.+Zhangauthor=Y.+Liauthor=Y.+Yuauthor=P.+Zouauthor=Y.+Jiangauthor=D.+Sun&title=Characterization+of+Celastrol+to+Inhibit+Hsp90+and+dc37+Interaction&doi=10.1074%2Fjbc.M109.051532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction</span></div><div class="casAuthors">Zhang, Tao; Li, Yanyan; Yu, Yanke; Zou, Peng; Jiang, Yiqun; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35381-35389</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (Hsp90) is required for the stabilization and conformational maturation of various oncogenic proteins in cancer.  The loading of protein kinases to Hsp90 is actively mediated by the co-chaperone Cdc37.  The crucial role of the Hsp90-Cdc37 complex has made it an exciting target for cancer treatment.  In this study, the authors characterize Hsp90 and Cdc37 interaction and drug disruption using a reconstituted protein system.  The GST pull-down assay and ELISA assay show that Cdc37 binds to ADP-bound/nucleotide-free Hsp90 but not ATP-bound Hsp90.  Celastrol disrupts Hsp90-Cdc37 complex formation, whereas the classical Hsp90 inhibitors (e.g., geldanamycin) have no effect.  Celastrol inhibits Hsp90 ATPase activity without blocking ATP binding.  Proteolytic fingerprinting indicates celastrol binds to Hsp90 C-terminal domain to protect it from trypsin digestion.  These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbfNGpAapIrVg90H21EOLACvtfcHk0ljusc8zcTuALw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurjN&md5=f8d15de4ecac58de8bb5274d9cf9cdcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.051532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.051532%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520Celastrol%2520to%2520Inhibit%2520Hsp90%2520and%2520dc37%2520Interaction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35381%26epage%3D35389%26doi%3D10.1074%2Fjbc.M109.051532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) SSSR of molecules in Library P. (B) The SSSR of molecules in Library M. (C) The SSSR of molecules in Library N. (D) The example of chemotypes assembly to known Hsp90 inhibitor ACO1. The pink color shows that the functional group does not include in chemotype-assembled motif. SSSR = smallest set of smallest rings.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Designing Hsp90 inhibitors through assembling privileged chemotypes. (A) Thirty fragments for building potential Hsp90 inhibitors. 5Har = five-membered heteroaromatic ring; 6Ar = six-membered aromatic ring; 6r = six-membered aliphatic ring. (B) Chemotypes assembling to form potential anti-Hsp90 scaffolds. (C) Chemotype <b>C1</b> or <b>C4</b> assembles with a non-anti-Hsp90 chemotype to form potential non-anti-Hsp90 scaffolds. (D) Click chemistry synthetical scheme for assembling potential Hsp90 inhibitors from privileged fragments (chemotypes). (E) Commercially available starting materials from active fragments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Binding model of compound <b>3d</b> with Hsp90α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>). Compound <b>3d</b> binds to Thr184 through a water bridge (red ball). (B) Overlay of compound <b>3d</b> with NVP-HSP990 (blue color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>). (C) Overlay of compound <b>3d</b> with NVP-AUY922 (red color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>). (D) Overlay of compound <b>3d</b> with TSA-116 (yellow color, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3">5ZR3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding model of compound <b>4f</b> with Hsp90α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T">4W7T</a>) and binding affinity of <b>4f</b> with WT-Hsp90α or mutated Hsp90α. The H-bonds are represented as yellow dashed lines. Waters are represented as the red ball.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vitro</i> and <i>in vivo</i> experiments prove <b>4f</b> is a promising lead against nasopharyngeal carcinoma. (A) Quantification of the apoptotic rate in control and different-dose <b>4f</b>-treated Annexin V-FITC/PI stained CNE2 cells at 48 h. (B) Western blots analysis of the effects of <b>4f</b> on Hsp90, AKT, <i>p</i>-mTOR, and Bcl-xL. (C) Changes in cell viability upon Hsp90α knockdown with and without compound <b>4f</b> at 70 nM. (D) Western blots analysis of the effects of <b>4f</b> on Hsp90, AKT, and Bcl-xL when Hsp90 is knockdown. (E) Cell apoptosis of CNE2 in the mock group and the Hsp90 overexpression group without and with <b>4f</b> treatment. (F) AKT and BCL-2 expression in the mock group and the Hsp90 overexpression group without and with <b>4f</b> treatment. ***: <i>P</i> ≤ 0.001 compared to related groups; ns: nonsignificant difference compared to related groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/medium/jm0c01521_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Images of tumors (<i>n</i> = 10) treated with <b>4f</b> or vehicle after 32 days. (B) Tumor weight treated with <b>4f</b> or vehicle after 32 days. (C) Tumor volume in mice (<i>n</i> = 10) treated for the indicated time with <b>4f</b> or vehicle. (D) Pharmacokinetic study of <b>4f</b> in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01521/20210218/images/large/jm0c01521_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01521&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71083" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71083" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2Fj.chembiol.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=30639261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=352-365&author=Z.+Liuauthor=H.+Liauthor=L.+Heauthor=Y.+Xiangauthor=C.+Tianauthor=C.+Liauthor=P.+Tanauthor=J.+Jingauthor=Y.+Tianauthor=L.+Duauthor=Y.+Huangauthor=L.+Hanauthor=M.+Liauthor=Y.+Zhou&title=Discovery+of+Small-Molecule+Inhibitors+of+the+HSP90-Calcineurin-NFAT+Pathway+against+Glioblastoma&doi=10.1016%2Fj.chembiol.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma</span></div><div class="casAuthors">Liu, Zhenzhen; Li, Hongli; He, Lian; Xiang, Yu; Tian, Chengsen; Li, Can; Tan, Peng; Jing, Ji; Tian, Yanpin; Du, Lupei; Huang, Yun; Han, Leng; Li, Minyong; Zhou, Yubin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-365.e7</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is among the most common and malignant types of primary brain tumors in adults, with a dismal prognosis.  Although alkylating agents such as temozolomide are widely applied as the first-line treatment for GBM, they often cause chemoresistance and remain ineffective with recurrent GBM.  Alternative therapeutics against GBM are urgently needed in the clinic.  We report herein the discovery of a class of inhibitors (YZ129 and its derivs.) of the calcineurin-NFAT pathway that exhibited potent anti-tumor activity against GBM.  YZ129-induced GBM cell-cycle arrest at the G2/M phase promoted apoptosis and inhibited tumor cell proliferation and migration.  At the mol. level, YZ129 directly engaged HSP90 to antagonize its chaperoning effect on calcineurin to abrogate NFAT nuclear translocation, and also suppressed other proto-oncogenic pathways including hypoxia, glycolysis, and the PI3K/AKT/mTOR signaling axis.  Our data highlight the potential for targeting the cancer-promoting HSP90 chaperone network to treat GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofnM49ki0s27Vg90H21EOLACvtfcHk0li-8iEgQA6y_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFOjug%253D%253D&md5=ebc761eb787ddda1532ea6f9a33192d4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Small-Molecule%2520Inhibitors%2520of%2520the%2520HSP90-Calcineurin-NFAT%2520Pathway%2520against%2520Glioblastoma%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D352%26epage%3D365%26doi%3D10.1016%2Fj.chembiol.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Unleashing the Full Potential of Hsp90 Inhibitors as Cancer Therapeutics through Simultaneous Inactivation of Hsp90, Grp94, and TRAP1</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/s12276-019-0360-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs12276-019-0360-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=31956271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=79-91&author=H.+K.+Parkauthor=N.+G.+Yoonauthor=J.+E.+Leeauthor=S.+Huauthor=S.+Yoonauthor=S.+Y.+Kimauthor=J.+H.+Hongauthor=D.+Namauthor=Y.+C.+Chaeauthor=J.+B.+Parkauthor=B.+H.+Kang&title=Unleashing+the+Full+Potential+of+Hsp90+Inhibitors+as+Cancer+Therapeutics+through+Simultaneous+Inactivation+of+Hsp90%2C+Grp94%2C+and+TRAP1&doi=10.1038%2Fs12276-019-0360-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1</span></div><div class="casAuthors">Park, Hye-Kyung; Yoon, Nam Gu; Lee, Ji-Eun; Hu, Sung; Yoon, Sora; Kim, So Yeon; Hong, Jun-Hee; Nam, Dougu; Chae, Young Chan; Park, Jong Bae; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-91</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The Hsp90 family proteins Hsp90, Grp94, and TRAP1 are present in the cell cytoplasm, endoplasmic reticulum, and mitochondria, resp.; all play important roles in tumorigenesis by regulating protein homeostasis in response to stress.  Thus, simultaneous inhibition of all Hsp90 paralogs is a reasonable strategy for cancer therapy.  However, since the existing pan-Hsp90 inhibitor does not accumulate in mitochondria, the potential anticancer activity of pan-Hsp90 inhibition has not yet been fully examd. in vivo.  Anal. of The Cancer Genome Atlas database revealed that all Hsp90 paralogs were upregulated in prostate cancer.  Inactivation of all Hsp90 paralogs induced mitochondrial dysfunction, increased cytosolic calcium, and activated calcineurin.  Active calcineurin blocked prosurvival heat shock responses upon Hsp90 inhibition by preventing nuclear translocation of HSF1.  The purine scaffold deriv. DN401 inhibited all Hsp90 paralogs simultaneously and showed stronger anticancer activity than other Hsp90 inhibitors.  Pan-Hsp90 inhibition increased cytotoxicity and suppressed mechanisms that protect cancer cells, suggesting that it is a feasible strategy for the development of potent anticancer drugs.  The mitochondria-permeable drug DN401 is a newly identified in vivo pan-Hsp90 inhibitor with potent anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvPfio5ICfWrVg90H21EOLACvtfcHk0li-8iEgQA6y_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislensr4%253D&md5=6bf153aba53f9ac1acf4cbf376f2a8f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs12276-019-0360-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-019-0360-x%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DYoon%26aufirst%3DN.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DHong%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DChae%26aufirst%3DY.%2BC.%26aulast%3DPark%26aufirst%3DJ.%2BB.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DUnleashing%2520the%2520Full%2520Potential%2520of%2520Hsp90%2520Inhibitors%2520as%2520Cancer%2520Therapeutics%2520through%2520Simultaneous%2520Inactivation%2520of%2520Hsp90%252C%2520Grp94%252C%2520and%2520TRAP1%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2020%26volume%3D52%26spage%3D79%26epage%3D91%26doi%3D10.1038%2Fs12276-019-0360-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenigsberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begassat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do-Vale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestadier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemecek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulaouic, H.</span></span> <span> </span><span class="NLM_article-title">The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25504634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=384-394&author=C.+Egileauthor=M.+Kenigsbergauthor=C.+Delaisiauthor=F.+Begassatauthor=V.+Do-Valeauthor=J.+Mestadierauthor=F.+Boncheauthor=T.+Benardauthor=J.+P.+Nicolasauthor=S.+Valenceauthor=C.+Lefrancauthor=E.+Francesconiauthor=C.+Castellauthor=A.+M.+Lefebvreauthor=C.+Nemecekauthor=L.+Calvetauthor=H.+Goulaouic&title=The+Selective+Intravenous+Inhibitor+of+the+MET+Tyrosine+Kinase+SAR125844+Inhibits+Tumor+Growth+in+MET-Amplified+Cancer&doi=10.1158%2F1535-7163.MCT-14-0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer</span></div><div class="casAuthors">Egile, Coumaran; Kenigsberg, Mireille; Delaisi, Christine; Begassat, Francoise; Do-Vale, Veronique; Mestadier, Jessica; Bonche, Fabrice; Benard, Tsiala; Nicolas, Jean-Paul; Valence, Sandrine; Lefranc, Celine; Francesconi, Elisa; Castell, Christelle; Lefebvre, Anne-Marie; Nemecek, Conception; Calvet, Loreley; Goulaouic, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">384-394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the MET/HGF pathway is common in human cancer and is thought to promote tumor initiation, metastasis, angiogenesis, and resistance to diverse therapies.  We report here the pharmacol. characterization of the triazolopyridazine deriv. SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for i.v. administration.  SAR125844 displayed nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and the M1250T and Y1235D mutants.  Broad biochem. profiling revealed that SAR125844 was highly selective for MET kinase.  SAR125844 inhibits MET autophosphorylation in cell-based assays in the nanomolar range, and promotes low nanomolar proapoptotic and antiproliferative activities selectively in cell lines with MET gene amplification or pathway addiction.  In two MET-amplified human gastric tumor xenograft models, SNU-5 and Hs 746T, i.v. treatment with SAR125844 leads to potent, dose- and time-dependent inhibition of the MET kinase and to significant impact on downstream PI3K/AKT and RAS/MAPK pathways.  Long duration of MET kinase inhibition up to 7 days was achieved with a nanosuspension formulation of SAR125844.  Daily or every-2-days i.v. treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body wt. loss.  Our data demonstrated that SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclin. toxicity profile, supporting its clin. development in patients with MET-amplified and MET pathway-addicted tumors.  Mol Cancer Ther; 14(2); 384-94. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphB-Rou5kYcLVg90H21EOLACvtfcHk0lggseWMQd-H_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsb0%253D&md5=12a76fc417063f4b5d7cdc970f2ec605</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0428%26sid%3Dliteratum%253Aachs%26aulast%3DEgile%26aufirst%3DC.%26aulast%3DKenigsberg%26aufirst%3DM.%26aulast%3DDelaisi%26aufirst%3DC.%26aulast%3DBegassat%26aufirst%3DF.%26aulast%3DDo-Vale%26aufirst%3DV.%26aulast%3DMestadier%26aufirst%3DJ.%26aulast%3DBonche%26aufirst%3DF.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DNicolas%26aufirst%3DJ.%2BP.%26aulast%3DValence%26aufirst%3DS.%26aulast%3DLefranc%26aufirst%3DC.%26aulast%3DFrancesconi%26aufirst%3DE.%26aulast%3DCastell%26aufirst%3DC.%26aulast%3DLefebvre%26aufirst%3DA.%2BM.%26aulast%3DNemecek%26aufirst%3DC.%26aulast%3DCalvet%26aufirst%3DL.%26aulast%3DGoulaouic%26aufirst%3DH.%26atitle%3DThe%2520Selective%2520Intravenous%2520Inhibitor%2520of%2520the%2520MET%2520Tyrosine%2520Kinase%2520SAR125844%2520Inhibits%2520Tumor%2520Growth%2520in%2520MET-Amplified%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D384%26epage%3D394%26doi%3D10.1158%2F1535-7163.MCT-14-0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanamaru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, S.</span></span> <span> </span><span class="NLM_article-title">Retinal Toxicity Induced by Small-Molecule Hsp90 Inhibitors in Beagle Dogs</span>. <i>J. Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.2131/jts.39.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.2131%2Fjts.39.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=24418710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=59-69&author=C.+Kanamaruauthor=Y.+Yamadaauthor=S.+Hayashiauthor=T.+Matsushitaauthor=A.+Sudaauthor=M.+Nagayasuauthor=K.+Kimuraauthor=S.+Chiba&title=Retinal+Toxicity+Induced+by+Small-Molecule+Hsp90+Inhibitors+in+Beagle+Dogs&doi=10.2131%2Fjts.39.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs</span></div><div class="casAuthors">Kanamaru, Chisako; Yamada, Yuichiro; Hayashi, Shuji; Matsushita, Tomochika; Suda, Atsushi; Nagayasu, Miho; Kimura, Kazuya; Chiba, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-69</span>CODEN:
                <span class="NLM_cas:coden">JTSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0388-1350</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicology</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a constitutively expressed mol. chaperone and plays an important role in the folding of client proteins with key regulatory roles in growth, survival, differentiation and metastasis.  Because inhibition of Hsp90 degrades multiple oncogenic client proteins, it is considered to be an attractive anticancer therapy, and clin. trials of several Hsp90 inhibitors have been carried out.  In the present study, two structurally distinct Hsp90 inhibitors, CH5164840 and CH5449302, were orally administered to beagle dogs to evaluate systemic toxicity.  CH5164840 induced symptoms that suggest visual disorder, and ophthalmol. observation and electroretinog. (ERG) revealed loss of pupillary light reflex and abnormal waveforms, resp.  Histopathol. examn. showed changes in the photoreceptor cell layer and the outer nuclear layer of retina.  On the other hand, while there were no clin. symptoms related to visual disorder, animals treated with CH5449302 showed similar abnormalities of ERG responses and histopathol. changes in the photoreceptor cell layer and the outer nuclear layer of retina.  The visual symptoms and abnormalities of ERG responses were noted at an earlier stage or lower dose than other toxicities in both compds.  Considering that two structurally distinct Hsp90 inhibitors induced a retinal toxicity in dogs after repeated administration, and that visual disorders were also reported in some clin. trials of Hsp90 inhibitors, it would seem highly likely that Hsp90 inhibition induces retinal toxicity.  Also, our study indicated that a detailed ocular examn. to evaluate the safety of Hsp90 inhibitors would be useful in both preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmECT70CVt7Vg90H21EOLACvtfcHk0lggseWMQd-H_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslynsbs%253D&md5=1b49f09d2e4de9184cb5dfd46104d84e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2131%2Fjts.39.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2131%252Fjts.39.59%26sid%3Dliteratum%253Aachs%26aulast%3DKanamaru%26aufirst%3DC.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DNagayasu%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DS.%26atitle%3DRetinal%2520Toxicity%2520Induced%2520by%2520Small-Molecule%2520Hsp90%2520Inhibitors%2520in%2520Beagle%2520Dogs%26jtitle%3DJ.%2520Toxicol.%2520Sci.%26date%3D2014%26volume%3D39%26spage%3D59%26epage%3D69%26doi%3D10.2131%2Fjts.39.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciarelli, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollapour, M.</span></span> <span> </span><span class="NLM_article-title">Targeting Hsp90 in Non-Cancerous Maladies</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2792</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.2174%2F1568026616666160413141753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27072697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2792-2804&author=M.+R.+Woodfordauthor=D.+M.+Dunnauthor=J.+G.+Ciciarelliauthor=K.+Beebeauthor=L.+Neckersauthor=M.+Mollapour&title=Targeting+Hsp90+in+Non-Cancerous+Maladies&doi=10.2174%2F1568026616666160413141753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Hsp90 in Non-Cancerous Maladies</span></div><div class="casAuthors">Woodford, Mark R.; Dunn, Diana M.; Ciciarelli, Joseph G.; Beebe, Kristin; Neckers, Len; Mollapour, Mehdi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2792-2804</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Heat shock protein-90 (Hsp90) is a mol. chaperone crit. to the folding, stability and activity of over 200 client proteins including many responsible for tumor initiation, progression and metastasis.  Hsp90 chaperone function is linked to its ATPase activity and Hsp90 inhibitors interfere with this activity, thereby making Hsp90 an attractive target for cancer therapy.  Also post-translational modification (PTM) and co-chaperone proteins modulate Hsp90 function, providing addnl. targets for secondary inhibition.  Recent reports have shown that pathogens utilize both their own Hsp90 and that of their host for the propagation of infectious elements.  In this review we will summarize our current knowledge of Hsp90 structure and function in both the pathogen and the host.  We will focus on the role of Hsp90 in viral and parasitic diseases and the potential beneficial application of Hsp90 inhibitors alone and in combination with disease-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIP4opz26nxLVg90H21EOLACvtfcHk0lggseWMQd-H_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsr7N&md5=e64b5c25cc96e0734fc319624a436033</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141753%26sid%3Dliteratum%253Aachs%26aulast%3DWoodford%26aufirst%3DM.%2BR.%26aulast%3DDunn%26aufirst%3DD.%2BM.%26aulast%3DCiciarelli%26aufirst%3DJ.%2BG.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DMollapour%26aufirst%3DM.%26atitle%3DTargeting%2520Hsp90%2520in%2520Non-Cancerous%2520Maladies%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2792%26epage%3D2804%26doi%3D10.2174%2F1568026616666160413141753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeier, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duellman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, S. C.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Inhibitors Block outgrowth of EBV-Infected Malignant Cells in vitro and in vivo Through an EBNA1-Dependent Mechanism</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3146</span>– <span class="NLM_lpage">3151</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910717107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.0910717107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=20133771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Clu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=3146-3151&author=X.+Sunauthor=E.+A.+Barlowauthor=S.+Maauthor=S.+R.+Hagemeierauthor=S.+J.+Duellmanauthor=R.+R.+Burgessauthor=J.+Tellamauthor=R.+Khannaauthor=S.+C.+Kenney&title=Hsp90+Inhibitors+Block+outgrowth+of+EBV-Infected+Malignant+Cells+in+vitro+and+in+vivo+Through+an+EBNA1-Dependent+Mechanism&doi=10.1073%2Fpnas.0910717107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1 dependent mechanism</span></div><div class="casAuthors">Sun, Xiaoping; Barlow, Elizabeth A.; Ma, Shidong; Hagemeier, Stacy R.; Duellman, Sarah J.; Burgess, Richard R.; Tellam, Judy; Khanna, Rajiv; Kenney, Shannon C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3146-3151, S3146/1-S3146/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">EBV causes infectious mononucleosis and is assocd. with certain malignancies.  EBV nuclear antigen 1 (EBNAI) mediates EBV genome replication, partition, and transcription, and is essential for persistence of the viral genome in host cells.  Here we demonstrate that Hsp90 inhibitors decrease EBNA1 expression and translation, and that this effect requires the Gly-Ala repeat domain of EBNA1.  Hsp90 inhibitors induce the death of established, EBV-transformed lymphoblastoid cell lines at doses nontoxic to normal cells, and this effect is substantially reversed when lymphoblastoid cell lines are stably infected with a retrovirus expressing a functional EBNA1 mutant lacking the Gly-Ala repeats.  Hsp90 inhibitors prevent EBV transformation of primary B cells, and strongly inhibit the growth of EBV-induced lymphoproliferative disease in SCID mice.  These results suggest that Hsp90 inhibitors may be particularly effective for treating EBV-induced diseases requiring the continued presence of the viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEeZuKjmP_1bVg90H21EOLACvtfcHk0lggseWMQd-H_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Clu7k%253D&md5=dafaee796e75d1e865daae2fb567d2ed</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910717107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910717107%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DBarlow%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DHagemeier%26aufirst%3DS.%2BR.%26aulast%3DDuellman%26aufirst%3DS.%2BJ.%26aulast%3DBurgess%26aufirst%3DR.%2BR.%26aulast%3DTellam%26aufirst%3DJ.%26aulast%3DKhanna%26aufirst%3DR.%26aulast%3DKenney%26aufirst%3DS.%2BC.%26atitle%3DHsp90%2520Inhibitors%2520Block%2520outgrowth%2520of%2520EBV-Infected%2520Malignant%2520Cells%2520in%2520vitro%2520and%2520in%2520vivo%2520Through%2520an%2520EBNA1-Dependent%2520Mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D3146%26epage%3D3151%26doi%3D10.1073%2Fpnas.0910717107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shatzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. I.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, an HSP90 Inhibitor, Kills Epstein-Barr Virus (EBV)-Infected B and T Cells and Reduces the Percentage of EBV-Infected Cells in the Blood</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1213823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1080%2F10428194.2016.1213823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27686857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOms7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=923-931&author=A.+Shatzerauthor=M.+A.+Aliauthor=M.+Chavezauthor=K.+Dowdellauthor=M.+J.+Leeauthor=Y.+Tomitaauthor=I.+El-Hariryauthor=J.+B.+Trepelauthor=D.+A.+Proiaauthor=J.+I.+Cohen&title=Ganetespib%2C+an+HSP90+Inhibitor%2C+Kills+Epstein-Barr+Virus+%28EBV%29-Infected+B+and+T+Cells+and+Reduces+the+Percentage+of+EBV-Infected+Cells+in+the+Blood&doi=10.1080%2F10428194.2016.1213823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood</span></div><div class="casAuthors">Shatzer, Amber; Ali, Mir A.; Chavez, Mayra; Dowdell, Kennichi; Lee, Min-Jung; Tomita, Yusuke; El-Hariry, Iman; Trepel, Jane B.; Proia, David A.; Cohen, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">923-931</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HSP90 inhibitors have been shown to kill Epstein-Barr virus (EBV)-infected cells by reducing the level of EBV EBNA-1 and/or LMP1.  We treated virus-infected cells with ganetespib, an HSP90 inhibitor currently being evaluated in multiple clin. trials for cancer and found that the drug killed EBV-pos. B and T cells and reduced the level of both EBV EBNA-1 and LMP1.  Treatment of cells with ganetespib also reduced the level of pAkt.  Ganetespib delayed the onset of EBV-pos. lymphomas and prolonged survival in SCID mice inoculated with one EBV-transformed B-cell line, but not another B-cell line.  The former cell line showed lower levels of EBNA-1 after treatment with ganetespib in vitro.  Treatment of a patient with T-cell chronic active EBV with ganetespib reduced the percentage of EBV-pos. cells in the peripheral blood.  These data indicate that HSP90 inhibitors may have a role in the therapy of certain EBV-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaYnthf9rXRbVg90H21EOLACvtfcHk0lgS95H77R2smw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOms7vL&md5=1a3d79c47523d0819a54eb7adbb8bedb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1213823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1213823%26sid%3Dliteratum%253Aachs%26aulast%3DShatzer%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DM.%2BA.%26aulast%3DChavez%26aufirst%3DM.%26aulast%3DDowdell%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26atitle%3DGanetespib%252C%2520an%2520HSP90%2520Inhibitor%252C%2520Kills%2520Epstein-Barr%2520Virus%2520%2528EBV%2529-Infected%2520B%2520and%2520T%2520Cells%2520and%2520Reduces%2520the%2520Percentage%2520of%2520EBV-Infected%2520Cells%2520in%2520the%2520Blood%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D923%26epage%3D931%26doi%3D10.1080%2F10428194.2016.1213823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srisutthisamphan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirakanwisal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramphan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tongluan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuadkitkan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. R.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Interacts with Multiple Dengue Virus 2 Proteins</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">4308</span> <span class="refDoi"> DOI: 10.1038/s41598-018-22639-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41598-018-22639-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29523827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsF2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=K.+Srisutthisamphanauthor=K.+Jirakanwisalauthor=S.+Ramphanauthor=N.+Tongluanauthor=A.+Kuadkitkanauthor=D.+R.+Smith&title=Hsp90+Interacts+with+Multiple+Dengue+Virus+2+Proteins&doi=10.1038%2Fs41598-018-22639-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 interacts with multiple dengue virus 2 proteins</span></div><div class="casAuthors">Srisutthisamphan Kanjana; Jirakanwisal Krit; Ramphan Suwipa; Tongluan Natthida; Kuadkitkan Atichat; Smith Duncan R</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Infections with the mosquito-borne dengue virus (DENV) remain a significant public health challenge.  In the absence of a commercial therapeutic to treat DENV infection, a greater understanding of the processes of cellular replication is required.  The abundant cellular chaperone protein heat shock protein 90 (Hsp90) has been shown to play a proviral role in the replication cycle of several viruses, predominantly through the stabilization of specific viral proteins.  To investigate any potential role of Hsp90 in DENV infection the interaction between Hsp90 and DENV proteins was determined through co-immunoprecipitation experiments.  Six DENV proteins namely envelope (E) and nonstructural (NS) proteins NS1, NS2B, NS3, NS4B and NS5 were shown to interact with Hsp90, and four of these proteins (E, NS1, NS3 and NS5) were shown to colocalize to a variable extent with Hsp90.  Despite the extensive interactions between Hsp90 and DENV proteins, inhibition of the activity of Hsp90 had a relatively minor effect on DENV replication, with inhibition of Hsp90 resulting in a decrease of cellular E protein (but not nonstructural proteins) coupled with an increase of E protein in the medium and an increased virus titer.  Collectively these results indicate that Hsp90 has a slight anti-viral effect in DENV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAACZdsi8QicScOqQTSkOffW6udTcc2eZyN47t5HCKurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsF2ltw%253D%253D&md5=d45e911734de981401f44ce9edcaa8ab</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-22639-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-22639-5%26sid%3Dliteratum%253Aachs%26aulast%3DSrisutthisamphan%26aufirst%3DK.%26aulast%3DJirakanwisal%26aufirst%3DK.%26aulast%3DRamphan%26aufirst%3DS.%26aulast%3DTongluan%26aufirst%3DN.%26aulast%3DKuadkitkan%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BR.%26atitle%3DHsp90%2520Interacts%2520with%2520Multiple%2520Dengue%2520Virus%25202%2520Proteins%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-22639-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann-Stroissnigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stripay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorronsoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchkonia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedernhofer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, P. D.</span></span> <span> </span><span class="NLM_article-title">Identification of HSP90 Inhibitors as a Novel Class of Senolytics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">422</span> <span class="refDoi"> DOI: 10.1038/s41467-017-00314-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41467-017-00314-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=28871086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1cbks1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=H.+Fuhrmann-Stroissniggauthor=Y.+Y.+Lingauthor=J.+Zhaoauthor=S.+J.+McGowanauthor=Y.+Zhuauthor=R.+W.+Brooksauthor=D.+Grassiauthor=S.+Q.+Greggauthor=J.+L.+Stripayauthor=A.+Dorronsoroauthor=L.+Corboauthor=P.+Tangauthor=C.+Bukataauthor=N.+Ringauthor=M.+Giaccaauthor=X.+Liauthor=T.+Tchkoniaauthor=J.+L.+Kirklandauthor=L.+J.+Niedernhoferauthor=P.+D.+Robbins&title=Identification+of+HSP90+Inhibitors+as+a+Novel+Class+of+Senolytics&doi=10.1038%2Fs41467-017-00314-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HSP90 inhibitors as a novel class of senolytics</span></div><div class="casAuthors">Fuhrmann-Stroissnigg Heike; Ling Yuan Yuan; Zhao Jing; McGowan Sara J; Brooks Robert W; Grassi Diego; Dorronsoro Akaitz; Corbo Lana; Tang Priscilla; Bukata Christina; Li Xuesen; Niedernhofer Laura J; Robbins Paul D; Zhu Yi; Tchkonia Tamara; Kirkland James L; Gregg Siobhan Q; Stripay Jennifer L; Ring Nadja; Giacca Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">422</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging is the main risk factor for many chronic degenerative diseases and cancer.  Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases.  Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging.  To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells.  We used primary Ercc1 (-/-) murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen.  This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells.  Treatment of Ercc1 (-/α) mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16(INK4a) expression.  These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.The accumulation of senescent cells is thought to contribute to the age-associated decline in tissue function.  Here, the authors identify HSP90 inhibitors as a new class of senolytic compounds in an in vitro screening and show that administration of a HSP90 inhibitor reduces age-related symptoms in progeroid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvWBwJCmQEN1UIs6wFK5xJfW6udTcc2ebKASYKbcdGz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbks1Cisg%253D%253D&md5=214359d8400f36e2ceccee3b0fed7dbf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00314-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00314-z%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann-Stroissnigg%26aufirst%3DH.%26aulast%3DLing%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMcGowan%26aufirst%3DS.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrooks%26aufirst%3DR.%2BW.%26aulast%3DGrassi%26aufirst%3DD.%26aulast%3DGregg%26aufirst%3DS.%2BQ.%26aulast%3DStripay%26aufirst%3DJ.%2BL.%26aulast%3DDorronsoro%26aufirst%3DA.%26aulast%3DCorbo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DP.%26aulast%3DBukata%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DN.%26aulast%3DGiacca%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTchkonia%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DJ.%2BL.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26atitle%3DIdentification%2520of%2520HSP90%2520Inhibitors%2520as%2520a%2520Novel%2520Class%2520of%2520Senolytics%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-00314-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishinevsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpaugh, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolaender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattahi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishima, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, L.</span></span> <span> </span><span class="NLM_article-title">HSP90-Incorporating Chaperome Networks as Biosensor for Disease-Related Pathways in Patient-Specific Midbrain Dopamine Neurons</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">4345</span> <span class="refDoi"> DOI: 10.1038/s41467-018-06486-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41467-018-06486-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=30341316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlCnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=S.+Kishinevskyauthor=T.+Wangauthor=A.+Rodinaauthor=S.+Y.+Chungauthor=C.+Xuauthor=J.+Philipauthor=T.+Taldoneauthor=S.+Joshiauthor=M.+L.+Alpaughauthor=A.+Bolaenderauthor=S.+Gutbierauthor=D.+Sandhuauthor=F.+Fattahiauthor=B.+Zimmerauthor=S.+K.+Shahauthor=E.+Changauthor=C.+Indaauthor=J.+Korenauthor=N.+G.+Sauratauthor=M.+Leistauthor=S.+S.+Grossauthor=V.+E.+Seshanauthor=C.+Kleinauthor=M.+J.+Tomishimaauthor=H.+Erdjument-Bromageauthor=T.+A.+Neubertauthor=R.+C.+Henricksonauthor=G.+Chiosisauthor=L.+Studer&title=HSP90-Incorporating+Chaperome+Networks+as+Biosensor+for+Disease-Related+Pathways+in+Patient-Specific+Midbrain+Dopamine+Neurons&doi=10.1038%2Fs41467-018-06486-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons</span></div><div class="casAuthors">Kishinevsky Sarah; Chung Sun Young; Fattahi Faranak; Zimmer Bastian; Saurat Nathalie G; Tomishima Mark J; Studer Lorenz; Kishinevsky Sarah; Chung Sun Young; Fattahi Faranak; Zimmer Bastian; Saurat Nathalie G; Tomishima Mark J; Studer Lorenz; Kishinevsky Sarah; Wang Tai; Rodina Anna; Xu Chao; Taldone Tony; Joshi Suhasini; Alpaugh Mary L; Bolaender Alexander; Shah Smit K; Inda Carmen; Koren John 3rd; Chiosis Gabriela; Kishinevsky Sarah; Philip John; Chang Elizabeth; Henrickson Ronald C; Alpaugh Mary L; Gutbier Simon; Leist Marcel; Sandhu Davinder; Gross Steven S; Inda Carmen; Koren John 3rd; Seshan Venkatraman E; Klein Christine; Tomishima Mark J; Erdjument-Bromage Hediye; Neubert Thomas A; Erdjument-Bromage Hediye; Neubert Thomas A; Chiosis Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4345</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Environmental and genetic risk factors contribute to Parkinson's Disease (PD) pathogenesis and the associated midbrain dopamine (mDA) neuron loss.  Here, we identify early PD pathogenic events by developing methodology that utilizes recent innovations in human pluripotent stem cells (hPSC) and chemical sensors of HSP90-incorporating chaperome networks.  We show that events triggered by PD-related genetic or toxic stimuli alter the neuronal proteome, thereby altering the stress-specific chaperome networks, which produce changes detected by chemical sensors.  Through this method we identify STAT3 and NF-κB signaling activation as examples of genetic stress, and phospho-tyrosine hydroxylase (TH) activation as an example of toxic stress-induced pathways in PD neurons.  Importantly, pharmacological inhibition of the stress chaperome network reversed abnormal phospho-STAT3 signaling and phospho-TH-related dopamine levels and rescued PD neuron viability.  The use of chemical sensors of chaperome networks on hPSC-derived lineages may present a general strategy to identify molecular events associated with neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFdxVcVE1DUYIRAdBLKY41fW6udTcc2ebKASYKbcdGz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlCnsw%253D%253D&md5=aec154a5d7acfa354296a29de4d166b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06486-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06486-6%26sid%3Dliteratum%253Aachs%26aulast%3DKishinevsky%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DS.%2BY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DAlpaugh%26aufirst%3DM.%2BL.%26aulast%3DBolaender%26aufirst%3DA.%26aulast%3DGutbier%26aufirst%3DS.%26aulast%3DSandhu%26aufirst%3DD.%26aulast%3DFattahi%26aufirst%3DF.%26aulast%3DZimmer%26aufirst%3DB.%26aulast%3DShah%26aufirst%3DS.%2BK.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DInda%26aufirst%3DC.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DSaurat%26aufirst%3DN.%2BG.%26aulast%3DLeist%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DSeshan%26aufirst%3DV.%2BE.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DTomishima%26aufirst%3DM.%2BJ.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DHenrickson%26aufirst%3DR.%2BC.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DStuder%26aufirst%3DL.%26atitle%3DHSP90-Incorporating%2520Chaperome%2520Networks%2520as%2520Biosensor%2520for%2520Disease-Related%2520Pathways%2520in%2520Patient-Specific%2520Midbrain%2520Dopamine%2520Neurons%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-018-06486-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Heat Shock Protein HSP90-pp60v-src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+Heat+Shock+Protein+HSP90-pp60v-src+Heteroprotein+Complex+Formation+by+Benzoquinone+Ansamycins%3A+Essential+Role+for+Stress+Proteins+in+Oncogenic+Transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0lhfV-WNXeWOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520Heat%2520Shock%2520Protein%2520HSP90-pp60v-src%2520Heteroprotein%2520Complex%2520Formation%2520by%2520Benzoquinone%2520Ansamycins%253A%2520Essential%2520Role%2520for%2520Stress%2520Proteins%2520in%2520Oncogenic%2520Transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">The Benzoquinone Ansamycin 17-Allylamino-17-demethoxygeldanamycin Binds to HSP90 and Shares Important Biologic Activities with Geldanamycin</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1007/s002800050817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1007%2Fs002800050817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=9744771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=273-279&author=T.+W.+Schulteauthor=L.+M.+Neckers&title=The+Benzoquinone+Ansamycin+17-Allylamino-17-demethoxygeldanamycin+Binds+to+HSP90+and+Shares+Important+Biologic+Activities+with+Geldanamycin&doi=10.1007%2Fs002800050817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</span></div><div class="casAuthors">Schulte, Theodor W.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Binding of 17-allylamino-17-demethoxygeldanamycin (17-AG) to the heat-shock protein HSP90 was studied in vitro using a geldanamycin (GA)-affinity beads competition assay.  The drug-induced destabilization was studied of p185erbB2, Raf-1, and mutant p53 in SKBR3 breast cancer cells by Western blotting.  The antiproliferative activities of 17-AG and GA were compared using the MTT assay.  The 17-AG bound specifically to HSP90 in a similar manner as GA itself.  It also led to degrdn. of the receptor Tyr kinase p185erbB2, the Ser/Thr kinase Raf-1, and mutant p53.  GA and 17-AG displayed comparable antiproliferative effects in SKBR3 and MCF7 cells.  Even though HSP90 binding with 17-AG was weaker than by GA, 17-AG and GA caused biol. effects in tumor cells at similar doses.  Since 17-AG had a better toxicity profile than GA, it was suggested as benzoquinone ansamycin candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouj3pMDUB7kLVg90H21EOLACvtfcHk0livQnH0BW3sjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Wlt7Y%253D&md5=3d6ac0592b10d66b391f824272523de2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs002800050817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050817%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DThe%2520Benzoquinone%2520Ansamycin%252017-Allylamino-17-demethoxygeldanamycin%2520Binds%2520to%2520HSP90%2520and%2520Shares%2520Important%2520Biologic%2520Activities%2520with%2520Geldanamycin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1998%26volume%3D42%26spage%3D273%26epage%3D279%26doi%3D10.1007%2Fs002800050817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher-Nielson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thillainathan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin: an Orally Bioavailable Heat Shock Protein 90 Modulator</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4813</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-03-0795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1078-0432.CCR-03-0795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=15269157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4813-4821&author=G.+Kaurauthor=D.+Belottiauthor=A.+M.+Burgerauthor=K.+Fisher-Nielsonauthor=P.+Borsottiauthor=E.+Riccardiauthor=J.+Thillainathanauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=R.+Giavazzi&title=Antiangiogenic+Properties+of+17-%28Dimethylaminoethylamino%29-17-demethoxygeldanamycin%3A+an+Orally+Bioavailable+Heat+Shock+Protein+90+Modulator&doi=10.1158%2F1078-0432.CCR-03-0795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator</span></div><div class="casAuthors">Kaur, Gurmeet; Belotti, Dorina; Burger, Angelika M.; Fisher-Nielson, Kirsten; Borsotti, Patrizia; Riccardi, Elena; Thillainathan, Jagada; Hollingshead, Melinda; Sausville, Edward A.; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4813-4821</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; NSC707545), a water-sol. benzoquinone ansamycin.  The activity of 17-DMAG, in vivo, was evaluated for inhibition of fibroblast growth factor (FGF)-2-induced angiogenesis in s.c. implanted Matrigel in mice.  In vitro, the activity of 17-DMAG on endothelial cells (human umbilical vein endothelial cells; HUVEC) was tested in FGF-2; and vascular endothelial growth factor (VEGF)-induced proliferation and apoptosis, motility, and extracellular matrix invasion; and on the alignment of capillary like structures in Matrigel.  The protein level of heat shock protein (Hsp)90 and client proteins was examd. by Western blot in FGF-2 and VEGF-stimulated HUVEC.  Daily oral administration of 17-DMAG affected the angiogenic response in Matrigel in a dose-dependent manner.  The Hb content in the Matrigel implants was significantly inhibited, and the histol. anal. confirmed a decrease of CD31+ endothelial cells and of structures organized in cord and erythrocyte-contg. vessels.  In vitro, the compd. inhibited dose-dependently the migration and the extracellular matrix-invasiveness of HUVEC and their capacity to form capillary like structures in Matrigel. 17-DMAG treatment also inhibited FGF-2 and VEGF-induced HUVEC proliferation and resulted in apoptosis.  Accordingly, the expression of Hsp90 direct client proteins (pAkt and c-Raf-1) or their downstream substrates including pERK was also affected. 17-DMAG consistently increased the expression of Hsp70.  Throughout the study similar results were obtained with 17-allylamino-17-demethoxygeldanamycin (17-AAG; NSC330507), the analog compd. currently undergoing clin. trials.  We show that the Hsp90 targeting agents 17-DMAG and 17-AAG inhibit angiogenesis.  The strong effects on endothelial cell functions, in vitro, indicate that the antiangiogenic activity of 17-DMAG/17-AAG could also be due to a direct effect on endothelial cells.  The oral bioavailability of 17-DMAG might be of advantage in investigating the potential of this compd. in clin. trials with antiangiogenic as well as antiproliferative endpoints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbGsLTxbCrQ7Vg90H21EOLACvtfcHk0livQnH0BW3sjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegs7s%253D&md5=e78331697485d2c1948adec2d4f124e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-03-0795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-03-0795%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DBelotti%26aufirst%3DD.%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DFisher-Nielson%26aufirst%3DK.%26aulast%3DBorsotti%26aufirst%3DP.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DThillainathan%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DAntiangiogenic%2520Properties%2520of%252017-%2528Dimethylaminoethylamino%2529-17-demethoxygeldanamycin%253A%2520an%2520Orally%2520Bioavailable%2520Heat%2520Shock%2520Protein%252090%2520Modulator%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4813%26epage%3D4821%26doi%3D10.1158%2F1078-0432.CCR-03-0795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4606</span>– <span class="NLM_lpage">4615</span>, <span class="refDoi"> DOI: 10.1021/jm0603116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4606-4615&author=J.+Geauthor=E.+Normantauthor=J.+R.+Porterauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=Y.+Gaoauthor=A.+T.+Georgesauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+Pattersonauthor=J.+R.+Sydorauthor=T.+T.+Tibbittsauthor=J.+K.+Tongauthor=J.+Adamsauthor=V.+J.+Palombella&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Hydroquinone+Derivatives+of+17-Amino-17-demethoxygeldanamycin+as+Potent%2C+Water-Soluble+Inhibitors+of+Hsp90&doi=10.1021%2Fjm0603116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90</span></div><div class="casAuthors">Ge, Jie; Normant, Emmanuel; Porter, James R.; Ali, Janid A.; Dembski, Marlene S.; Gao, Yun; Georges, Asimina T.; Grenier, Louis; Pak, Roger H.; Patterson, Jon; Sydor, Jens R.; Tibbitts, Thomas T.; Tong, Jeffrey K.; Adams, Julian; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4606-4615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clin. trials for the treatment of cancer.  However, 17-AAG faces challenging formulation issues due to its poor soly.  Here we report the synthesis and evaluation of a highly sol. hydroquinone hydrochloride deriv. of 17-AAG, I (IPI-504), and several of the physiol. metabolites.  These compds. show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homolog, the 94 kDa glucose regulated protein (Grp94).  Furthermore, the compds. inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition.  There is a clear correlation between the measured binding affinity of the compds. and their cellular activities.  Upon the basis of its potent activity against Hsp90 and a significant improvement in soly., I is currently under evaluation in Phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9IjX75MjbULVg90H21EOLACvtfcHk0livQnH0BW3sjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVelurw%253D&md5=892e372e121f75465edc6f1251e55dc6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0603116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGeorges%26aufirst%3DA.%2BT.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DTibbitts%26aufirst%3DT.%2BT.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Hydroquinone%2520Derivatives%2520of%252017-Amino-17-demethoxygeldanamycin%2520as%2520Potent%252C%2520Water-Soluble%2520Inhibitors%2520of%2520Hsp90%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4606%26epage%3D4615%26doi%3D10.1021%2Fjm0603116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.+M.+Cheungauthor=I.+Collinsauthor=N.+G.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+Chaperone+Inhibitors%3A+Potential+Therapeutic+Agents+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lgHwA4ikXD31A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520Chaperone%2520Inhibitors%253A%2520Potential%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The Novel HSP90 Inhibitor STA-9090 Exhibits Activity against Kit-Dependent and -Independent Malignant Mast Cell Tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&author=T.+Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+Novel+HSP90+Inhibitor+STA-9090+Exhibits+Activity+against+Kit-Dependent+and+-Independent+Malignant+Mast+Cell+Tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0lgHwA4ikXD31A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520Novel%2520HSP90%2520Inhibitor%2520STA-9090%2520Exhibits%2520Activity%2520against%2520Kit-Dependent%2520and%2520-Independent%2520Malignant%2520Mast%2520Cell%2520Tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois Oindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-Dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-dihydrois+Oindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+Novel+Inhibitor+of+the+Molecular+Chaperone+Hsp90+by+Fragment+Based+Drug+Design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0lhS0UVTLlFCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-Dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-dihydrois%2520Oindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520the%2520Molecular%2520Chaperone%2520Hsp90%2520by%2520Fragment%2520Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed High-affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors that Exhibit Potent Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+Designed+High-affinity+2-Amino-6-halopurine+Heat+Shock+Protein+90+Inhibitors+that+Exhibit+Potent+Antitumor+Activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lhS0UVTLlFCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520Designed%2520High-affinity%25202-Amino-6-halopurine%2520Heat%2520Shock%2520Protein%252090%2520Inhibitors%2520that%2520Exhibit%2520Potent%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span> <span> </span><span class="NLM_article-title">A phase 1, Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1078-0432.CCR-13-1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=24097863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=445-455&author=M.+W.+Saifauthor=C.+Takimotoauthor=M.+Mitaauthor=U.+Banerjiauthor=N.+Lamannaauthor=J.+Castroauthor=S.+O%E2%80%99Brienauthor=C.+Stogardauthor=D.+Von+Hoff&title=A+phase+1%2C+Dose-escalation%2C+Pharmacokinetic+and+Pharmacodynamic+Study+of+BIIB021+Administered+Orally+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-13-1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Saif, Muhammad Wasif; Takimoto, Chris; Mita, Monica; Banerji, Udai; Lamanna, Nicole; Castro, Januario; O'Brien, Susan; Stogard, Christopher; Von Hoff, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-455</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin-based HSP90 inhibitor that showed activity in preclin. models at low nanomolar concns.  We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors.  Exptl. Design: Sixty patients received BIIB021 capsules orally on days 1, 4, 8, 11, 15, and 18 of each course in schedule 1, and on days 1, 4, 8, 11, 15, 18, 22, and 25 of each course in schedule 2.  The treatment schedules were repeated every 28 days.  In addn. to detg. the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)].  Results: The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 wk out of each 4-wk course.  The MTD for continuous dosing regimen was established at 600 mg twice weekly.  Gastrointestinal (nausea, vomiting), hot flashes, and neurol. (dizziness) events characterize the safety profile of BIIB021 dosed twice weekly, with events mostly mild or moderate.  Plasma exposure to BIIB021 was dose-dependent.  Cmax occurred at approx. 90 min and t1/2 was approx. 1 h across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.  The biol. activity of BIIB021 was demonstrated in serum, PBMCs, and tumor tissue.  Hsp70 levels were increased (>150% from baseline) and serum HER2-ECD was significantly decreased (>15% inhibition from baseline).  Conclusions: BIIB021 twice weekly, given with or without the 1 of 4-wk rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active.  Clin Cancer Res; 20(2); 445-55. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkorAuPfyrLVg90H21EOLACvtfcHk0lhS0UVTLlFCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7Y%253D&md5=48266b9da5e440eda185af9d42e9739b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1257%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DTakimoto%26aufirst%3DC.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DStogard%26aufirst%3DC.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DA%2520phase%25201%252C%2520Dose-escalation%252C%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520BIIB021%2520Administered%2520Orally%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D445%26epage%3D455%26doi%3D10.1158%2F1078-0432.CCR-13-1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. S.</span></span> <span> </span><span class="NLM_article-title">Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">59</span> <span class="refDoi"> DOI: 10.1208/s12248-018-0216-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1208%2Fs12248-018-0216-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29633051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1MjgsVOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&author=Y.+Bianauthor=X.+S.+Xie&title=Computational+Fragment-Based+Drug+Design%3A+Current+Trends%2C+Strategies%2C+and+Applications&doi=10.1208%2Fs12248-018-0216-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications</span></div><div class="casAuthors">Bian Yuemin; Xie Xiang-Qun Sean; Bian Yuemin; Xie Xiang-Qun Sean; Bian Yuemin; Xie Xiang-Qun Sean; Xie Xiang-Qun Sean; Xie Xiang-Qun Sean</div><div class="citationInfo"><span class="NLM_cas:title">The AAPS journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fragment-based drug design (FBDD) has become an effective methodology for drug development for decades.  Successful applications of this strategy brought both opportunities and challenges to the field of Pharmaceutical Science.  Recent progress in the computational fragment-based drug design provide an additional approach for future research in a time- and labor-efficient manner.  Combining multiple in silico methodologies, computational FBDD possesses flexibilities on fragment library selection, protein model generation, and fragments/compounds docking mode prediction.  These characteristics provide computational FBDD superiority in designing novel and potential compounds for a certain target.  The purpose of this review is to discuss the latest advances, ranging from commonly used strategies to novel concepts and technologies in computational fragment-based drug design.  Particularly, in this review, specifications and advantages are compared between experimental and computational FBDD, and additionally, limitations and future prospective are discussed and emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVNCyUwVvezS86Js-BCLiifW6udTcc2eYJWSYq4DX3Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjgsVOrtg%253D%253D&md5=baf72e9387aacf16ee225570a0d5fdfd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1208%2Fs12248-018-0216-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-018-0216-7%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%2BS.%26atitle%3DComputational%2520Fragment-Based%2520Drug%2520Design%253A%2520Current%2520Trends%252C%2520Strategies%252C%2520and%2520Applications%26jtitle%3DAAPS%2520J.%26date%3D2018%26volume%3D20%26doi%3D10.1208%2Fs12248-018-0216-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descoteaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1386</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1002%2Fcmdc.201800161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=29722149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVelsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1377-1386&author=Y.+Ayotteauthor=F.+Bilodeauauthor=A.+Descoteauxauthor=S.+R.+LaPlante&title=Fragment-Based+Phenotypic+Lead+Discovery%3A+Cell-Based+Assay+to+Target+Leishmaniasis&doi=10.1002%2Fcmdc.201800161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis</span></div><div class="casAuthors">Ayotte, Yann; Bilodeau, Francois; Descoteaux, Albert; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1377-1386</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A rapid and practical approach for the discovery of new chem. matter for targeting pathogens and diseases is described.  Fragment-based phenotypic lead discovery (FPLD) combines aspects of traditional fragment-based lead discovery (FBLD), which involves the screening of small-mol. fragment libraries to target specific proteins, with phenotypic lead discovery (PLD), which typically involves the screening of drug-like compds. in cell-based assays.  To enable FPLD, a diverse library of fragments was first designed, assembled, and curated.  This library of sol., low-mol.-wt. compds. was then pooled to expedite screening.  Axenic cultures of Leishmania promastigotes were screened, and single hits were then tested for leishmanicidal activity against intracellular amastigote forms in infected murine bone-marrow-derived macrophages without evidence of toxicity toward mammalian cells.  These studies demonstrate that FPLD can be a rapid and effective means to discover hits that can serve as leads for further medicinal chem. purposes or as tool compds. for identifying known or novel targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC85ixZC9T9bVg90H21EOLACvtfcHk0lgFTy9YL2PxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVelsrjF&md5=6b732097feb3a6f81f0c4d6309fbae63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800161%26sid%3Dliteratum%253Aachs%26aulast%3DAyotte%26aufirst%3DY.%26aulast%3DBilodeau%26aufirst%3DF.%26aulast%3DDescoteaux%26aufirst%3DA.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DFragment-Based%2520Phenotypic%2520Lead%2520Discovery%253A%2520Cell-Based%2520Assay%2520to%2520Target%2520Leishmaniasis%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1377%26epage%3D1386%26doi%3D10.1002%2Fcmdc.201800161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jencks, W. P.</span></span> <span> </span><span class="NLM_article-title">On the Attribution and Additivity of Binding Energies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">4046</span>– <span class="NLM_lpage">4050</span>, <span class="refDoi"> DOI: 10.1073/pnas.78.7.4046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.78.7.4046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=16593049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADyaL3MXlvVamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1981&pages=4046-4050&author=W.+P.+Jencks&title=On+the+Attribution+and+Additivity+of+Binding+Energies&doi=10.1073%2Fpnas.78.7.4046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">On the attribution and additivity of binding energies</span></div><div class="casAuthors">Jencks, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4046-50</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">It can be useful to describe the Gibbs free energy changes for the binding to a protein of a mol., A-B, and of its component parts, A and B, in terms of the intrinsic binding energies of A and B, ΔGiA and ΔGiB, and a connection Gibbs energy, ΔGs, that is derived largely from changes in translational and rotational entropy.  The relation between ΔGsand ΔGiA and ΔGiB is discussed.  This empirical approach avoids the difficult of interpreting obsd. ΔH and TΔS values for aq. solns.  The ΔGi and ΔGsterms can be large for binding to enzymes and other proteins.  The use and interpretation of these binding energies are discussed, esp. with respect to ATP interaction with myosin ATPase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2X3Thp5VESLVg90H21EOLACvtfcHk0lgFTy9YL2PxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlvVamtbo%253D&md5=1cdbbb8b6e3f9d3ff0ba2c662c772375</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.78.7.4046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.78.7.4046%26sid%3Dliteratum%253Aachs%26aulast%3DJencks%26aufirst%3DW.%2BP.%26atitle%3DOn%2520the%2520Attribution%2520and%2520Additivity%2520of%2520Binding%2520Energies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1981%26volume%3D78%26spage%3D4046%26epage%3D4050%26doi%3D10.1073%2Fpnas.78.7.4046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giacomo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koralek, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Cobimetinib Combined with Vemurafenib in Advanced BRAF(V600)-mutant Melanoma (coBRIM): Updated Efficacy Results from a Randomised, Double-blind, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2FS1470-2045%2816%2930122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27480103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1248-1260&author=P.+A.+Asciertoauthor=G.+A.+McArthurauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=A.+M.+Di+Giacomoauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=Y.+Yanauthor=M.+Wongchenkoauthor=I.+Changauthor=J.+J.+Hsuauthor=D.+O.+Koralekauthor=I.+Rooneyauthor=A.+Ribasauthor=J.+Larkin&title=Cobimetinib+Combined+with+Vemurafenib+in+Advanced+BRAF%28V600%29-mutant+Melanoma+%28coBRIM%29%3A+Updated+Efficacy+Results+from+a+Randomised%2C+Double-blind%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2816%2930122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Ascierto, Paolo A.; McArthur, Grant A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabrielle; Di Giacomo, Anna Maria; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Yan, Yibing; Wongchenko, Matthew; Chang, Ilsung; Hsu, Jessie J.; Koralek, Daniel O.; Rooney, Isabelle; Ribas, Antoni; Larkin, James</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1248-1260</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAFV600-mutant advanced melanoma, as previously reported in the coBRIM study.  In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.  In this double-blind, randomized, placebo-controlled, multicenter study, adult patients (aged ≥18 years) with histol. confirmed BRAFV600 mutation-pos. unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) using an interactive response system to receive cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) or placebo, in combination with oral vemurafenib (960 mg twice daily).  Progression-free and overall survival were primary and secondary endpoints, resp.; all analyses were done on the intention-to-treat population.  This study is registered with ClinicalTrials.gov, no. NCT01689519, and is ongoing but no longer recruiting participants.  Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248).  At a median follow-up of 14·2 mo (IQR 8·5-17·3), the updated investigator-assessed median progression-free survival was 12·3 mo (95% CI 9·5-13·4) for cobimetinib and vemurafenib vs. 7·2 mo (5·6-7·5) for placebo and vemurafenib (HR 0·58 [95% CI 0·46-0·72], p<0·0001).  The final anal. for overall survival occurred when 255 (52%) patients had died (Aug 28, 2015).  Median overall survival was 22·3 mo (95% CI 20·3-not estimable) for cobimetinib and vemurafenib vs. 17·4 mo (95% CI 15·0-19·8) for placebo and vemurafenib (HR 0·70, 95% CI 0·55-0·90; p=0·005).  The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were obsd. with longer follow-up.  The most common grade 3-4 adverse events occurring at a higher frequency in patients in the cobimetinib and vemurafenib group compared with the vemurafenib group were γ-glutamyl transferase increase (36 [15%] in the cobimetinib and vemurafenib group vs 25 [10%] in the placebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase (28 [11%] vs 15 [6%]).  Serious adverse events occurred in 92 patients (37%) in the cobimetinib and vemurafenib group and 69 patients (28%) in the vemurafenib group.  Pyrexia (six patients [2%]) and dehydration (five patients [2%]) were the most common serious adverse events reported in the cobimetinib and vemurafenib group.  A total of 259 patients have died: 117 (47%) in the cobimetinib and vemurafenib group and 142 (58%) in the vemurafenib group.  The primary cause of death was disease progression in most patients: 109 (93%) of 117 in the cobimetinib and vemurafenib group and 133 (94%) of 142 in the vemurafenib group.  These data confirm the clin. benefit of cobimetinib combined with vemurafenib and support the use of the combination as a std. first-line approach to improve survival in patients with advanced BRAFV600-mutant melanoma.F Hoffmann-La Roche-Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4OAKivAOwrVg90H21EOLACvtfcHk0ljL-XR05wqK8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsL%252FL&md5=e2823328573964158a9884043cf99acf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930122-X%26sid%3Dliteratum%253Aachs%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DDi%2BGiacomo%26aufirst%3DA.%2BM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWongchenko%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DHsu%26aufirst%3DJ.%2BJ.%26aulast%3DKoralek%26aufirst%3DD.%2BO.%26aulast%3DRooney%26aufirst%3DI.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DCobimetinib%2520Combined%2520with%2520Vemurafenib%2520in%2520Advanced%2520BRAF%2528V600%2529-mutant%2520Melanoma%2520%2528coBRIM%2529%253A%2520Updated%2520Efficacy%2520Results%2520from%2520a%2520Randomised%252C%2520Double-blind%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D1248%26epage%3D1260%26doi%3D10.1016%2FS1470-2045%2816%2930122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oltersdorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augeri, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckwerth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinges, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitten, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettesheim, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleksijew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petros, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1038/nature03579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fnature03579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=15902208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ogtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=677-681&author=T.+Oltersdorfauthor=S.+W.+Elmoreauthor=A.+R.+Shoemakerauthor=R.+C.+Armstrongauthor=D.+J.+Augeriauthor=B.+A.+Belliauthor=M.+Brunckoauthor=T.+L.+Deckwerthauthor=J.+Dingesauthor=P.+J.+Hajdukauthor=M.+K.+Josephauthor=S.+Kitadaauthor=S.+J.+Korsmeyerauthor=A.+R.+Kunzerauthor=A.+Letaiauthor=C.+Liauthor=M.+J.+Mittenauthor=D.+G.+Nettesheimauthor=S.+Ngauthor=P.+M.+Nimmerauthor=J.+M.+O%E2%80%99Connorauthor=A.+Oleksijewauthor=A.+M.+Petrosauthor=J.+C.+Reedauthor=W.+Shenauthor=S.+K.+Tahirauthor=C.+B.+Thompsonauthor=K.+J.+Tomaselliauthor=B.+Wangauthor=M.+D.+Wendtauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenberg&title=An+Inhibitor+of+Bcl-2+Family+Proteins+Induces+Regression+of+Solid+Tumours&doi=10.1038%2Fnature03579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of Bcl-2 family proteins induces regression of solid tumours</span></div><div class="casAuthors">Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R.; Armstrong, Robert C.; Augeri, David J.; Belli, Barbara A.; Bruncko, Milan; Deckwerth, Thomas L.; Dinges, Jurgen; Hajduk, Philip J.; Joseph, Mary K.; Kitada, Shinichi; Korsmeyer, Stanley J.; Kunzer, Aaron R.; Letai, Anthony; Li, Chi; Mitten, Michael J.; Nettesheim, David G.; Ng, Shi Chung; Nimmer, Paul M.; O'Connor, Jacqueline M.; Oleksijew, Anatol; Petros, Andrew M.; Reed, John C.; Shen, Wang; Tahir, Stephen K.; Thompson, Craig B.; Tomaselli, Kevin J.; Wang, Baole; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">7042</span>),
    <span class="NLM_cas:pages">677-681</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and contribute to tumor initiation, progression and resistance to therapy.  Bcl-XL expression correlates with chemo-resistance of tumor cell lines, and redns. in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival.  The development of inhibitors of these proteins as potential anticancer therapeutics has been previously explored, but obtaining potent small-mol. inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction.  Here, using NMR-based screening, parallel synthesis and structure-based design, the authors have discovered ABT-737, a small-mol. inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compds.  Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.  ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBt7_zVt8HrbVg90H21EOLACvtfcHk0ljL-XR05wqK8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ogtb0%253D&md5=4940d06838506f181b6310d3458a595f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature03579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03579%26sid%3Dliteratum%253Aachs%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DDeckwerth%26aufirst%3DT.%2BL.%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26aulast%3DKunzer%26aufirst%3DA.%2BR.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DNettesheim%26aufirst%3DD.%2BG.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BM.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26aulast%3DTomaselli%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26atitle%3DAn%2520Inhibitor%2520of%2520Bcl-2%2520Family%2520Proteins%2520Induces%2520Regression%2520of%2520Solid%2520Tumours%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D677%26epage%3D681%26doi%3D10.1038%2Fnature03579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Twenty Years on: the Impact of Fragments on Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fnrd.2016.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=27417849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=605-619&author=D.+A.+Erlansonauthor=S.+W.+Fesikauthor=R.+E.+Hubbardauthor=W.+Jahnkeauthor=H.+Jhoti&title=Twenty+Years+on%3A+the+Impact+of+Fragments+on+Drug+Discovery&doi=10.1038%2Fnrd.2016.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years on: the impact of fragments on drug discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Fesik, Stephen W.; Hubbard, Roderick E.; Jahnke, Wolfgang; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">605-619</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream.  More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials.  FBDD has been widely applied in both academia and industry, as evidenced by the large no. of papers from universities, non-profit research institutions, biotechnol. companies and pharmaceutical companies.  Moreover, FBDD draws on a diverse range of disciplines, from biochem. and biophysics to computational and medicinal chem.  As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future.  This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them.  It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrXQhFttydkrVg90H21EOLACvtfcHk0ljYR_pLFa7I4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE&md5=fc2bcf0da6b7b1083a5ff263057cfa80</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.109%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DTwenty%2520Years%2520on%253A%2520the%2520Impact%2520of%2520Fragments%2520on%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D605%26epage%3D619%26doi%3D10.1038%2Fnrd.2016.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A ‘Rule of Three’ for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2eZuVNcvE6T56bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span> <span> </span><span class="NLM_article-title">Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-Like Bioisosteric Groups</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1021/ci0255782</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0255782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Cmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=374-380&author=P.+Ertl&title=Cheminformatics+Analysis+of+Organic+Substituents%3A+Identification+of+the+Most+Common+Substituents%2C+Calculation+of+Substituent+Properties%2C+and+Automatic+Identification+of+Drug-Like+Bioisosteric+Groups&doi=10.1021%2Fci0255782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups</span></div><div class="casAuthors">Ertl, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-380</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A large set of more than 3 million mols. was processed to find all the org. substituents contained in the set and to identify the most common ones.  During the anal., 849 574 unique substituents were found.  Extrapolated to the no. of known org. mols., this result suggests that about 3.1 million substituents are known.  Based on these findings the size of virtual org. chem. space accessible using currently known synthetic methods is estd. to be between 1020 and 1024 mols.  The extd. substituents were characterized by calcd. electronic, hydrophobic, steric, and hydrogen bonding properties as well as by the drug-likeness index.  Various possible applications of such a large database of drug-like substituents characterized by calcd. properties are discussed and illustrated by ref. to a Web-based tool for automatic identification of bioisosteric groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqODLrwzH2t4LVg90H21EOLACvtfcHk0ljtBcwRHJ4dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Cmtbs%253D&md5=9debc7ddfbb1c57ff85b7ff55c44a7d0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci0255782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0255782%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DCheminformatics%2520Analysis%2520of%2520Organic%2520Substituents%253A%2520Identification%2520of%2520the%2520Most%2520Common%2520Substituents%252C%2520Calculation%2520of%2520Substituent%2520Properties%252C%2520and%2520Automatic%2520Identification%2520of%2520Drug-Like%2520Bioisosteric%2520Groups%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D374%26epage%3D380%26doi%3D10.1021%2Fci0255782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4990</span>– <span class="NLM_lpage">5003</span>, <span class="refDoi"> DOI: 10.1021/bi3005126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3005126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4990-5003&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=S.+A.+Hudsonauthor=C.+Abell&title=Fragment-Based+Approaches+in+Drug+Discovery+and+Chemical+Biology&doi=10.1021%2Fbi3005126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Hudson, Sean A.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4990-5003</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fragment-based approaches to finding novel small mols. that bind to proteins are now firmly established in drug discovery and chem. biol.  Initially developed primarily in a few centers in the biotech and pharma industry, this methodol. has now been adopted widely in both the pharmaceutical industry and academia.  After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes.  Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, β-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase.  The role of fragment-based approaches in an academic research environment is also examd. with an emphasis on neglected diseases such as tuberculosis.  The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2ry6mWC83bVg90H21EOLACvtfcHk0ljtBcwRHJ4dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D&md5=39a6f0f741e711fd572e24c95142f55d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi3005126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3005126%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DHudson%26aufirst%3DS.%2BA.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-Based%2520Approaches%2520in%2520Drug%2520Discovery%2520and%2520Chemical%2520Biology%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D4990%26epage%3D5003%26doi%3D10.1021%2Fbi3005126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregori-Puigjane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krojer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velupillai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz Torres, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span> <span> </span><span class="NLM_article-title">Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1580</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1580-1598&author=M.+Korczynskaauthor=D.+D.+Leauthor=N.+Youngerauthor=E.+Gregori-Puigjaneauthor=A.+Tumberauthor=T.+Krojerauthor=S.+Velupillaiauthor=C.+Gileadiauthor=R.+P.+Nowakauthor=E.+Iwasaauthor=S.+B.+Pollockauthor=I.+Ortiz+Torresauthor=U.+Oppermannauthor=B.+K.+Shoichetauthor=D.+G.+Fujimori&title=Docking+and+Linking+of+Fragments+To+Discover+Jumonji+Histone+Demethylase+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors</span></div><div class="casAuthors">Korczynska, Magdalena; Le, Daniel D.; Younger, Noah; Gregori-Puigjane, Elisabet; Tumber, Anthony; Krojer, Tobias; Velupillai, Srikannathasan; Gileadi, Carina; Nowak, Radoslaw P.; Iwasa, Eriko; Pollock, Samuel B.; Ortiz Torres, Idelisse; Oppermann, Udo; Shoichet, Brian K.; Fujimori, Danica Galonic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1580-1598</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of tool mols. that inhibit Jumonji demethylases allows for the investigation of cancer-assocd. transcription.  While scaffolds such as 2,4-pyridinedicarboxylic acid (2,4-PDCA) are potent inhibitors, they exhibit limited selectivity.  To discover new inhibitors for the KDM4 demethylases, enzymes overexpressed in several cancers, we docked a library of 600 000 fragments into the high-resoln. structure of KDM4A.  Among the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overlapping orientations.  Docking poses informed the design of covalently linked fragment compds., which were further derivatized.  This combined approach improved affinity by ∼3 log-orders to yield compd. 35 (Ki = 43 nM).  Several hybrid inhibitors were selective for KDM4C over the related enzymes FIH, KDM2A, and KDM6B while lacking selectivity against the KDM3 and KDM5 subfamilies.  Cocrystal structures corroborated the docking predictions.  This study extends the use of structure-based docking from fragment discovery to fragment linking optimization, yielding novel KDM4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0n7_U9JkllrVg90H21EOLACvtfcHk0ljtBcwRHJ4dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGjs7k%253D&md5=ee6bc4c9e355ab4ed5fe2a2e0b2dc3f2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01527%26sid%3Dliteratum%253Aachs%26aulast%3DKorczynska%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DYounger%26aufirst%3DN.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DKrojer%26aufirst%3DT.%26aulast%3DVelupillai%26aufirst%3DS.%26aulast%3DGileadi%26aufirst%3DC.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DIwasa%26aufirst%3DE.%26aulast%3DPollock%26aufirst%3DS.%2BB.%26aulast%3DOrtiz%2BTorres%26aufirst%3DI.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26atitle%3DDocking%2520and%2520Linking%2520of%2520Fragments%2520To%2520Discover%2520Jumonji%2520Histone%2520Demethylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1580%26epage%3D1598%26doi%3D10.1021%2Facs.jmedchem.5b01527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jehle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiana, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">Ligand Deconstruction: Why Some Fragment Binding Positions are Conserved and Others are Not</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E2585</span>– <span class="NLM_lpage">2594</span>, <span class="refDoi"> DOI: 10.1073/pnas.1501567112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1073%2Fpnas.1501567112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25918377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E2585-2594&author=D.+Kozakovauthor=D.+R.+Hallauthor=S.+Jehleauthor=L.+Luoauthor=S.+O.+Ochianaauthor=E.+V.+Jonesauthor=M.+Pollastriauthor=K.+N.+Allenauthor=A.+Whittyauthor=S.+Vajda&title=Ligand+Deconstruction%3A+Why+Some+Fragment+Binding+Positions+are+Conserved+and+Others+are+Not&doi=10.1073%2Fpnas.1501567112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand deconstruction: Why some fragment binding positions are conserved and others are not</span></div><div class="casAuthors">Kozakov, Dima; Hall, David R.; Jehle, Sefan; Luo, Lingqi; Ochiana, Stefan O.; Jones, Elizabeth V.; Pollastri, Michael; Allen, Karen N.; Whitty, Adrian; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">E2585-E2594</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) relies on the premise that the fragment binding mode will be conserved on subsequent expansion to a larger ligand.  However, no general condition has been established to explain when fragment binding modes will be conserved.  We show that a remarkably simple condition can be developed in terms of how fragments coincide with binding energy hot spots-regions of the protein where interactions with a ligand contribute substantial binding free energy-the locations of which can easily be detd. computationally.  Because a substantial fraction of the free energy of ligand binding comes from interacting with the residues in the energetically most important hot spot, a ligand moiety that sufficiently overlaps with this region will retain its location even when other parts of the ligand are removed.  This hypothesis is supported by eight case studies.  The condition helps identify whether a protein is suitable for FBDD, predicts the size of fragments required for screening, and dets. whether a fragment hit can be extended into a higher affinity ligand.  Our results show that ligand binding sites can usefully be thought of in terms of an anchor site, which is the top-ranked hot spot and dominates the free energy of binding, surrounded by a no. of weaker satellite sites that confer improved affinity and selectivity for a particular ligand and that it is the intrinsic binding potential of the protein surface that dets. whether it can serve as a robust binding site for a suitably optimized ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH6jbOut_iv7Vg90H21EOLACvtfcHk0ljKmys-jwUaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitrY%253D&md5=d56b18fb4e4befde24037b07e52d8b62</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501567112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501567112%26sid%3Dliteratum%253Aachs%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DJehle%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DJones%26aufirst%3DE.%2BV.%26aulast%3DPollastri%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DK.%2BN.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DLigand%2520Deconstruction%253A%2520Why%2520Some%2520Fragment%2520Binding%2520Positions%2520are%2520Conserved%2520and%2520Others%2520are%2520Not%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3DE2585%26epage%3D2594%26doi%3D10.1073%2Fpnas.1501567112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">A De Novo Substructure Generation Algorithm for Identifying the Privileged Chemical Fragments of Liver X Receptorbeta Agonists</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">11121</span> <span class="refDoi"> DOI: 10.1038/s41598-017-08848-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1038%2Fs41598-017-08848-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=28894088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmvFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=H.+Pengauthor=Z.+Liuauthor=X.+Yanauthor=J.+Renauthor=J.+Xu&title=A+De+Novo+Substructure+Generation+Algorithm+for+Identifying+the+Privileged+Chemical+Fragments+of+Liver+X+Receptorbeta+Agonists&doi=10.1038%2Fs41598-017-08848-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists</span></div><div class="casAuthors">Peng He; Liu Zhihong; Yan Xin; Ren Jian; Xu Jun</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Liver X receptorβ (LXRβ) is a promising therapeutic target for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases.  Druggable LXRβ agonists have been explored over the past decades.  However, the pocket of LXRβ ligand-binding domain (LBD) is too large to predict LXRβ agonists with novel scaffolds based on either receptor or agonist structures.  In this paper, we report a de novo algorithm which drives privileged LXRβ agonist fragments by starting with individual chemical bonds (de novo) from every molecule in a LXRβ agonist library, growing the bonds into substructures based on the agonist structures with isomorphic and homomorphic restrictions, and electing the privileged fragments from the substructures with a popularity threshold and background chemical and biological knowledge.  Using these privileged fragments as queries, we were able to figure out the rules to reconstruct LXRβ agonist molecules from the fragments.  The privileged fragments were validated by building regularized logistic regression (RLR) and supporting vector machine (SVM) models as descriptors to predict a LXRβ agonist activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2fjqYJFxP4EcLvDNbOD4DfW6udTcc2eb2PlMIxs_oFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmvFajug%253D%253D&md5=9454fcf78d2658673f0daf8a0befdf24</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-08848-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-08848-4%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DA%2520De%2520Novo%2520Substructure%2520Generation%2520Algorithm%2520for%2520Identifying%2520the%2520Privileged%2520Chemical%2520Fragments%2520of%2520Liver%2520X%2520Receptorbeta%2520Agonists%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-08848-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5885</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVekt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5885-5900&author=C.+Zhaoauthor=D.+Huangauthor=R.+Liauthor=Y.+Xuauthor=S.+Suauthor=Q.+Guauthor=J.+Xu&title=Identifying+Novel+Anti-Osteoporosis+Leads+with+a+Chemotype-Assembly+Approach&doi=10.1021%2Facs.jmedchem.9b00517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach</span></div><div class="casAuthors">Zhao, Chao; Huang, Dane; Li, Ruyue; Xu, Yida; Su, Shimin; Gu, Qiong; Xu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5885-5900</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we applied a chemotype-assembly approach for ligand-based drug discovery (LBDD) to discover novel anti-osteoporosis leads.  With this new approach, we identified 12 chemotypes and derived 18 major chemotype assembly rules from 245 known anti-osteoporosis compds.  Then, we selected 19 compds. from an inhouse compd. library using chemotype-assembly approach for anti-osteoporosis assays, which resulted in 13 hits.  Based on structural features in these 13 compds., we synthesized 50 possible anti-osteoporosis compds. from the anti-osteoporosis chemotypes by means of click chem. techniques and discovered a compd. (10a, IC50 = 2 nM) with nanomolar activity.  Compd. 10a was then proved to be an anti-osteoporosis lead since it can prevent bone loss in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodLGTK4nNTrVg90H21EOLACvtfcHk0ljKmys-jwUaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVekt77M&md5=b935f96d9194383d8e981f5a5731b368</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00517%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DIdentifying%2520Novel%2520Anti-Osteoporosis%2520Leads%2520with%2520a%2520Chemotype-Assembly%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5885%26epage%3D5900%26doi%3D10.1021%2Facs.jmedchem.9b00517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonsing-Carter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saadatzadeh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spragins, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprouse, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunter, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minto, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchal, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batuello, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanenberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Territo, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eischen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K. E.</span></span> <span> </span><span class="NLM_article-title">Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2850</span>– <span class="NLM_lpage">2863</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-15-0237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=26494859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2850-2863&author=E.+Tonsing-Carterauthor=B.+J.+Baileyauthor=M.+R.+Saadatzadehauthor=J.+Dingauthor=H.+Wangauthor=A.+L.+Sinnauthor=K.+M.+Petermanauthor=T.+K.+Spraginsauthor=J.+M.+Silverauthor=A.+A.+Sprouseauthor=T.+M.+Georgiadisauthor=T.+Z.+Gunterauthor=E.+C.+Longauthor=R.+E.+Mintoauthor=C.+C.+Marchalauthor=C.+N.+Batuelloauthor=A.+R.+Safaauthor=H.+Hanenbergauthor=P.+R.+Territoauthor=G.+E.+Sanduskyauthor=L.+D.+Mayoauthor=C.+M.+Eischenauthor=H.+E.+Shannonauthor=K.+E.+Pollok&title=Potentiation+of+Carboplatin-Mediated+DNA+Damage+by+the+Mdm2+Modulator+Nutlin-3a+in+a+Humanized+Orthotopic+Breast-to-Lung+Metastatic+Model&doi=10.1158%2F1535-7163.MCT-15-0237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model</span></div><div class="casAuthors">Tonsing-Carter, Eva; Bailey, Barbara J.; Saadatzadeh, M. Reza; Ding, Jixin; Wang, Haiyan; Sinn, Anthony L.; Peterman, Kacie M.; Spragins, Tiaishia K.; Silver, Jayne M.; Sprouse, Alyssa A.; Georgiadis, Taxiarchis M.; Gunter, T. Zachary; Long, Eric C.; Minto, Robert E.; Marchal, Christophe C.; Batuello, Christopher N.; Safa, Ahmad R.; Hanenberg, Helmut; Territo, Paul R.; Sandusky, George E.; Mayo, Lindsey D.; Eischen, Christine M.; Shannon, Harlan E.; Pollok, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2850-2863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) are typically resistant to treatment, and strategies that build upon frontline therapy are needed.  Targeting the murine double minute 2 (Mdm2) protein is an attractive approach, as Mdm2 levels are elevated in many therapy-refractive breast cancers.  The Mdm2 protein-protein interaction inhibitor Nutlin-3a blocks the binding of Mdm2 to key signaling mols. such as p53 and p73α and can result in activation of cell death signaling pathways.  In the present study, the therapeutic potential of carboplatin and Nutlin-3a to treat TNBC was investigated, as carboplatin is under evaluation in clin. trials for TNBC.  In mutant p53 TMD231 TNBC cells, carboplatin and Nutlin-3a led to increased Mdm2 and was strongly synergistic in promoting cell death in vitro.  Furthermore, sensitivity of TNBC cells to combination treatment was dependent on p73α.  Following combination treatment, γH2AX increased and Mdm2 localized to a larger degree to chromatin compared with single-agent treatment, consistent with previous observations that Mdm2 binds to the Mre11/Rad50/Nbs1 complex assocd. with DNA and inhibits the DNA damage response.  In vivo efficacy studies were conducted in the TMD231 orthotopic mammary fat pad model in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice.  Using an intermittent dosing schedule of combined carboplatin and Nutlin-3a, there was a significant redn. in primary tumor growth and lung metastases compared with vehicle and single-agent treatments.  In addn., there was minimal toxicity to the bone marrow and normal tissues.  These studies demonstrate that Mdm2 holds promise as a therapeutic target in combination with conventional therapy and may lead to new clin. therapies for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_pRwn_Ma__7Vg90H21EOLACvtfcHk0lgCTrXrveWORw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7vI&md5=aec5201362aff4b1b1f0c51999bde645</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0237%26sid%3Dliteratum%253Aachs%26aulast%3DTonsing-Carter%26aufirst%3DE.%26aulast%3DBailey%26aufirst%3DB.%2BJ.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSinn%26aufirst%3DA.%2BL.%26aulast%3DPeterman%26aufirst%3DK.%2BM.%26aulast%3DSpragins%26aufirst%3DT.%2BK.%26aulast%3DSilver%26aufirst%3DJ.%2BM.%26aulast%3DSprouse%26aufirst%3DA.%2BA.%26aulast%3DGeorgiadis%26aufirst%3DT.%2BM.%26aulast%3DGunter%26aufirst%3DT.%2BZ.%26aulast%3DLong%26aufirst%3DE.%2BC.%26aulast%3DMinto%26aufirst%3DR.%2BE.%26aulast%3DMarchal%26aufirst%3DC.%2BC.%26aulast%3DBatuello%26aufirst%3DC.%2BN.%26aulast%3DSafa%26aufirst%3DA.%2BR.%26aulast%3DHanenberg%26aufirst%3DH.%26aulast%3DTerrito%26aufirst%3DP.%2BR.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26aulast%3DMayo%26aufirst%3DL.%2BD.%26aulast%3DEischen%26aufirst%3DC.%2BM.%26aulast%3DShannon%26aufirst%3DH.%2BE.%26aulast%3DPollok%26aufirst%3DK.%2BE.%26atitle%3DPotentiation%2520of%2520Carboplatin-Mediated%2520DNA%2520Damage%2520by%2520the%2520Mdm2%2520Modulator%2520Nutlin-3a%2520in%2520a%2520Humanized%2520Orthotopic%2520Breast-to-Lung%2520Metastatic%2520Model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2850%26epage%3D2863%26doi%3D10.1158%2F1535-7163.MCT-15-0237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voloshin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alishekevitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machluf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apte, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaked, Y.</span></span> <span> </span><span class="NLM_article-title">Blocking IL1beta Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25887886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1385-1394&author=T.+Voloshinauthor=D.+Alishekevitzauthor=L.+Kanetiauthor=V.+Millerauthor=E.+Isakovauthor=I.+Kaplanovauthor=E.+Voronovauthor=E.+Fremderauthor=M.+Benharauthor=M.+Machlufauthor=R.+N.+Apteauthor=Y.+Shaked&title=Blocking+IL1beta+Pathway+Following+Paclitaxel+Chemotherapy+Slightly+Inhibits+Primary+Tumor+Growth+but+Promotes+Spontaneous+Metastasis&doi=10.1158%2F1535-7163.MCT-14-0969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis</span></div><div class="casAuthors">Voloshin, Tali; Alishekevitz, Dror; Kaneti, Limor; Miller, Valeria; Isakov, Elina; Kaplanov, Irena; Voronov, Elena; Fremder, Ella; Benhar, Moran; Machluf, Marcelle; Apte, Ron N.; Shaked, Yuval</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1385-1394</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired resistance to therapy is a major obstacle in clin. oncol., and little is known about the contributing mechanisms of the host response to therapy.  Here, we show that the proinflammatory cytokine IL1β is overexpressed in response to paclitaxel chemotherapy in macrophages, subsequently promoting the invasive properties of malignant cells.  In accordance, blocking IL1β, or its receptor, using either genetic or pharmacol. approach, results in slight retardation of primary tumor growth; however, it accelerates metastasis spread.  Tumors from mice treated with combined therapy of paclitaxel and the IL1 receptor antagonist anakinra exhibit increased no. of M2 macrophages and vessel leakiness when compared with paclitaxel monotherapy-treated mice, indicating a prometastatic role of M2 macrophages in the IL1β-deprived microenvironment.  Taken together, these findings demonstrate the dual effects of blocking the IL1 pathway on tumor growth.  Accordingly, treatments using "add-on" drugs to conventional therapy should be investigated in appropriate tumor models consisting of primary tumors and their metastases.  Mol Cancer Ther; 14(6); 1385-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn-_I15IspmbVg90H21EOLACvtfcHk0lgCTrXrveWORw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOnsLw%253D&md5=cbc7c4620b4cecd70ad73911b27ba76a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0969%26sid%3Dliteratum%253Aachs%26aulast%3DVoloshin%26aufirst%3DT.%26aulast%3DAlishekevitz%26aufirst%3DD.%26aulast%3DKaneti%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DIsakov%26aufirst%3DE.%26aulast%3DKaplanov%26aufirst%3DI.%26aulast%3DVoronov%26aufirst%3DE.%26aulast%3DFremder%26aufirst%3DE.%26aulast%3DBenhar%26aufirst%3DM.%26aulast%3DMachluf%26aufirst%3DM.%26aulast%3DApte%26aufirst%3DR.%2BN.%26aulast%3DShaked%26aufirst%3DY.%26atitle%3DBlocking%2520IL1beta%2520Pathway%2520Following%2520Paclitaxel%2520Chemotherapy%2520Slightly%2520Inhibits%2520Primary%2520Tumor%2520Growth%2520but%2520Promotes%2520Spontaneous%2520Metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1385%26epage%3D1394%26doi%3D10.1158%2F1535-7163.MCT-14-0969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrild, J. C.</span>; <span class="NLM_string-name">Lauritsen, A.</span>; <span class="NLM_string-name">Björkling, F.</span>; <span class="NLM_string-name">Vadlamudi, S. M.</span></span> <span> </span><span class="NLM_article-title">4-Substituted-6-isopropyl-benzene-1,3-diol Compounds and Their use</span>. <span class="NLM_patent">WO2009/066060A2</span>, May 28, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+C.+Norrild&author=A.+Lauritsen&author=F.+Bj%C3%B6rkling&author=S.+M.+Vadlamudi&title=4-Substituted-6-isopropyl-benzene-1%2C3-diol+Compounds+and+Their+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNorrild%26aufirst%3DJ.%2BC.%26atitle%3D4-Substituted-6-isopropyl-benzene-1%252C3-diol%2520Compounds%2520and%2520Their%2520use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 Alpha and Beta, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+Highly+Selective+Inhibitor+of+Heat+Shock+Protein+90+Alpha+and+Beta%2C+Demonstrates+Potent+Antitumor+Activity+and+Minimal+Ocular+Toxicity+in+Preclinical+Models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0lir-xEWA4Wmow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520Highly%2520Selective%2520Inhibitor%2520of%2520Heat%2520Shock%2520Protein%252090%2520Alpha%2520and%2520Beta%252C%2520Demonstrates%2520Potent%2520Antitumor%2520Activity%2520and%2520Minimal%2520Ocular%2520Toxicity%2520in%2520Preclinical%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of Celastrol to Inhibit Hsp90 and dc37 Interaction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35381</span>– <span class="NLM_lpage">35389</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.051532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=10.1074%2Fjbc.M109.051532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=19858214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35381-35389&author=T.+Zhangauthor=Y.+Liauthor=Y.+Yuauthor=P.+Zouauthor=Y.+Jiangauthor=D.+Sun&title=Characterization+of+Celastrol+to+Inhibit+Hsp90+and+dc37+Interaction&doi=10.1074%2Fjbc.M109.051532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction</span></div><div class="casAuthors">Zhang, Tao; Li, Yanyan; Yu, Yanke; Zou, Peng; Jiang, Yiqun; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35381-35389</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (Hsp90) is required for the stabilization and conformational maturation of various oncogenic proteins in cancer.  The loading of protein kinases to Hsp90 is actively mediated by the co-chaperone Cdc37.  The crucial role of the Hsp90-Cdc37 complex has made it an exciting target for cancer treatment.  In this study, the authors characterize Hsp90 and Cdc37 interaction and drug disruption using a reconstituted protein system.  The GST pull-down assay and ELISA assay show that Cdc37 binds to ADP-bound/nucleotide-free Hsp90 but not ATP-bound Hsp90.  Celastrol disrupts Hsp90-Cdc37 complex formation, whereas the classical Hsp90 inhibitors (e.g., geldanamycin) have no effect.  Celastrol inhibits Hsp90 ATPase activity without blocking ATP binding.  Proteolytic fingerprinting indicates celastrol binds to Hsp90 C-terminal domain to protect it from trypsin digestion.  These data suggest that celastrol may represent a new class of Hsp90 inhibitor by modifying Hsp90 C terminus to allosterically regulate its chaperone activity and disrupt Hsp90-Cdc37 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbfNGpAapIrVg90H21EOLACvtfcHk0lir-xEWA4Wmow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurjN&md5=f8d15de4ecac58de8bb5274d9cf9cdcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.051532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.051532%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520Celastrol%2520to%2520Inhibit%2520Hsp90%2520and%2520dc37%2520Interaction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35381%26epage%3D35389%26doi%3D10.1074%2Fjbc.M109.051532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4W7T','PDB','4W7T'); return false;">PDB: 4W7T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI','PDB','2VCI'); return false;">PDB: 2VCI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZR3','PDB','5ZR3'); return false;">PDB: 5ZR3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01521">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16202"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01521?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01521</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra and HPLC traces of compound <b>4f</b>; SPR response of hit fragments with HSP90 (Figure S1); nontoxicity of compound <b>4f</b> on normal human hepatic cells (Figure S2); gray values of AKT expression in CNE2 cells after <b>4f</b> treatment (Figure S3); anti-Hsp90 fragments and their frequencies (Table S1); selectivity of 17-AAG, <b>3d</b>, and <b>4f</b> among Hsp90 isoforms (Table S2); and cytotoxicity of <b>4a–f</b> on normal cell 293T (Table S3) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_001.pdf">jm0c01521_si_001.pdf (2.25 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01521/suppl_file/jm0c01521_si_002.csv">jm0c01521_si_002.csv (2.0 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01521&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01521%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01521" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993122dfb93c52","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
